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Abstract
The recent discovery of the vaccinia virus protein phosphatase VH1, and its 
mammalian counterparts has highlighted a novel subfamily of protein phosphatases 
that exhibit dual specificity towards phosphotyrosine- and phosphoserine/threonine- 
residues. The aim of this thesis was to isolate and characterise further members of this 
phosphatase subfamily.
Employing the technique of polymerase chain reaction (PCR), degenerate PCR 
primers, designed from amino acid sequences conserved between two members of this 
dual specificity phosphatase family, were used to amplify related sequences from poly 
(A)+ RNA isolated from the human squamous cell line A431. Screening cDNA 
libraries with probes derived from the PCR analysis resulted in the isolation of five 
novel genes, which show significant homology to the catalytic domain of the dual 
specificity phosphatases, such as the human phosphatase CL100. Two of these, TYP 1 
and TYP 2 (threonine-tyrosine phosphatase), have been analysed further. Interestingly, 
whilst TYP 2 expression is regulated with similar kinetics to CL100, TYP 1 differs 
dramatically in its regulation. The TYP 1 gene is not expressed in human fibroblasts 
unlike other CLIOO-like genes. Furthermore, northern analysis has demonstrated that 
following mitogenic stimulation of squamous cells, induction of TYP 1 mRNA reaches 
its maximal levels after four hours, in contrast to the immediate-early CLIOO-like 
genes. Both TYP 1 and CL100 mRNAs are induced upon transforming growth factor- 
beta treatment of squamous cell lines sensitive to the growth factors antiproliferative 
effects.
Investigations were undertaken to determine if TYP 1 demonstrated substrate 
specificity towards the mitogen-activated protein kinases, a function peculiar to the 
other CLIOO-like phosphatases. Indeed, transient transfection of TYP 1 into COS-1 
cells resulted in the inhibition of both ERK2 and p54JNK MAP kinase isoforms. In 
addition, purified TYP 1 protein efficiently inactivates recombinant ERK2 in vitro by 
the concomitant dephosphorylation of both the phosphothreonine and -tyrosine 
residues. The subcellular localisation of TYP 1 was investigated, and shown to encode
XI
a nuclear protein. Interestingly, the mitogenic induction of TYP 1 results in an increase 
in the half-life of the protein.
The results presented in this thesis suggest that the dual specificity phosphatases 
are an expanding family, some members of which are differentially regulated, therefore 
providing alternative mechanisms for the control of cellular responses to different 
ligands in different cell types. As discussed, TYP 1 is particularly exciting as its 
kinetics of induction and cell specificity of expression make it unique in terms of its 
possible roles.
xn
CHAPTER 1 
INTRODUCTION
1
1. Introduction
1.1. Signal transduction- an overview
The biochemical process through which a cell responds to an extracellular 
stimulus involves the interplay of multiple intracellular signalling pathways that operate 
in a stimulus- and cell type-dependent manner. A critical aspect that is not yet fully 
understood is how cells integrate the complex array of positive and negative signals 
they receive in such a way that each cell assumes and maintains its proper identity and 
function in an appropriate spatial and temporal context. Many of these signalling 
events initiate at the cell surface via specific receptor-ligand interactions and are 
relayed through the cytoplasm to the nucleus, where transcription factors, thought to 
be among the ultimate targets of such signalling pathways, elicit a response by 
modulating gene expression. Thus, co-ordinated regulation of transcription factor 
activity represents a logical integration point for the various inductive and suppressive 
signals received by each cell.
1.1.1. Mitogens and the cell cycle
Mitogenic signal transduction is the result of a series of events initiated by the 
binding of growth factors to their cognate receptors at the cell surface (reviewed in 
Aaronson 1991; Baserga et al., 1993). Growth factors produced by a cell stimulate a 
vast network of cellular interactions, integrating cell proliferation (thus referred to as 
mitogens), growth inhibition and differentiation. It is becoming clear that in vivo, the 
majority of soluble growth factors are effective locally, exerted via autocrine, paracrine 
and intracrine mechanisms, (Spom and Todara, 1980; Re, 1989), whilst cell surface 
growth factors are brought into juxtaposition (juxtacrine) by cell-cell contact 
(Massague, 1990). Mitogenic growth factors, such as epidermal growth factor (EGF), 
insulin, and platelet-derived growth factor (PDGF) stimulate cells in the quiescent 
state (GO) to enter and proceed through the cell cycle, via a number of "control 
points" which require both competence and progression factors (Muller et al., 1993).
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Cell cycle transitions are orchestrated by the sequential assembly and activation 
of cyclin-dependent kinases, whose formation depends on the cell cycle-regulated 
expression of cyclins (the regulatory subunit), associating with pre-existing catalytic 
subunits known as cyclin dependent kinases (Cdks), reviewed in Pines, 1995. In 
vertebrate cells, the main cyclin-Cdks are cyclin D-Cdk4, Cyclin E-Cdk2, Cyclin A- 
Cdk2, and Cyclin B-Cdc2, acting in G l, at Gl/S, in S, and at G2/M, respectively. 
Cdks act as integrators of positive and negative signals that determine progression 
towards a point in late Gl beyond which the cell cycle proceeds autonomously, until 
further checkpoints in G2. According to this paradigm, cell cycle stage is determined 
by the constellation of proteins activated or inactivated by phosphorylation as a result 
of the activity of Cdks. The Cdk subunits are themselves| subject to modification by 
phosphorylation and dephosphorylation (Pines, 1995). To be fully activated, the Cdk 
component needs to be phosphoiylated on a conserved threonine (T160 in Cdk2). 
Interestingly, the analogous residue is phosphoiylated in most, if not all, other families 
of protein kinases. There are also two inhibitory phosphorylation sites in mammalian 
Cdc2 and Cdk2, threonine 14 and tyrosine 15 (in Cdk4 the threonine is replaced by an 
alanine). These sites lie within the ATP-binding region, and the onset of mitosis is 
determined by the dephosphoiylation of these two residues. Negative controls on cell 
cycle progression are exerted during development, differentiation, senescence, and cell 
death (apoptosis), and consequently may play an important role in preventing 
tumouxigenesis.
1.1.2. Antimitogenic signals and cell cycle arrest
In many mammalian cell types, transforming growth factor-beta (TGFP) 
promotes growth arrest in G l that is thought to be mediated through elements of the 
cell cycle machinery (reviewed in Massague and Polyak, 1995). These antiproliferative 
effects are initiated through the activation of the TGFp receptor (Wrana et al.f 1994), 
and are particularly pronounced in epithelial, endothelial, and hematopoietic cells. It is 
now widely accepted that the Cdk complexes are needed during G l to phosphorylate 
and thus inactivate the retinoblastoma susceptibility gene (pRb), which inhibits cell
cycle progression in its underphosphorylated state (Weinberg, 1995). It is thought that 
TGFP causes G l arrest by inhibiting Gl cyclin-Cdk activities, thereby suppressing pRb 
phosphorylation. Consistent with this model, it has been demonstrated that TGFP can 
inhibit cyclin E-Cdk2 kinase activity (Koff et al., 1993). In addition, it has been 
reported that TGFp treatment inhibits the synthesis of Cdk4 and that overexpression 
of the Cdk4 gene precludes the TGFp cytoinhibitory effect in a sensitive cell line 
(Ewen et al., 1993). Interestingly, these effects are concomitant with inhibition of 
phosphorylation of pRb. These studies are indicative that Cdk-inhibitors are involved 
in TGFp cell cycle arrest, and led to the recent discovery of several mammalian Cdk 
inhibitors which physically associate with cyclin-Cdk complexes (reviewed in Peter and 
Herskowitz, 1994; Peters, 1994). These have been implicated as effectors of 
TGFp-induced cell cycle arrest, whereby TGFP causes a rapid and significant increase 
in levels of the inhibitors p21 (also called Cipl and WAF1) and pl5*NK4Bf which leads 
to an increased association with, and consequent inhibition of the Cdk complexes 
(Datto et al., 1995; Li et al., 1995; Hannon and Beach, 1994). An alternative model 
has been suggested in the case of the inhibitor p27^Pl, which in untreated cells is 
bound to cyclin D-Cdk4. Upon stimulation with TGFp Cdk4 levels are decreased 
(Ewen et al., 1993), which subsequently lowers the levels of cyclin D-Cdk4, thus 
releasing p27. This effectively elevates the level of free p27 allowing it to associate 
with and inhibit cyclin E and A complexes (Polyak et al., 1994; Toyoshima and 
Hunter, 1994). However, these two models should not be conceived as mutually 
separate mechanisms. Recent data would suggest that TGFP imparts antimitogenic 
signals through the co-operative action of pl5lNK4B and p27, or p21, and then, 
subsequent cell cycle arrest leads to a decline in Cdk2 and Cdk4 levels, possibly as a 
measure of the cell adapting to the quiescent state (Reynisdottir et al., 1995). Further 
understanding of the various cell cycle regulators will greatly facilitate our 
understanding of the complex pathways constituting cellular sensitivity to TGFp.
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1.1.3. The growth factor connection to cancer
Present knowledge indicates that the constitutive activation of growth factor 
signalling pathways, through multiple genetic alterations affecting their genes, 
inextricably contributes to the development and progression of most cancers, as well 
as a variety of chronic diseases (Aaronson and Tronick 1991). However, cancer cells 
do not simply arise from uncontrolled cellular growth but rather from a process of 
cellular evolution accelerated by genetic instability (Nowell, 1986). Oncogenes 
activated by a variety of mechanisms (Bishop 1991), have frequently been shown to 
encode growth factors such as Sis, receptor tyrosine kinases such as ErbB/Neu, and 
other intracellular enzymes including Myc, Ras and Src, that participate in mitogenic 
signalling, some of which have therefore been identified as potential targets for drug 
design (Levitzki and Gazit, 1995; Dudley et al., 1995).
1.1.4. The significance of protein phosphorylation
Protein phosphorylation is an important cellular regulatory modification, and is 
recognised as a fundamental mechanism for the transduction of external and internal 
stimuli. Regulatory protein phosphorylation occurs most frequently on serine (Ser) and 
threonine (Thr) residues (Roach, 1991) and until 1980, only phosphoserine and 
phosphothreonine had been identified as naturally occurring phosphoamino acids. 
However, tyrosine (Tyr) phosphorylation began to receive greater attention when it 
was determined that v-Src, the transforming principle of the Rous sarcoma virus, was 
a unique protein tyrosine kinase (Hunter and Sefton, 1980). These observations, 
coincident with the discovery that the epidermal growth factor receptor also possesses 
intrinsic tyrosyl kinase activity (Ushiro and Cohen, 1980), led to the suggestion that 
tyrosine kinases may be linked to the removal of growth restraint from cells, and 
stimulated a great deal of biochemical and genetic experimentation on the role of 
tyrosine kinase oncogenes and proto-oncogenes in normal and malignant cells.
Tyrosine phosphorylation may be the primary, or even the exclusive, | initiator' 
of signal transduction in multicellular organisms critical for key biologic functions (for 
extensive reviews on receptor tyrosine kinase signalling see Ullrich and Schlessinger,
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1990, van der Geer and Hunter, 1994). Within the intricate signalling network, 
intermediary serine/threonine and tyrosine protein kinases propagate signals initiated 
from cell surface receptors with tyrosine kinase activity to modulate events leading up 
to and including gene expression. To date, the focus of much research has centered 
around the mitogen-activated protein kinase (MAPK) pathway, which is firmly 
established as the paradigm for signal transduction cascades. The mechanisms involved 
at the different steps of this cascade are, however, not completely clear yet and 
accumulating evidence indicates complex regulatory relationships between the various 
components.
1.2. The mitogen-activated protein kinases
The mitogen-activated protein kinase cascade is a sophisticated signal 
transduction pathway involved in diverse responses in eukaryotic cells. MAPKs are 
one element in a series of kinases which have remained highly conserved throughout 
evolution, being present in various species, including yeasts, Xenopus, C. elegans, 
Drosophila and mammals (see reviews in Herskowitz, 1995; Gotoh et al., 1995; 
Selfors and Stem, 1994; Perrimon, 1993; Cano and Mahadevan, 1995 respectively). It 
has become apparent that signals from receptor tyrosine kinases, cytokine receptors, 
seven spanning heterotrimeric G protein coupled receptors, and presumptively some 
receptors linked to protein kinase C, result in the activation of the MAPK family: 
proteins which have served as a point to trace signal transduction back through a 
kinase cascade to the plasma membrane, and forward to transcription factors in the 
nucleus. Subversion of this cascade can lead to, and is critical for, cellular 
transformation and oncogenesis (Cowley et al., 1994). The components of this 
pathway shall be outlined below.
1.2.1. The MAP kinase family
Historically, the MAPKs were originally described as a rapidly stimulated 
insulin-sensitive serine/threonine protein kinase activity in 3T3-LI preadipocytes by
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Ray and Sturgill (1987); and subsequently named MAP2 kinases far their ability to 
phosphorylatc microtubule-associated protein-2. The discovery of the kinase was a 
fortuitous event, since at the same time it became clear that the ribosomal protein S6 
was controlled through phosphorylation. Consequently, Sturgill and co-workers 
(1988) demonstrated that S6 kinase was phosphorylated by partially purified 
insulin-stimulated MAPK2, the first evidence implicating a signal transduction 
phosphorylation cascade. This was recognised independently in other laboratories, and 
the MAPKs became known by a variety of designations reflecting the protein 
substrates that were originally used for their detection, MBP kinase (after myelin basic 
protein), RSK (after ribosomal S6 kinase) and MAPK2. Other names such as mitogen- 
activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) 
point to the vast array of agents that stimulate the activation of the MAPK family (for 
reviews see L'Allemain, 1994; Robbins et al., 1994).
Currently three MAPK pathways are known in mammalian cells, the best 
understood of these involves the ERKs. These archetypal members of the MAPK 
family have many isoforms: ERK l/p44mapk, ERK2/p42mapk, ERK3/p63- and 
p97mapk, ERK4/p46mapk, and p57mapk (Gonzalez et al., 1992; Robbins et al., 1994; 
Zhu et al., 1994). ERK1 and ERK2 are the best characterised, ubiquitously expressed 
in all tissues and cell lines, although their subcellular distributions are less certain. Both 
of these MAPKs have been reported to be activated biphasically in fibroblasts treated 
with mitogens, with the first peak occurring between 5 and 20 minutes, and the second 
occurring between 1 and 4 hours. Activation of ERK1 and -2 during the second phase 
is correlated with both nuclear translocation and initiation of DNA synthesis (Seth 
et al., 1992). A particular member of the MAPK family is ERK3, which has the 
highest expression level in early development, a restricted expression pattern (mainly 
neuronal cells and muscle), and a different substrate specificity (L'Allemain, 1994). 
Furthermore, ERK3 proteins possess a completely different regulatory site sequence, 
discussed below.
Distinct from the above classical MAPK proteins, recent work has identified a 
multifamily of MAPK proteins, which include the JNK/SAPK subfamily. JNK1 and -2
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were identified as novel protein kinase activities that bind to the oncogene c-Jun within 
the transactivation domain and phosphorylate two serine residues, hence c-Jun 
NH2-terminal kinases (JNK), (Hibi et al., 1993; Derijard et al., 1994). Simultaneous 
studies identified three further MAPK-related proteins through the screening of a rat 
cDNA library (Kyrialds et al., 1994). These kinases (a, and y) are strongly activated 
by stress-inducing stimuli, including translational inhibitors, heat shock and tumour 
necrosis factor (TNF), and were subsequently designated stress-activated protein 
kinases (SAPKs). The third type of mammalian MAPK to be identified is p38, which is 
activated by heat shock and hyperosmolar medium (Han et al., 1994). It is interesting 
that p38 is most closely related to HOG1, an enzyme required for adaption to osmotic 
stress in Saccharomyces cerevisiae.
There are several other recently discovered mammalian kinases that are 
probably of the MAPK family, although how these proteins fall within the scheme of 
the three known cascades discussed above is presently not known. These include 
Fos-regulating kinase (FRK), which augments the transcriptional activity of c-Fos 
through phosphorylation at Thr-232, the homologue of Ser-73 of c-Jun (Deng and 
Karin, 1994). The other is reactivating kinase, RK, which both stimulates MAPK- 
activated protein kinase-2 and phosphorylation of the small heat shock proteins, and 
appears to be identical or at least closely related to p38 (Rouse et al., 1994).
1.2.2. Selective activation of ERKs, JNK/SAPKs and p38
Transactivation of the MAPKs is through an ordered phosphorylation of both a 
threonine and a tyrosine residue, which form part of the dual-phosphorylation 
tripeptide motif, the sequence of which distinguishes the three MAPK subgroups. 
Phosphorylation on TEY is the defining property of the ERK subfamily, whilst the 
JNK/SAPKs and p38 MAPKs are phosphorylated on TPY and TGY respectively 
(Cano and Mahadevan, 1995). However, as previously mentioned, ERK3 is the 
anomaly being phosphorylated on SEG. Preceding the tripeptide motif, which is 
located between subdomain VII and VIII of the MAPK gene, is an 
autophosphorylation site. Whilst there is evidence that ERK1 and -2 can
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autophosphorylate at the tyrosine and threonine within the motif, the basal rate of 
autophosphorylation is too slow to account for the rapid activation of MAPK activity 
upon mitogen stimulation (Seger et al., 1991). It has become apparent that these 
phosphorylations are in fact mediated by upstream components called MAP kinase 
kinases (MKKs or MEKs, for continuity I shall use the designation MKK). A crucial 
question is how specificity of signalling through the MAPK subtypes is organised? 
There is strong evidence which implicates that the TEY, TPY and TGY motifs are 
targeted by different dual specificity kinases, which are selectively activated by various 
agonists. Present data argues for a complex interconnected system of upstream 
components that have access to separate, but co-ordinately regulated cascades 
controlling the distinct, dual specific MKKs.
Although hyperosmolarity can potentially activate all three MAPK subtypes 
(Matsuda et a/., 1995), the relative activation of the MAPKs is characteristic of the 
stimulus used (reviewed in Cano and Mahadevan, 1995). ERKs are potently activated 
by EGF (e.g. growth factors) and |phorbol esters (TPA); whilst protein synthesis 
inhibitors, inflammatory cytokines (tumour necrosis factor a  and | interleukin-1), heat 
shock and ultraviolet irradiation strongly activate the JNK/SAPKs. Conversely, TPA 
has no effect on p38, which appears to be activated in the inflammatory response to 
lipopolysaccharides or to inflammatory mediators such as interleukin-1. However, the 
important caveat is that the comparative activation of the MAPKs subtypes in 
response to the above stimuli is specifically cell-type dependent
1.2.3. MAP kinase activator: A dual-specific kinase
A 45 kDa protein factor that can induce phosphorylation and activation of 
inactive MAPK in vitro was first purified from Xenopus unfertilised eggs (Matsuda 
et al., 1992) and subsequently two isoforms (MKK1 and MKK2) were isolated and 
cloned from mammalian cells (Seger et al., 1992; Crews et al., 1992; Ashworth et al., 
1992; Wu et al., 1993). These dual specific kinases show a high degree of homology, 
and are themselves phosphorylated by Ser/Thr kinases at two sites located in the 
catalytic subdomain VIII. A distinctive feature of the vertebrate MKKs is a
proline-rich region inserted between kinase subdomain IX and X. The function of this 
domain is not clear, but it is interesting that in some isoforms (MKK1) this region 
contains phosphorylation sites and negative regulatory sequences (Wu et al., 1993), 
implicating differences in feedback controls for MKKs.
Thus, as previously mentioned, recent evidence has established that the 
molecular basis for the separate identity of the MAPK signal transduction pathways is 
that each subtype is activated by a specific MKK in response to a certain stimuli, see 
figure 1.1, pl3. The identification of further MKKs, namely MKK3 and MKK4 
(Derijard et al., 1995), has led to the demonstration that MKK1 and MKK2 
exclusively activate the ERKs, whilst MKK3 is a specific activator of p38. In 
contrast, MKK4 activates both p38 and JNK. Sanchez and co-workers (1994) have 
also identified a novel protein kinase called SAPK/ERK kinase-1 (SEK1), which is the 
murine homolog of human MKK4; and a distinct upstream RK kinase (RKK) has been 
isolated by Rouse et al. (1994). It seems only plausible that as novel MAPK isoforms 
are being identified, the MKKs will follow suit, and in keeping with this Zhou et al. 
(1995) have recently identified an additional MKK5 along with its partner ERK5. 
Their results show that ERK5 does not interact with MKK1 or -2, and its predicted 
size is twice that of all known ERKs due to additional carboxy-terminal sequences, 
which may target the enzyme to cytoskeletal components of the cell MKK5 is distinct 
from all other MKKs in that it contains a long amino terminal sequence which shows 
homology to the S. cerevisiae gene CDC24. The CDC24 encoded protein has GDP 
releasing activity and binds to the GTPase CDC42, the mammalian equivalent of which 
is Cdc42Hs, a member of the Rho subfamily. This may provide a mechanism for 
coupling GTPases to downstream protein kinase signalling cascades, a mechanism 
referred to later.
1.2.4. The MAP kinase kinase kinase family
The initial experiments that demonstrated that MKK was inactivated by 
Ser/Thr-specific but not Tyr-specific phosphatases led to the existence of a MAP 
kinase kinase kinase. The first to be identified was p74Raf-l the product of the
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c-Raf-1 proto-oncogene. Immunoprecipitates of oncogenically activated Raf, or of 
p74Raf-l from growth factor stimulated cells, phosphorylate and reactivate 
dephosphorylated MKK (Dent et al., 1992; Howe et al., 1992; Kyriakis et al., 1992). 
Further studies utilising PCR with degenerate oligonucleotides designed against the 
yeast MKKKs identified the mammalian MKK kinase, MEKK (Lange-Carter et al.,
1993). Finally, work from Nebreda and Hunt (1993) has demonstrated that Mos may 
also act as a MKK kinase. Thus, three distinct protein kinases appear to activate 
MKKs, increasing the complexity of the MAP kinase cascade.
13. Is the MAP kinase cascade redundant?
- Evidence for the differential activation of the MAPK subfamilies
Intracellular signalling has been dominated by the MAPKs, more specifically 
the ERKs, which are activated through a kinase cascade which links the MKK kinase 
Raf to p21Ras. This is recognised as the classical transduction pathway and is 
discussed in the next section. However, the recent discovery of two other MAPK 
subtypes, the JNK/SAPKs and p38/RK isoforms has revealed the existence of parallel 
MAPK cascades that can be activated simultaneously. The concept of multiple MAP 
kinase cascades is by no means new, and presently are best characterised in
S. cerevisiae, which has at least six identified pathways that contain MAPKs or their 
presumed upstream regulators (Herskowitz, 1995). The important distinction between 
these and mammalian MAPKs is that the various yeast pathways regulate separate 
physiological functions; they seem not to be activated in parallel in response to the 
same stimulus. Hence, we now need to reassess our understanding of the mammalian 
MAPKs. The balance between functional separation and crosstalk between these 
pathways is an interesting problem. However, it is anticipated that any crosstalk will 
promote the existence of a physiologically flexible and complex network.
The evidence for parallel cascades has been demonstrated by numerous studies. 
The expression of constitutively active oncogenic forms of Ras has been shown to 
potently induce the ERK subtypes (reviewed in Blenis, 1993), however, Ras fails to
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fully activate JNK (Ras is necessary only for growth factor activation of JNK), 
(Derijard et al., 1994; Minden et al., 1994). Furthermore, a division between the ERK 
and JNK cascades is implied by the evidence that Raf is not directly involved in JNK 
activation (Minden et al., 1994). Instead the JNK cascade is strongly activated by the 
MAPKK kinase MEKK/SEK, which, unless overexpressed, does not lead to ERK 
activation (Sanchez et al., 1994; Yan et al., 1994). Although MEKK activity is 
stimulated by growth factors in a Ras-dependent manner (Lange-Carter et al., 1993), 
the mechanism of its activation is not clear, and has been linked to G protein-coupled 
receptors as opposed to receptor tyrosine kinase receptors. These results support the 
contention that at least two signal transduction cascades exist in mammals with distinct 
functions: the MEKK/SEK/S APK-mediated stress response and the
Raf/MKK/MAPK-mediated mitogenic response, (see figure 1.1, p i3). Hence, the 
specificity of SEKs and MKKs defines the segregation of the stress and mitogenic 
pathways. Intriguingly, two recent studies have implicated that the GTPase proteins 
Rac and Cdc42Hs, members of the Ras subfamily Rho, are specific activators of the 
JNK pathway (Minden et al., 1995, Coso et al., 1995a). The GTP-bound forms erf 
Racl and Cdc42 can specifically associate and activate a novel Ser/Thr kinase, the 
p21-activated kinase (PAK65). This situation is highly analogous to the Ras 
GTPase-Raf interaction, suggesting that the Rho family of GTP-binding proteins might 
also initiate activity of a kinase cascade. The rationale is that either PAK65 or related 
kinases link Racl and Cdc42 to the MEKK/SEK/JNK module. As previously 
mentioned, it is interesting that a newly identified MKK5 contains a region 
homologous to the yeast protein CDC24 (Zhou et al., 1995). CDC24 acts as a guanine 
nucleotide-exchange factor for the GTPase CDC42, which has been demonstrated to 
have a direct signalling role in the mating-pheromone response between the G protein 
and the downstream protein kinase cascade (Simon et al., 1995). Thus, Cdc42Hs 
may provide the link between G proteins and the MEKK/SEK cascade, leading to the 
activation of JNK/SAP kinases. These studies suggest the divergence of signal 
transduction pathways at the levels of Ras and Raf, as opposed to the MAPKs as 
originally thought. This will prove to be an interesting area for future research.
12
Figure 1.1.
Schematic representation of the protein kinase cascades leading to the activation 
of distinct members of the MAP kinase family.
Accumulating evidence suggests that parallel kinase cascades control the activity of 
the MAPK isoforms. In mammalian cells, three hierarchical levels have been identified, 
represented by MAPK, MKK, and Raf-l/MEKK. The small GTP-binding protein Ras 
activates the classical ERK cascade, whereby binding of Ras to Raf-1 localises Raf to 
the plasma membrane, upon which a second (undefined) event takes place to activate 
the Raf kinase activity. In the JNK/SAPK signalling route, two members of the Rho 
family, Rac-1 and Cdc42, activate PAK65 which has been postulated to activate 
MEKK, however this connection may not be direct (broken arrow). Although MEKK 
activation can be Ras dependent, there is no evidence for a direct interaction. Both a 
distinct MKK isoform that is specific for the JNK/SAPK proteins, and the upstream 
kinases for the p38/RK pathway remain to be established (question marks). The thick 
arrows indicate the major response to the stimulus, note that not all stimuli leading to 
Raf-1 activation may be mediated by Ras. The precise pathways connecting cell 
surface receptors to the GTP-binding proteins are yet to be elucidated. There also 
exist cell line differences in the way these cascades are organised (for details see text).
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1.4. Protein interactions that regulate the MAP kinase cascade
1.4.1. Coupling to the receptor
Two major mechanisms exist for transmembrane signalling in intracellular 
communication, mediated respectively by receptor tyrosine kinases (RTKs) and by 
G-protein-coupled receptors (GPCRs). While traditionally, these two pathways have 
been considered to be totally independent, recent evidence has shown that these 
pathways can converge on the same effectors, namely the Ras-MAPK cascade.
1.4.2. Receptor tyrosine kinase mediated activation of Ras
A variety of extracellular ligands (growth factors or cytokines) have been 
shown to cause an activation of p21Ras, among these are EGF, insulin, PDGF and 
macrophage-colony stimulating factor. Other tyrosine kinases such as Src, Abl and 
Neu also transduce signals which stimulate Ras (reviewed in Maruta and Burgess, 
1994; Medema and Bos, 1993). Considerable recent attention has focused on 
developing a detailed model for explaining how EGF activates Ras, and it is this 
pathway that will be discussed here, although undoubtedly, aspects of this intracellular 
signalling mechanism will be common to all extracellular stimuli and RTKs.
The epidermal growth factor receptor is a 170-kDa transmembrane glycoprotein 
with an extracellular domain that binds EGF and a cytoplasmic domain with intrinsic 
tyrosine kinase activity (reviewed in Prigent and Lemoine, 1992). The binding of EGF 
causes an increase in the receptor tyrosine kinase activity by an allosteric mechanism 
that involves receptor dimerisation (Schlessinger, 1988; Lemmon and Schlessinger,
1994). The activated EGF receptor then undergoes both autophosphorylation of the 
carboxy-terminal domain, and phosphorylation of substrate proteins such as RasGAP, 
phospholipase C-y, and phosphatidyl inositol 3-kinase. With the exception of the insulin 
receptor family, all known receptors with tyrosine kinase activity undergo dimerisation 
upon binding of their cognate ligand, and multiplicity of tyrosine autophosphoryladon 
sites is thought to underlie the pleiotropic cellular response to growth factors. These 
autophosphorylation sites represent recognition structures for specific target proteins
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containing Src homology 2 (SH2) domains. SH2 domains are conserved sequences of 
approximately 100 amino acids found in various signalling molecules and oncogenic 
proteins (reviewed in Margolis, 1992; Cohen et al., 1995), and they provide a 
mechanism whereby growth factor stimulation can couple to| multiple intracellular 
signalling pathways. Different SH2s bind to distinct phosphotyrosine containing 
regions, the specificity of which are determined by the residues immediately adjacent to 
the phosphotyrosine residue. SH2 domains are often accompanied by a stretch of 
conserved sequences termed SH3 domains, which are proline-rich binding sites, 
indicative of a role in the intracellular compartmentalisation of proteins. Some 
molecules with SH2 or SH3 domains have intrinsic enzymatic activity, for example Src 
and RasGAP. Others, often with multiple SH2 and/or SH3 domains, serve as bivalent 
or multibivalent adaptors that mediate interactions among signalling molecules.
Two proteins that appear to mediate EGF receptor-induced Ras activation 
include Grb2 and Sos. Grb2 (Growth factor receptor-bound protein 2) is a cytosolic 
protein, whose entire sequence is composed of a single SH2 domain flanked by two 
SH3 domains. Identification of Grb2 was through the high affinity binding of the SH2 
domain to autophosphorylated EGF receptors (Lowenstein et al., 1992). Grb2 binds 
to a second protein, mSos (mammalian homolog to the Drosophila Ras activator Son 
of sevenless), which is also cytosolic and functions as a guanine nucleotide-releasing 
factor (GNRF), facilitating the activation of Ras (Bonfini et al., 1992; Bowtell et al.,
1992). In most cells, prior to receptor stimulation, Grb2 and Sos are already 
associated forming a stable interaction through the carboxy terminal proline-rich 
domain of Sos and an SH3 domain of Grb2. Following receptor stimulation, 
autophosphorylated receptor binds the Grb2/Sos complex through the SH2 domain of 
Grb2, thereby recruiting the cytosolic complex to the plasma membrane where Ras is 
localised, see figure 1.2, pl7 (Buday and Downward, 1993; Rozakis-Adcock et al.,
1993). The binding of Sos to Grb2 is not essential for Ras activation since truncated 
5'-Sos, which no longer binds Grb2, is an efficient activator of Ras provided it is 
targeted to the plasma membrane by means of a myristoylation signal (Aronheim et al.,
1994). In these experiments the truncated Sos derivatives were considerably more
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active, suggesting that a further mechanism may relieve the inhibitory effect of the Sos 
carboxy-terminus, such as allosteric changes induced upon Grb2 binding to the 
receptor, or indeed phosphorylation of Sos. It is possible that kinases downstream of 
Ras act in a positive feedback loop by phosphoryladng the mammalian homolog of 
Sos. It is becoming apparent that Grb2 can be "plugged in" to many other receptor 
systems. Indeed, Schlaepfer et al. (1994) demonstrate that integrin-stimulated signal 
transduction leads to the subsequent phosphorylation of FAK (focal adhesion protein- 
tyrosine kinase) by c-Src or related kinases. This creates an SH2-binding site for Grb2 
which may link integrin engagement to the activation of the Ras/MAPK signal 
transduction pathway. Grb2 represents a newly emerging class of adaptor proteins, 
whose common feature is signal transmission to Ras. One such protein Crk, consists of 
an SH2 and an SH3 domain, but unlike Sos and Grb2 is highly oncogenic, suggesting 
that Crk oncogenicity is not totally dependent on Sos. In accordance with this, a 
recently identified GNRF for Ras, C3G, has been demonstrated to bind to the SH3 
domain of Crk (Tanaka et al., 1994). A third adaptor protein is She, consisting of only 
an SH2 domain, which also binds autophosphorylated EGF receptor. Once bound, She 
is itself tyrosine phosphorylated and consequendy able to bind the Grb2/Sos complex, 
see figure 1.2, pl7 (Pelicei et al., 1992, Sasaoka et al.t 1994). Free Shc Grb2/Sos 
complexes are known to exist, consistent with either dissociation from the receptor, or 
a parallel pathway containing an intermediary tyrosine kinase, such as Src, which 
phosphorylates She such that it binds Grb2. Hence, it is clear that many molecules with 
different surface interfaces are capable of transmitting extracellular stimuli to activate 
the p21Ras pathway.
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Figure 1.2.
A model depicting possible interactions between receptor tyrosine kinases
and Ras.
Tyrosine autophosphorylated EGF receptor binds to the SH2 domain of She, which is 
itself tyrosine phosphorylated enabling the binding of the SH2 domain of Grb2. Grb2 
binds with the guanine nucleotide-exchange factor Sos, via one of its SH3 domains, 
thus forming a multimeric unit which enhances the formation and stimulation of 
p21Ras-GTP. Alternatively, the EGF receptor can bind directly to the Grb2 SH2 
domain foiming an EGFR*Grb2/Sos complex. It is possible that a single EGF receptor 
can concomitantly associate with both Grb2/Sos and Shc*Grb2/Sos complexes. 
Finally, following EGF stimulation, Shc*Grb2/Sos complexes could exist, independent 
of the EGF receptor.
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1.4.3. G protein coupled-receptor activation of Ras
In addition to the widely studied ligands of RTKs, certain agonists of GPCRs 
are also capable of stimulating DNA synthesis in responsive cells. Such mitogens 
include the lipid lysophosphaddic acid (LPA), a platelet-derived serum factor, although 
preliminary analysis suggests that LPA is also released by growth factor stimulated 
fibroblasts (Fukami and Takenawa, 1992). LPA has long been known as a critical 
precursor in glycerolipid biosynthesis, however, its function as a "first messenger" has 
only recently been recognised (for review see Moolenaar, 1995). A major signalling 
event induced by LPA is the rapid and transient activation of the proto-oncogene 
product p21Ras in quiescent fibroblasts. There is compelling evidence to indicate that 
LPA-induced mitogenesis is through a pertussis toxin (PTX)-sensitive pathway, 
assigning a central role for a heterotrimeric G protein of the Gj subfamily; yet it 
appears that Gj-mediated p21Ras activation is independent of known PTX-senstive 
effector routes (Van Corven et al., 1993). One such pathway is the LPA stimulated 
inhibition of adenylyl cyclase (Van Corven et al., 1989), however, raising cAMP levels 
does not affect Ras activation. Gj-mediated activation of the Ras-MAPK pathway is 
not unique for LPA: it is also observed after stimulation of the endogenous thrombin 
receptor in hamster fibroblasts (Van Corven et al., 1993), and transfected muscarinic 
M2 or CC2- adrenoceptors in Rat-1 cells (Winitz et al., 1993; Alblas et al., 1993).
At present, relatively little is understood about the intermediary signals that 
couple Gj to Ras-MAPK activation. However, increasing evidence implicates that it is 
the py-subunits of the G proteins which are specifically involved, see figure 1.3, p20 
(Faure et al., 1994; Crespo et al.t 1994). Further studies also demonstrate that 
dominant-negative versions of the Ras and Raf kinases inhibit LPA-induced activation 
of MAPK (Cook et al., 1993; Howe and Marshall, 1993). It has been proposed that 
the effector pathway comprises a non-receptor tyrosine kinase, since tyrosine kinase 
inhibitors such as staurosporine, selectively inhibit LPA-induced Ras-GTP 
accumulation at doses that do not effect EGF-induced Ras activation (Hordijk et al.,
1994). Obvious candidates are the members of the Src family of tyrosine kinases, since 
Ras acts downstream of activated pbO3^  in proliferation and transformation of
fibroblasts (Smith et al., 1986), and LPA and thrombin rapidly activate Src in their
target cells (Jalink et al., 1993; Chen et al., 1994a), although it remains to be seen
whether this activation is Gj mediated. However, the use of Sic-neutralising antibodies
suggests that Src family kinases are not critically involved in LPA-induced mitogenesis
(Roche et al., 1995). Additional studies by Tsukada and colleagues (1994), have
demonstrated a direct interaction between the fty-subunits of Gj protein and the
pleckstrin homology (PH) domain of Bruton tyrosine kinase, Btk. Btk is a
non-receptor tyrosine kinase linked to B-cell deficiencies in humans and mice, and
defective proteins are the result of mutations in the PH domain. The PH domain is a
region of approximately 100 amino acids found in a wide variety of signalling and
cytoskeletal proteins. The function of PH domains is unknown, but it is clear that they 
provide an interface through which kinases can couple to membrane-anchored Gjfy
subunits in a stimulus-dependent manner (for a review on protein binding domains see 
Cohen et al., 1995). Transmission of the signal from Gjfy to Ras could then be realised
through binding of beta/gamma dimers to the PH domain present in several Ras
interacting molecules as in GRF, the GDP releasing factor, in SOS, the GDP to GTP
exchange factor, or in GAP, the GTPase activating protein, or indeed through the
interaction with non-receptor tyrosine kinases such as Btk. It is interesting that both
the RTK and GPCR pathways recruit cytoplasmic intermediates to the membrane by 
lipid-modified G proteins such as Ras and Gjfy Whether the PH domains serve as a
general mechanism for protein-protein interactions analogous to those mediated by
SH2- and SH3 domains is currently speculative. Blesen and colleagues (1995), have
demonstrated that activation of Gj-coupled receptors by LPA leads to the tyrosine 
phosphorylation of She, mediated entirely through the Gjfy subunits. Concurrent with
She phosphorylation is the functional recruitment of the Grb2/Sos complex, which 
subsequently leads to Ras-dependent MAPK activation. It is feasible that Gjfy subunits
might activate Ras by a Sos PH domain-directed translocation event, however,
disruption of the Shc*Grb2/Sos interaction blocks MAPK activation, demonstrating 
that both She and Grb2 are necessary to transmit the Gjfy signal to MAPK.
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It is worth mentioning at this point that a recent study by |Cosoif al. (1995b) 
demonstrated that G protein-coupled receptors can lead to the activation of JNK, 
which is temporally distinct from the activation of p21Ras and ERKs. Whilst evidence 
presented by Vara Prasad et al., (1995) describe a Ras-dependent signal transduction 
pathway involving the a  subunit of the G proteins regulating the JNK/SAPKs. These 
findings are corroborative with previous studies that parallel pathways evidently exist 
leading to the activation of either ERKs or JNKs.
Figure 13.
Proposed model of early LPA signalling pathway triggering 
Gj-mediated Ras activation.
LPA activates its cognate G protein-coupled receptor to trigger inhibition of adenylate 
cyclase (flat headed arrow), and activation of p21Ras which subsequently leads to 
activation of the MAP kinase pathway. Both these events are mediated through the 
pertussis toxin sensitive Gj protein. Ligand binding to the G protein-coupled receptor 
leads to the dissociation of Gpy from G a upon GTP-GDP exchange. Ga-subunits 
inhibit adenylyl cyclase, resulting in decreased cAMP levels, while free Gfty-subunits 
activate p21Ras via a putative staurosporine- and genistein-sensitive protein tyrosine 
kinase. For further details, see text.
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1.4.4. The role of Ras in signal transduction
The requirement for ras activity in RTK signalling was proposed as early as 
1986 on the basis of experiments with neutralising antibodies against p21Ras (Smith 
et al., 1986). In all eukaryotic organisms examined, Ras homologues have been 
identified which act as key, pivotal signal transducers in receptor-activated pathways. 
Significantly, mutations of Ras are prevalent in many different forms of human 
cancers, accounting for approximately 30% of carcinomas. Consequently their role in 
signal transduction and transformation has been studied extensively, (for 
comprehensive reviews see Maruta and Burgess, 1994; Boguski and McCormick, 
1993; Medema and Bos, 1993).
Mammalian cells express four "true" Ras proteins (encoded by H-ras, N-ras, 
K-rasA, K-rasB), each of which can function as an oncogene following mutational 
activation. These isoforms are plasma membrane-associated guanine nucleotide- 
binding proteins which function as binary switches, cycling between active and inactive 
states bound to GTP and GDP respectively. The GTP-bound form is slowly converted 
to the GDP-bound form by the protein's intrinsic capacity to hydrolyse GTP, a process 
accelerated by GTPase-acdvating proteins (GAPs), of which there are two in 
mammalian cells: p i 20-GAP and neurofibromin, which thereby negatively regulate Ras 
function (Trahey and McCormick, 1987; Xu et al., 1990; Buchberg et al., 1990). 
Activation in turn involves the replacement of GDP for GTP, an event mediated by 
guanine nucleotide-exchange proteins (or guanine nucleodde-release factors), such as 
SOS and Ras-GRF (Downward, 1992; Buday and Downward, 1993).
The elucidation of the identities of the critical cellular targets, or "effectors" 
through which Ras proteins exert their biological effects has long been an area of 
intense research. The domain of Ras that interacts with the effectors has been 
delineated by a set of mutations in activated mutant Ras that ablates its biological 
activity, without reducing GTP binding. This region, between residues 32-40, is 
defined as the effector domain (reviewed in Marshall, 1993). The first protein for 
which evidence for a possible effector role was found was p 120-GAP (Cales et al., 
1988). This protein interacts only with GTP-bound Ras and fails to interact with most
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effector region mutants. This is also true for the GAP-related protein neurofibromin 
(Downward, 1992). Because both these proteins negatively regulate Ras, this activity 
could be incorporated in an effector as a negative feedback mechanism. Strong 
evidence indicates that p i 20-GAP can have an influence downstream of Ras in various 
signalling pathways (Yatani et al., 1990; Schweighoffer et al.t 1992; Duchesne et al.,
1993). Studies by Medema and co-workers (1992), suggest that GAP SH2-SH3 
domains serve to induce gene expression by p21Ras, but that additional signals coming 
from p21Ras are required for full functioning. However, contrasting data demonstrates 
only a negative regulatory function for pl20-GAP (Zhang et al.t 1990; Gaul et al.t
1992). Therefore, although GAP can mediate Ras activity in some situations, it seems 
unlikely that it can account for all the signals emerging from Ras.
Significant evidence suggests that GTP-Ras is an essential component of the 
pathway leading to the activation of MAPK (reviewed in Blenis, 1993). The 
introduction of oncogenic forms of ras into cells activates MAPK in the absence of 
growth factor stimulation (Leevers and Marshall, 1992), while transfection with 
dominant negative mutants of ras, overexpressed from a dexamethasone-inducible 
promoter, blocks the activation of MAPK in response to growth factors (Thomas 
et al., 1992; Wood et al., 1992). Furthermore, microinjection of oncogenic Ras into 
Xenopus oocytes or its addition to cell-free extracts leads to MAPK activation 
(Hattori et al., 1992). The effectors discovered so far that are most likely to mediate 
the growth stimulatory signals from Ras are the cytoplasmic serine/threonine Raf 
kinases. These function downstream of Ras and activate the MAPK, and possibly 
other, pathways.
1.4.5. Ras-Raf interactions
That p21Ras and Raf-1 kinase function in the same signalling pathway has been 
demonstrated by several laboratories: expression of oncogenic forms of p21Ras leads 
to enhanced phosphorylation of raf-1 kinase in NIH3T3 and PC12 cells ( Wood et al.,
1992), whilst transformation by v-raf does not require the function of p21Ras (Smith
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et al.y 1986). Recently, a number of independent studies have converged to clearly 
establish the direct Ras-Raf association.
The structure of p74Raf-l contains three regions (CR1, CR2 and CR3) 
conserved among all Raf family members (Daum et al., 1994). CR3 in the carboxy- 
terminal half of the protein is the catalytic domain, while CR1 and CR2 comprise the 
amino-terminal domain. The Ras-Raf association has been demonstrated through the 
use of fusion-binding proteins in vitro (Wame et al., 1993; Vojtek et al., 1993), as 
well as the yeast two hybrid system that detects protein-protein interactions (Van Aelst 
et al., 1993; Vojtek et al., 1993). Ras-Raf binding requires the effector domain of 
transformation-competent Ras and the CR1 of Raf, where the putative zinc finger 
motif is necessary for optimal binding to the lipid bilayer. Activation of the 
transforming potential of Raf-1 has been associated with amino-terminal truncation 
and/or fusion of Raf-1 to other proteins, suggesting that the amino-terminal half 
harbours a negative regulatory domain. However, recent findings demonstrate that the 
amino-terminal deletions in Raf-1 do not necessarily result in constitutive kinase 
activity (Chow et al.y 1995).
Recent work shows that the role of p21Ras in Raf-1 activation is for 
p21Ras-GTP to translocate cytosolic p74Raf-l to the plasma membrane, where Raf 
then becomes activated (Traverse et al.y 1993). Whilst this association can occur in the 
absence of GTP, interaction between Ras and Raf is reported to be much stronger in 
the presence of GTP, perhaps a GTP-induced conformational change occurs which 
enables Raf to become stabilised in the plasma membrane. (Wame et al., 1993). 
However, activation of purified Raf by Ras-GTP has not yet been demonstrated, 
implicating that additional components or modifications may be required, and several 
lines of evidence suggest that the Ras-Raf complex must contain some other protein(s) 
(Maruta and Burgess, 1994; Wartmann and Davis, 1994).
1.4.6. Components of the Raf-binding multicomplex
Physiological activation of Raf-1 is paralleled by its hyperphosphorylation, 
which occurs mainly on serine residues, but is also present on threonine and tyrosine
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residues (Daum et al., 1994). Previous work in which Raf-1 and oncogenic Src are 
overexpressed in insect cells indicates a role for tyrosine phosphorylation in the 
activation of Raf-1 (Fabian et al., 1993). Marais and co-workers (1995), have 
demonstrated that in mammalian cells, the maximal level of activation of Raf-1 is 
observed when it is co-expressed with oncogenic Ras and Src, thereby it is the 
combination of the synergy between Ras and Src in promoting both membrane-bound 
activation and tyrosine phosphorylation of p74Raf-l. In vertebrate cells, the 
phosphorylation of tyrosine appears to be an additional level of control imposed on 
Raf-1, since Raf proteins of D. melanogaster and C. elegans have negatively charged 
amino acids in place of the modified tyrosine residues. However, this supports the idea 
that there must be additional membrane-localised events that can activate Raf-1, since 
a negative charge can be achieved through an acidic amino acid, as is the case with 
mammalian B-Raf, or by phosphorylation of tyrosine residues.
The highly conserved 14-3-3 family of proteins also function as potential 
co-activators of Raf-1. Several experimental approaches have identified the 14-3-3 
proteins complexed with Raf-1, both in the cytosol and the plasma membrane 
(Yamamori et al., 1995; Fu et al., 1994; Freed et al., 1994). However, while these 
studies suggest that 14-3-3 proteins can stimulate Raf-1 activity, no direct activation 
of recombinant Raf-1 by 14-3-3 proteins in vitro has been demonstrated. In fact, their 
interaction with inactive, cytosolic Raf-1 would suggest, therefore, that 14-3-3 acts as 
a co-factor that is necessary, but not sufficient for Raf-1 activation. It has been 
recognised for some time that the 14-3-3 proteins interact with many different kinases 
(reviewed in Burbelo and Hall, 1995; Aitken, 1995). One possible function is that cells 
have recruited these proteins to regulate key kinases such as protein kinase C, Raf and 
Bcr, so that multiple signal transduction pathways can be simultaneously co-ordinated. 
Alternatively, 14-3-3 proteins may act independently in these transduction pathways, 
as co-factors or scaffolds, allowing multiple kinases to function in an ordered fashion.
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1.4.7. The linearity of the Ras/Raf pathway
In the eye development of Drosophila and the vulval induction of C. elegans, 
Ras, Raf-1 and MAPK have been suggested to form a linear pathway (reviewed in 
Perrimon, 1993; Selfors and Stem, 1994). It is clear however, that coupling of Ras/Raf 
with the MAPK signal transduction pathway has many branches, and is subject to 
regulation by other signalling proteins, depending on the cellular background (Gallego 
et cU.t 1992). Ras is now implicated not only in the activation of Raf-1 and MEKK, but 
has other effectors including phosphatidylinositol-3-OH kinase and p i 20-GAP 
(Rodriguez-Viciana et al., 1994; Duchesne et al.y 1993). In line with this, Raf-1 has 
substrates other than MKK, such as IKB, a component of the NF-KB transcription 
factor (Li and Sedivy, 1993); and interestingly, Raf-1 activation is not always 
accompanied by MAPK activation (Porras et al.y 1994). There also exist 
Ras-independent pathways for Raf-1 activation, protein kinase C is one candidate 
(Sozeri et al.y 1992; Kolch et al.y 1993). Significantly, the activation of protein kinase 
A by cyclic AMP levels suppresses the activity of Raf-1 (Cook and McCormick,
1993). Furthermore, as previously mentioned in section 1.3, some subtypes of MAPK 
can be activated without activation of Ras or Raf-1, in a MEKK/SEK-dependent 
manner. It is also clear that ERK2 activation can be mediated by a protein kinase C 
cascade independent of Ras (Burgering et al.y 1993), presumably this pathway 
converges at the level of Raf-1 activation. The cloning of an intracellular receptor for 
protein kinase C which shows homology to the (3 subunit of heterotrimeric G proteins, 
defines a way that protein kinase C could be activated itself from the growth factor 
receptor (Ron et al., 1994). It would seem that independent pathways to regulate 
MAPKs co-exist within one cell type, but the nature of these pathways is cell type 
specific by virtue of the agonist employed by that cell, although a stimulus can exert an 
effect through different combinations of these pathways.
A model for the signal transduction pathway regulating the MAPKs, and their 
substrates, is illustrated in figure 1.4, overleaf.
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Figure 1.4.
Schematic representation of the signal transduction pathways regulating the 
MAP kinase family and their substrates.
Greater detail for this model is provided in the text For simplicity, JAK/STAT- 
mediated signalling, and some of the regulatory feedback loops described in the text 
are omitted. Briefly, the SH2-adaptor protein She is tyrosine phosphorylated in 
response to growth factor-activated tyrosine kinases. The tyrosine phosphorylated She 
then interacts with Grb2 via its SH2 domain. Alternatively, Grb2 may directly interact 
with activated receptors. Grb2 then recruits the Ras effector molecule Sos to the 
plasma membrane to activate p21Ras. Ras then activates Raf-1 by an as yet unknown 
mechanism, but which involves the 14-3-3 proteins, and then subsequendy activates a 
phosphorylation cascade within which reside the MKKs, MAPKs and RSK. Raf is also 
activated by PKCa, although precisely how PKC participates in this phosphorylation 
cascade is not known. This pathway may also be regulated by the heterotrimeric G 
proteins via activated MEKK protein. MAP kinase and RSK have been shown to be 
both cytoplasmic and nuclear, and possess the potential for directly regulating gene 
expression by transcription factor phosphorylation. (Diagram adapted from Blenis,
1993).
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1.5. The substrates of MAP kinase
The sequence of the MAPK phosphorylation site in MBP led investigators to 
realise the specificity of the amino add environment around the phosphorylated 
residues. A MAP kinase consensus sequence was thus established as being P-X-S/T-P, 
where X is a basic or neutral amino acid, (see reviews in L'Allemain, 1994; Robbins 
et al., 1994). Using this consensus phosphorylation site for MAPK targets, a series of 
putative in vivo substrates have been characterised.
1.5.1. Cytosolic targets
The initial interest in MAPK arose after in vitro studies demonstrated that an 
insulin-stimulated protein kinase activity was able to phosphorylate and activate the 
ribosomal protein S6 (Sturgill et al., 1988). The physiological relevance of activated 
S6 kinase in mitogenicity is unclear, however, phosphorylated p90Rsk does translocate 
into the nucleus (as does MAPK), where there is the possibility of interaction with 
proteins involved in the regulation of transcription. Further cytosolic substrates include 
MBP, MAPKAP Kinase 2 (MAP Kinase-Activated Protein Kinase), and 
phospholipase A2 (PLA2). PLA2 causes hormone-dependent release of arachidonic 
acid, the precursor of biosynthesis pathways involved in the inflammatory response. 
Whilst MAPK signalling is not the only way to activate PLA2» t^s potential as an 
in vivo substrate implies that the MAPKs lie at a pivotal point in a pathway that 
controls numerous second messengers derived from arachidonic acid. A number of 
other substrates that have been identified in vitro are part of the MAPK cascade, and 
therefore have the capability of functioning within a regulatory feedback loop. These 
proteins include the EGF receptor, RaffMKK and Sos. The phosphorylation of the 
EGF receptor by MAPK at Thr 669 was reported to regulate receptor internalisation, 
however, presently there is no evidence for the phosphorylation affecting tyrosine 
kinase activity of the receptor. MAPK phosphorylation sites are also present at the 
carboxy-terminus of the MKK proteins. Recent evidence from a number of 
laboratories suggests that phosphorylation of the two sites in MKK1 is not
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accompanied by activation of the protein, and indeed, mutation of the threonine 
residues within these two MAPK consensus sites suggests that MKK1 protein is 
negatively regulated by MAPK-directed threonine phosphorylation (L'Allemain, 1994). 
The phosphorylation pattern of Raf is exceedingly complex, and as with Sos, the 
MKKs and the EGF receptor, more research is necessary to accurately decipher how 
these MAPK-catalysed phosphorylations are involved, if at all, in a regulatory 
feedback loop on the MAPK cascade.
1.5.2. Nuclear targets- Transcription factors
Primary gene induction or repression of "immediate-early" genes in eukaryotes 
does not require de novo protein synthesis, suggesting the involvement of post- 
translational modifications. Since stimuli that affect gene expression also lead to the 
activation of protein kinases, it is not surprising that transcription factors are directly 
regulated by protein phosphorylation (Meek and Street, 1992). Transcriptional targets 
for the MAPKs comprise the components of the AP-1 activator, the proto-oncogene 
c-Myc, and NF-IL6, whilst other nuclear substrates include the anti-oncogene p53 and 
the nuclear lamins. This introduction will briefly outline the phosphorylation of a 
selected number of nuclear proteins involved in the AP-1 complex, for a more 
comprehensive review of nuclear targets see L'Allemain (1994). Phosphorylation of 
transcription factors by MAPKs is made attractive by the observation that activated 
MAPKs can enter the nucleus (Seth et al., 1992). However, this process is 
independent of the activation state of MAPK since the mutation of one or two of the 
regulatory sites of MAPK do not alter the kinetics of nuclear localisation (Lenormand 
et al., 1993). It is possible that nuclear translocation of MAPK requires a chaperone, 
as the MAPK sequence does not contain a nuclear localisation signal.
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L5.2.1. The regulation of AP-1 activity by MAP kinases
The activator protein-1 (AP-1) transcription factor modulates the expression of 
genes implicated in growth regulation, differentiation, and neoplastic transformation by 
binding to consensus DNA sequences, the TRE (TPA Responsive Element), within 
gene promoter regions. Activation of AP-1 is postulated to involve a network of 
kinases which may be classified as those that increase the abundance of AP-1 
components, i.e. their transcription, and those that stimulate their activity, 
i.e. transactivation.
Most of the genes that encode AP-1 components behave as "immediate-early" 
genes, and among these the regulation of c-fos and c-jun transcription is best 
understood. Several cis elements mediate c-Fos induction: a cAMP response element, 
a serum response element, and a Sis-inducible enhancer that mediates induction by 
stimuli that activate the JAK (Janus) group of protein kinases. In this situation, a 
"direct effector" model has been proposed which involves the activation of 
cytoplasmic transcription factors by tyrosine phosphorylation. For example, the ligands 
interferon a  and 7 employ a pathway that leads to the phosphorylation of two 
polypeptides, p i 13 and p91 or p84, by a membrane receptor-associated tyrosine 
kinase(s). These activated polypeptides, termed STATs (signal transducers and 
activators of transcription), then translocate to the nucleus to associate with p48, thus 
forming the ISGF-3 (IFN-stimulated gene factor-3) complex, which binds to the SIE 
to initiate transcription of the c-Fos gene (Fu and Zhang, 1993 and references therein). 
Further evidence has suggested that p91, through its SH2 domain, can directly interact 
with the EGF receptor in a ligand-dependent manner, and subsequently mediate the 
induction of c-Fos (Fu and Zhang, 1993; Silvennoinen et al., 1993). Although p i 13 
and p84 seem not to be involved in EGF signalling, the association of a different 
combination of p91 and other related protein(s) is a possibility, and might be a way to 
differentiate and maintain specificity between various ligands. The serum response 
element mediates c-Fos induction through stimuli that activate the MAPKs, and is 
recognised by the serum response factor. This is a ubiquitous transcription factor that 
forms a dimer and binds to the SRE promoting the recruitment of the ternary complex
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factor (TCF). The activity defined as TCF includes the proteins of the Ets-related gene 
family: p62TCF, Elk-1 and Sap-1. Following mitogenic stimulation, the candidate 
TCFs are rapidly phosphorylated within their carboxy-terminal region by specific 
MAPK subtypes, the ERKs (Zinck et al., 1993; Gille et al., 1995; Janknecht et al.,
1995). Although recent evidence would suggest that Elk-1 provides a potential 
convergence point for the ERK and SAPK signalling pathways, since SAPKa also 
efficiently phosphorylates the Elk-1 carboxy-terminal domain (Zinck et al., 1995). The 
MAPK-induced phosphorylation increases the transcriptional activity of the TCF, 
thereby resulting in increased c-Fos synthesis (reviewed in Karin, 1995). Interestingly, 
Rao and Reddy (1994) have introduce a novel concept that MAP kinase activators can 
also be non-kinase proteins, through their demonstration that Elk-1, apart from being a 
MAPK substrate, can also interact with MAPK to selectively enhance MAPK 
autophosphorylation and activation.
By comparison with c-Fos, the c-Jun promoter is much simpler, with its 
inducers operating through one major cis element, the c-Jun TRE. This differs from 
the AP-1 consensus TRE sequence by 1-base pair insertion, and due to this subtle 
change it is more efficiently recognised by c-Jun»ATF2 heterodimers than by 
conventional AP-1 complexes. Following exposure to stimuli that activate the JNK 
group of MAPKs, both c-Jun, discussed below, and ATF2 (Gupta et al., 1995) are 
rapidly phosphorylated, which stimulates their ability to activate transcription of c-Jun 
(reviewed in Karin, 1995).
The biologic function of c-Jun as a transcription factor is regulated by two 
distinct phosphorylation systems. The transcriptional potential of c-Jun is augmented 
by serine phosphorylations (Ser-63 and -73) in the amino-terminal transactivation 
domain, in response to signalling pathways that culminate in the activation of the 
MAPKs, all of which potentially phosphorylate c-Jun, albeit with varying efficacy 
(Minden et al., 1994; Derijard et al., 1994; Kyriakis et al., 1994). So far, the 
JNK/SAPKs are the only kinases found to efficiently phosphorylate these 
amino-terminal sites in c-Jun, and the mechanism underlying this high degree of 
substrate specificity most likely involves the interaction of the docking-site, located
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upstream of the Ser phosphorylations in c-Jun, with a region near the catalytic pocket 
of the MAPKs. The amino adds within this region are variable amongst all MAPKs, 
and the docking-site in c-Jun shows substrate specificity towards MAPKs of the JNK 
subtype, with JNK2 displaying a higher affinity for c-Jun than JNK1 (Kallunki et al.,
1994). In contrast, phosphorylation of three residues within the carboxy-terminus of 
c-Jun precludes DNA binding activity. The regulation of these phosphorylations is not 
certain, however, ERK1 and -2 have been shown to phosphorylate c-Jun at a carboxy 
Ser residue (Minden et al., 1994); and recent evidence suggests that phosphorylation 
of the Ser residues in the amino-terminus causes a conformational change in the c-Jun 
protein, stimulating the dephosphorylation of the carboxy-terminal sites, and 
consequently increasing DNA-binding (Papavassiliou et al.t 1995).
Hence, the transcriptional regulation of AP-1 activity is through the induction 
of both j c-fos and c-jun genes. The newly synthesised c-Fos and c-Jun proteins 
combine to form stable heterodimers, and a further increase in AP-1 activity is brought 
about by post-translational regulation of both c-Fos and c-Jun. Increased 
transactivation of c-Jun is through the phosphorylation of the amino-terminal serines 
by JNKs, in a similar manner to the phosphorylation of c-Jun when it is complexed 
with ATF2. The sequence surrounding the amino-terminal phosphoacceptors of c-Jun 
are also conserved in the carboxy-terminal activation domain of c-Fos, suggesting that 
c-Fos also undergoes phosphorylation. This presumably is brought about by the newly 
identified FRK protein (Deng and Karin, 1994). In the context of c-Jun*c-Fos 
heterodimers, phosphorylation of each protein makes a similar contribution to 
stimulation of transcription via AP-1. Thus, specificity is brought about by the 
formation of complexes involving members of the MAPK cascade and their substrates: 
ERKs to TCF proteins, JNK/SAPKs to c-Jun, and FRK to c-Fos, see figure 1.5, p34. 
There is evidence of another TGY containing MAPK, Mxi2, capable of dimerising 
with and phosphorylating the transcription factor binding Max (Cano and Mahadevan,
1995).
In addition to the differences in substrate specificities, the types of MAPKs that 
affect AP-1 activity differ in their responses to extracellular stimuli, discussed in
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section 1.2.2. The induction of the two components of the AP-1 complex through 
different and distinctly regulated members of the MAPK subtypes could ensure that 
AP-1 activity responds to a large spectrum of extracellular stimuli. It is also possible 
that through the divergent activation of ERKs and JNKs, different extracellular stimuli 
induce different types of AP-1 complexes (e.g. Jun»Jun homodimers versus Jun*Fos 
heterodimers) and thereby lead to activation of overlapping yet distinct sets of target 
genes.
1.6. Cellular differentiation versus proliferation.
Receptor tyrosine kinases are involved in signalling both cell proliferation and 
differentiation (van der Geer and Hunter, 1994). Numerous studies show that 
depending on the cellular context, the same receptor can signal proliferation or 
differentiation (reviewed in Marshall, 1995). For example, the fibroblast growth factor 
receptor signals differentiation in PC12 neuronal cells, whilst in fibroblasts stimulates 
proliferation. The response of PC12 cells to receptor tyrosine kinase activation has 
been extensively used as an experimental system to study proliferation versus 
differentiation. Treatment of PC12 cells with fibroblast growth factor (FGF), or nerve 
growth factor (NGF), leads to the differentiation of neurites, whereas treatment with 
EGF leads to a proliferative signal. Notable quantitative differences were found 
between these two pathways, namely that ERK activation is sustained for several 
hours following NGF stimulation, but it is short lived after EGF stimulation (Traverse 
et al., 1992). This may reflect differences in the down-regulation of the EGF receptor 
and the NGF receptor, TrkA, or the fact that the EGF receptor utilise both the 
Grb2-Sos complex and the Shc*Grb2-Sos complex to activate p21Ras, whereas TrkA 
stimulates She phosphorylation and the formation of Shc*Grb2-Sos complexes (Buday 
and Downward, 1993). However, there is much evidence to suggest that there is no 
specific pathway for differentiation (Marshall, 1995, and references therein). Whilst 
stimulation of the endogenous EGF receptor in PC12 cells leads to proliferation, 
overexpression of the EGF receptor induces differentiation and sustained ERK 
activation (Traverse et al., 1992). Furthermore, the appropriate mutations in the Raf
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phosphorylation sites of MKK1 demonstrate that interfering mutants block ligand 
activation of ERK and growth factor-induced PC12 differentiation, while the 
activating mutants induce neuronal differentiation in the absence of differentiating 
factors (Cowley et al., 1994). This has led to a model whereby the temporal activation 
of ERKs is sufficient for cells to enact proliferative or differentiation responses. This is 
also linked to the spatial distribution of the ERKs, since only sustained ERK activation 
in PC12 cells is associated with nuclear translocation. Transient activation will 
therefore have very different consequences for gene expression. However, it is not a 
requirement of this model that sustained activation of ERKs invariably leads to 
differentiation. In other cell types the converse might be true, so that receptor tyrosine 
kinase signalling depends both on the duration of MAPK activation and the cell 
context.
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Figure 1.5.
Three distinct MAP kinases contribute to induction of AP-1 activity.
The serum response element in the c-Fos promoter binds both the SRF and the TCF 
(which includes Elk-1, p62TCF and Sap-1). The TCF is phosphorylated by the ERKs, 
which consequently stimulates transcriptional activity, thus mediating c-Fos induction. 
JNK-mediates phosphorylation of ATF2 and c-Jun bound to the TP A responsive 
element in the c-Jun promoter, leading to c-Jun induction. The newly synthesised 
c-Fos and c-Jun proteins combine to form stable AP-1 heterodimers. A further 
increase in AP-1 activity is brought about by the JNKs and FRK, which phophorylate 
c-Jun and c-Fos respectively, on sites that augment their transcriptional activities. 
c-Fos is phosphorylated on many sites, although the number of sites attributable to 
FRK is presently unknown. Refer to text for details, Diagram taken from Karin, 
(1995).
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1.7. Protein phosphatases- regulators of signal transduction
As mentioned at the onset, receptors for a variety of hormones and growth 
factors, as well as the transforming proteins of certain acutely oncogenic retroviruses, 
possess intrinsic kinase activity, consistent with protein phosphorylation playing a 
major role in signal transduction. However, the sequence of events through which a 
signal is initially activated at the receptor tyrosine kinase and then amplified via a 
cascade of intracellular kinases to the nucleus, is only one dimension of the signalling 
response. This system must be tighdy regulated if a cell is to co-ordinate functions 
such as proliferation and differentiation, and the modulation of the protein 
phosphorylation state is realised through an interplay between protein kinases and 
protein phosphatases, two antagonistic, but integrated enzymes. Approximately two 
hundred protein kinases have been identified (Hunter, 1987). By comparison, the 
number of protein phosphatases is limited and does not equal the diversity of the 
protein kinases. Indeed, until recently, it was generally assumed that the kinase 
reaction was the key regulatory process for determining the level of phosphorylated 
proteins, and that the dephosphorylation reaction was an unregulated event: a "house 
keeping" function. There is now strong evidence that this is not the case, and protein 
phosphatases are recognised as playing a central role in regulating many cellular 
activities. Although, compared to the protein kinases, the role of phosphatases in 
transformation has remained obscure. At present, there are no known oncogenes that 
encode protein phosphatases, although dephosphorylation of an inhibitory tyrosine 
residue in the proto-oncogene c-Src is required for its functioning.
Protein phosphatases represent a diverse family of biological catalysts, and 
have been broadly classified according to amino acid specificity: the non-specific 
phosphatases, the serine/threonine (Ser/Thr) phosphatases, and the tyrosine (Tyr) 
phosphatases. However, this initial distinction is now complicated by the recent 
discovery of protein phosphatases with dual specificity towards both 
phosphoserine/threonine and phosphotyrosine. For purposes of introduction, each of 
the classes of protein phosphatase will be described together with their putative
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functions in signal transduction, specifically their interplay with the MAPK cascade, 
illustrated in figure 1.6, p58.
1.7.1. The non-specific phosphatases
This class includes proteins such as the alkaline and acid phosphatases, 
enzymes capable of hydrolysing both proteinaceous and non-proteinaceous (e.g. 
alcohols) phosphate monoesters. The non-specific phosphatases typically function in 
degradative or catabolic pathways and due to their wide distribution are believed to 
serve as "phosphate scavengers". In contrast to the other classes of phosphatase, and 
indeed the kinases, these diverse enzymes do not share amino acid sequence 
similarities with one another. Mechanistically, the alkaline phosphatases function 
through the formation of a covalent phosphoseryl intermediate, while phosphate ester 
hydrolysis by at least some acid phosphatases proceeds through a phosphohistidine 
intermediate (reviewed in Coleman, 1992).
1.7.2. Classification of serine/threonine phosphatases
In mammalian cells, biochemical characterisation has identified four major 
classes of Ser/Thr phosphatase, which are presently classified into two categories 
(reviewed in DePalaoli-Roach et a/., 1994; Walter and Mumby, 1993; Cohen, 1989). 
The type 1 phosphatases (PP1), preferentially dephosphorylate the p subunit of 
phosphorylase kinase, and are defined as containing a catalytic subunit that is inhibited 
by two small heat- and acid-stable proteins, termed inhibitor-1 (1-1) and inhibitor-2 
(1-2). While 1-1 is active as an inhibitor only after phosphorylation by the 
cAMP-dependent protein kinase; 1-2 is spontaneously active, with phosphorylation at 
Thr-72 inactivating 1-2. The type 2 phosphatases (PP2), specifically dephosphorylate 
the a  subunit of phosphorylase kinase, and are insensitive to 1-1 and 1-2. These 
enzymes are further subdivided into three distinct classes, PP2A, 2B, and 2C in a 
number of ways, but most simply by their dependence on divalent cations. Based on 
new insights into the molecular and biochemical properties of these enzymes, revision 
of the above scheme is now necessary. For example, the catalytic subunits of PP2A
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and PP2B share considerable sequence similarity with PP1, but not with PP2C. 
Moreover, recent studies have revealed an increasing number of novel phosphatases 
which structurally do not fit into any of the above four categories. These include 
mammalian PP4, also termed PPX (da Cruz e. Silva et al., 1988; Brewis et al., 1993), 
which is localised at centrosomes, and shows 45% and 65% identity to the PP1 and 
PP2A catalytic subunits, respectively. A furthemuclear phosphatase, PP5, shows less 
than 40% similarity to any known member (Chen et al., 1994b), and a novel 
membrane-anchored phosphatase, designated PP3, has also been described (Honkanen 
e ta l , 1991).
I.7.2.I. Serine/threonine phosphatase catalytic subunits
Molecular cloning has defined the primary structures of the phosphatase 
catalytic subunits which belong to a single gene family, except for PP2C. Four PP1 
and two PP2A, PP2B and PP2C catalytic subunit isoforms have been predicted from 
cDNAs isolated from mammalian sources. There is a high degree of structural 
information conserved not only among isoforms, but between different organisms; for 
example, the PP1 and PP2A catalytic subunits are more than 80% identical from yeast 
to mammals. This argues for a fundamental role of these enzymes in essential cell 
functions, and in support of this, these two classes of phosphatase represent more than 
90% of the activity present in most tissues examined. However, at present there are 
approximately twelve known Ser/Thr phosphatase catalytic subunits to counteract the 
vast numbers of Ser/Thr kinases so far identified (Hunter, 1987). Furthermore, protein 
phosphatases exhibit relatively broad specificity in vitro and the use of synthetic 
peptides as substrates has revealed litde about the determinants for phosphatase 
recognition. Do protein phosphatases simply display extremely broad specificity or do 
other factors impose a greater selectivity of function? A key point is that all Ser/Thr 
phosphatases characterised biochemically, with the exception of PP2C, are in fact 
multi-subunit enzymes. Increasing evidence has established that the non-catalytic 
subunits serve to regulate or specify the function of the catalytic moiety. The structural 
components of the four classes of Ser/Thr phosphatases are outlined briefly below.
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•PP1 There are four isoforms of the catalytic subunit of PP1 which are generated by 
alternative splicing. The free catalytic subunits have not been detected in cells, but are 
identified as parts of larger molecular complexes. Hence, heterogeneity of PP1 is 
generated by the combination of a similar catalytic component, the holoenzyme, with 
various accessory proteins which are responsible for regulating both the enzymatic 
activity and targeting of PP1 to specific subcellular locations. The catalytic isoforms 
are 90% identical and differ mainly at the carboxy-terminus of the protein, suggesting 
that this region may be involved in the interaction with the different regulatory 
proteins. At least four molecular forms of PP1 have been identified: (a) the ATP-Mg- 
dependent phosphatase for which 1-2 is the regulatory component, (b) the 
glycogen/sarcoplasmic reticulum-associated phosphatase, (c) the myosin-associated 
phosphatase and (d) a nuclear phosphatase which is associated with chromatin. This 
compartmentalisation of the holoenzymes means that specific association of the 
regulatory subunits with distinct isoforms cannot be ruled out. Beullens and 
co-workers (1992), isolated a nuclear inhibitor of PP1, N1PP1, which associates with 
the catalytic subunit to form a heterodimeric holoenzyme. Phosphorylation of NIPP1 
by the cAMP-dependent protein kinase renders the protein less effective and decreases 
its affinity for the catalytic subunit (Beullens et al., 1993). This effect of 
phosphorylation is opposite to that seen with I-1. In the cytosol PP1 interacts with 1-1 
and 1-2, preventing illicit dephosphorylation events; however, the function of 1-2 is not 
simply that of an inhibitor and may be a regulatory subunit acting as a chaperone to 
fold PP1 into its native conformation (Alessi et al., 1993b).
•PP2A The enzyme PP2A is mainly cytosolic, and has been isolated in a trimeric 
form composed of a catalytic subunit (C), an accessory subunit (A) and one of three 
regulatory subunits (B). Dimeric A/C forms of PP2A have frequently been reported 
but there is increasing evidence that these represent artifacts generated from the 
trimeric form due to dissociation and/or proteolysis of the B-subunit (Cohen, 1989). 
Heterogeneity of PP2A phosphatases is accomplished by the binding of one of the 
three B-subunits to the AC core, and by the existence of multiple isoforms of all three 
of these components. PP2A substrate specificity is influenced by the subunit complex,
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and experimental approaches point to a critical role for the B-subunits in determining 
PP2A function. Similar to PP1, a nuclear, chromatin-associated form of PP2A has 
been identified (Jakes et al., 1986).
•PP2B This enzyme was initially isolated as an activity that dephosphorylated the a  
subunit of phosphorylase kinase, and was subsequently shown to be a calcium- 
dependent calmodulin-binding protein showing striking resemblance to that of 
calcineurin (Stewart et al., 1982). Further experiments confirmed that caldneurin was 
a calciunVcalmodulin-regulated protein phosphatase. PP2B is found predominantly in 
nervous tissue, and as is the case with PP1 and PP2A, there are multiple isoforms of 
the catalytic subunit-A, which contains the calmodulin-binding domain, whilst the 
regulatory B-subunit is the calcium-binding component.
•PP2C PP2C is unique in that it is monomeric comprising of only a catalytic subunit, 
which requires magnesium for half-maximal activity, and is insensitive to many 
phosphatase inhibitors (Cohen, 1989). It is located mainly in the cytosol, and genes 
encoding two isozymes of PP2C have been identified in mammals, the sequences of 
which are unrelated to the catalytic subunits of other types of phosphatases.
1.7.3. Involvement of serine/threonine phosphatases in growth control
Although tyrosine phosphorylation has a special significance for the events 
proximal to the receptor, much of the intracellular signalling is mediated by Ser/Thr 
phosphorylation. Hence, the Ser/Thr phosphatases are important candidates for major 
regulatory roles in the control of signal transduction. However, PP1, PP2A, and PP2C 
have broad and overlapping specificities in vitro, and account for virtually all 
measurable activity in tissue extracts towards a variety of phosphoproteins. Their 
precise functions in vivo have consequently remained enigmatic, although evidence 
implicating that the Ser/Thr phosphatases must be directly involved in growth control 
is provided by the demonstration that okadaic acid, a potent inhibitor of PP1 and 
PP2A (Bialojan and Takai, 1988), behaves as a tumour promoting agent (Suganuma 
et al., 1988). Tentative roles for Ser/Thr phosphatases in the MAPK signal 
transduction cascade have been postulated, since several of the enzymes in this
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pathway are themselves regulated by phosphorylation. In this regard, PP2A has been 
shown to dephosphorylate and inactivate both MKK and MAPK in vitro (Dent et al., 
1992; Kyriakis et al., 1992), whilst Raf-1 and p90Rsk are also dephosphorylated by 
PP2A in vitro (Kovacina et al., 1990, Sturgill et al., 1988), refer to figure 1.6, p58. 
Phosphatases may also influence the final targets of signal transduction pathways: the 
transcription factors, whereby changes in phosphorylation could alter their nuclear 
translocation, their DNA binding activity, or their transactivation properties. Evidence 
that PP2A might be involved in the control of c-Jun phosphorylation was provided by 
Alberts et al. (1993), who demonstrated that gene expression controlled by the TRE 
was stimulated upon microinjection of the catalytic subunit and AC form of PP2A. 
This is suggestive that PP2A may dephosphorylate the inhibitory carboxy-terminal 
residues of c-Jun, thus promoting DNA binding to the TRE sequence. Biochemical 
studies have suggested that Ser/Thr phosphatases are involved in cell cycle regulation 
through the control of Cdc2 kinase activity (Walter and Mumby, 1993). The 
identification of a PP2A-like activity, INH, in extracts of Xenopus oocytes, has led to 
the demonstration that INH appears to target Thr-161, thus inhibiting the formation of 
active cyclin-Cdc2 complexes (Lee et al., 1991). So, whilst there is evidence for many 
substrates in vitro, it is extremely difficult to prove that the same proteins are 
substrates in vivo. A future direction will be to isolate or develop inhibitors that are 
specific for individual phosphatases. Presumably, the subcellular localisation of the 
phosphatases will confer important regulatory properties upon them, and this concept 
is best established for PP1. The holoenzyme of PP1 associates with regulatory subunits 
that target the phosphatase to particular locations, enhancing its activity towards 
certain substrates, for example the glycogen-bound enzyme (PP1G), and the 
myofibrillar form (PP1M), found in skeletal muscle. The activities of the Ser/Thr 
phosphatases are also controlled by second messengers, which adds a further temporal 
dimension to their regulation and potential substrates. As previously mentioned, PP2B 
is dependent on calcium and calmodulin, while PP1 is controlled in a variety of ways 
that depend on the form and the tissue. PP1 can be inhibited by cAMP through the 
PKA-catalysed phosphorylation of 1-1. Furthermore, phosphorylation of PP1G by
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PKA promotes translocation of the catalytic subunit from glycogen particles to the 
cytosol, thus inhibiting the dephosphorylation of glycogen-metabolising enzymes. PP1 
can also be activated indirectly by calcium through the ability of PP2B to 
dephosphorylate 1-1. Recent studies by Wang and co-workers (1995) have 
demonstrated that the phosphorylation of 1-2, which results in activation of the 
ATP-Mg-dependent PP1, is mediated by MAPK. These findings suggest that MAPK 
may be the physiological kinase that activates cytosolic PP1 in growth factor 
stimulated cells. This is particularly interesting when it is considered that glycogen 
synthase kinase-3 (GSK-3), which is presently assumed to be the kinase responsible 
for activating the ATP-Mg-dependent PP1, is inactivated following insulin and growth 
factor stimulation, when PP1 is rapidly and transiently activated. In summary, it is 
believed that the regulatoiy subunits will play the important role in determining the 
properties and substrates of the Ser/Thr phosphatases, and hence their physiological 
functions.
1.7.4. Protein tyrosine phosphatases
Protein phosphorylation on tyrosine residues is the initial stimulus at the 
plasma membrane in eukaryotic signalling, and plays a pivotal role in a range of 
cellular pathways. The protein tyrosine kinases constitute a well characterised family 
of both cytoplasmically localised as well as transmembrane enzymes, and their function 
in signal transduction has been extensively studied. Whilst the increase in number and 
structural diversity of the protein tyrosine phosphatases (PTPs) is well recognised, in 
comparison, their precise involvement in signal transduction cascades is less well 
understood. In spite of the fact that the majority of phosphorylation in the cell is 
associated with serine/threonine residues, the greatest number of protein phosphatases 
identified so far belong to the phosphotyrosine-specific class. The first evidence for the 
existence of the phosphotyrosyl dephosphorylation system came from in vitro studies 
with the A431 human epidermoid carcinoma cells, which are high in EGF receptor 
phosphotyrosyl kinase activity (Ushiro and Cohen, 1980). These experiments 
demonstrated that when A431 cell membrane proteins were labelled at tyrosine
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residues with [y-^pjATP in the presence of EGF, a slow and time-dependent release 
of [32p]pi from the labelled proteins could be observed, suggesting that an activity in 
the membrane preparation was responsible for dephosphorylating phosphotyrosyl 
proteins (Brautigan et al., 1981). The presence of PTPs in intact cells was deduced 
from experiments using tumour viruses with temperature-sensitive transforming 
proteins. At the permissive temperature, cells infected with Rous sarcoma virus rapidly 
incorporate phosphate into tyrosine residues of proteins. However, when the 
transformed cells are shifted to nonpermissive temperatures, the degree of cellular 
Tyr(P) declines to the basal (untransformed) level, presumably due to the activities of 
cellular PTPs (Sefton et al.t 1980). These important observations were followed by 
numerous attempts to identify and characterise the PTPs, which now consist of over 
40 enzymes, most of which have been cloned using recombinant techniques based on 
the sequence homology of the catalytic domain (for extensive reviews see Walton and 
Dixon, 1993; Charbonneau and Tonks, 1992; Brautigan, 1992). Without exception, all 
PTPases contain an active site signature motif, (1/V)HCXAGXGR(S/T)G, located 
within the catalytic domain. This sequence has an absolutely conserved nucleophilic 
cysteine residue that is essential for PTP activity, specifically involved in the formation 
of a phosphoenzyme reaction intermediate. PTPase catalysis has been clarified through 
the elucidation of the crystal structures of the Yersinia PTPase and the mammalian 
PTP1B (Stuckey et a/., 1994; Barford et al., 1994). Although these two enzymes 
show only 20% sequence identity, it is clear from crystalline studies that these 
molecules share close similarities in secondary and tertiary structure. Biochemical 
characterisation of PTPases has broadly classified them into two families: 
transmembrane or cytosolic.
Most transmembrane PTPs contain two cytoplasmic catalytic PTPase domains, 
the most proximal to the membrane exhibiting the majority of the PTP activity. 
However, in some cases the second domain also possesses detectable, but low PTP 
activity (Wang and Pallen, 1991), and it is possible that the presence of two catalytic 
domains may allow for differential substrate specificity within the same enzyme. 
Alternatively, the second domain may purely function to regulate the activity of the
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first domain, or possibly associate with second tyrosine-phosphorylated proteins in a 
manner analogous to an SH2 domain. Whether the extracellular domain of 
transmembrane PTPs can bind ligands, which potentially modulate PTP activity, 
perhaps by inducing oligomerisation of the PTP-receptors, remains to be determined. 
A subset of receptor-like PTPases have extracellular domains that share sequence 
similarities with the cell adhesion molecules (CAMs), with the implication that these 
PTPases may participate in cell-cell interactions. The best characterised of these are 
the mammalian phosphatases PTPp. and PTPk, which both display a single 
extracellular immunoglobulin-like domain and four fibronectin type HI repeats. 
Expression of these phosphatases in insect cells mediates cell-cell aggregation via 
"hemophilic" interactions (Sap et al., 1994; Gebbink et al., 1993). Since cellular 
proliferation is frequently associated with tyrosine phosphorylation, it is interesting 
that cell confluence often results in cell quiescence, with an increase in membrane 
PTPase activity (Pallen and Tong, 1991).
The cytosolic PTPs are further divided into subfamilies, based on their 
structural features in the non-catalytic regions which serve to localise these enzymes 
within the cell, which, as for all enzymes, offers a powerful means of controlling 
activity by limiting available substrates. Examples include PTP IB and the T-cell 
PTPase, which have intracellular localisation signals at their carboxy-terminus. This 
targets PTP1B to the endoplasmic reticulum (Frangioni et al., 1992), whilst expression 
of the carboxyl-truncated form of the T-cell PTPase produces multinucleated cells, 
presumably through a failure in cytokinesis, concomitant with a reduced growth rate 
(Cool et al., 1992). An intimate association between PTPs and focal adhesion is 
supported by the finding that the related PTPs: PTPH1, PTPMEG1, and PTPD1 
contain regions of homology to cytoskeletal proteins, such as erzin and talin (Moller 
et al., 1994 and references therein). A further motif identified in cytosolic PTPases is 
the SH2 domain, which has great implications for PTPase activity towards growth 
factor signalling pathways, discussed below. In line with this, a PTP has been identified 
which shows homology with the basic domains of the transcription factors Fos and Jun 
(Swarup et al., 1991), implicating a nuclear signalling function for this phosphatase. A
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full accounting of the protein tyrosine phosphatases is beyond the scope of this 
introduction, and consequently only examples implicated in RTK pathways will be 
discussed below.
1.7.5. Physiological roles of tyrosine phosphatases in signal transduction
Since de-regulated PTKs have been found to be encoded by oncogenes, then 
conceptually, PTPs are potential tumour supressors or anti-oncogenes. Indeed, 
inactivating mutations in genes encoding PTPs may contribute to the aberrant tyrosine 
phosphorylation associated with certain neoplastic conditions. Considerable progress 
has been made in determining the chromosomal localisation of genes encoding PTPs, 
with the aim of correlating map positions with sites of abnormality in human disease. 
Most notable is the gene for PTPy on chromosome 3p21, a loci frequently altered in 
renal and small-cell lung carcinomas (Laforgia et al., 1991). Several studies have 
reported the inhibitory effects of PTPs on cellular transformation. Overexpression of 
PTP1B within a tissue culture system has been demonstrated to revert the transformed 
phenotype of w-src and suppress subsequent transformation by both the oncogenes neu 
and \-erbB2 (Woodford-Thomas et al., 1992; Brown-Shimer et al., 1992). Evidence 
that PTPs function as negative-regulators of cellular proliferation is supported by the 
observations that PTPase inhibitors, such as sodium vanadate, are able to transiently 
substitute for growth factors and induce mitogenic responses (Klarlund et al., 1985). 
However, it is apparent that some PTPs are able to promote signalling responses 
through the activation of members of the Src family of PTKs. These kinases have an 
inhibitory tyrosyl phosphorylation in their carboxyl termini, dephosphorylation of 
which promotes kinase activity. A specific example is illustrated in T-cell receptor 
signalling, which is mediated by the receptor PTP, CD45, also known as leukocyte 
common antigen (Trowbridge and Thomas, 1994). The Src-related PTKs in the 
hematopoietic system, p56^c^ and p59*yn, are associated with the T-cell receptor, and 
have been implicated as the targets of CD45 in this signalling response.
The interplay between PTKs and PTPs has been strikingly illustrated by the 
discovery of a subfamily of cytoplasmic PTPs containing SH2 domains. PTP 1C (Shen
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et al., 1991), also termed SH-FIP1 (Plutzky et al., 1992), HCP (Yi et al., 1992) or 
SHP (Matthews et al., 1992), is a hematopoietic cell PTPase characterised by two 
amino-terminal SH2 domains, however its expression has also been observed in breast 
cancer epithelial cell lines. This phosphatase has been shown to interact with 
autophosphorylated EGF receptor in vitro (Shen et al., 1991), mediated via the most 
amino-terminal SH2 domain. Consistent with PTP 1C being preferentially expressed in 
the hematopoietic system, is the finding that this phosphatase transiently associates 
with the activated Kit and IL-3 receptors in myeloid cells. Homozygously carried 
defects in the murine homolog of PTP 1C lead to the motheaten phenotype, whereby 
mice develop systemic autoimmune disease, suggestive that PTP 1C protein normally 
acts to restrict the proliferation of hematopoietic cells (Tsui and Tsui, 1994). Perhaps 
this is through the phosphatase antagonising the effects of growth factors which 
stimulate the Kit and IL-3 receptors. A second phosphatase to be cloned that contains 
SH2 domains is Syp (Feng et al., 1993), also variously called SH-PTP2 (Freeman 
et al., 1992), PTP1D (Vogel et al., 1993), and PTP2C (Ahmad et al., 1993). This 
phosphatase is expressed ubiquitously, and growing evidence implicates that it is 
involved with growth factor signalling and in MAPK activation, playing a positive 
regulatory role as opposed to that of PTP1C. Syp stably associates through its SH2 
domains to the activated PDGF- and EGF receptors (Kazlauskas et al., 1993; Vogel 
et al., 1993). In addition, Syp also binds to the insulin receptor substrate IRS-1 
(Noguchi et al., 1994), and overexpression of a catalytically inactive Syp blocks both 
the EGF and insulin-induced MAPK induction and c-Fos transcription (Zhao et al., 
1995; Noguchi et al., 1994). The SH2 domains appear to not only mediate the 
targeting of Syp, but also regulate its activity, since unoccupied SH2 domains maintain 
phosphatase activity in a repressed state. It has been demonstrated that Syp becomes 
tyrosine phosphorylated within the carboxy-terminus following stimulation with PDGF 
and EGF, although this is not dependent upon Syp binding with the receptor. As 
regards the PDGF receptor, this induced phosphorylation creates a binding site for the 
SH2 domain of Grb2, see figure 1.6, p58 (Li et al., 1994; Bennett et al., 1994). This 
indicates that Syp can potentially act as an adaptor between activated PDGF receptor
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and the Grb2/Sos complex, thereby stimulating Ras and the MAPK pathway. It would 
seem that while the EGF receptor can directly bind Grb2, or indeed function through 
Shc«Grb2 (Buday and Downward, 1993), the PDGF receptor binds Grb2 through 
complexing with Syp, indicating that different growth factor receptors can interact 
with the same downstream signalling molecule by different mechanisms. However, Syp 
may not function as an adaptor protein that couples IRS-1 to the Grb2/Sos complex, 
since Syp is not phosphorylated on tyrosine residues following insulin treatment 
(Noguchi et al.t 1994). In this system, it is possible that the phosphatase functions to 
down-regulate GAP activity; thus the inactivation of GAP would result in a relative 
increase in Ras activity. The importance of SH2-containing PTPases is further 
underscored by recent developmental studies. The Drosophila gene, corkscrew (csw), 
is the homolog of Syp, and is required maternally as a positive signal transducer in 
concert with D-raf, downstream from the Torso receptor tyrosine kinase (Perkins 
et al., 1992). Additionally, Syp is expressed maternally in Xenopus during 
embryogenesis, acting as a positive component in FGF signalling downstream of the 
FGF receptor and upstream of MAPK (Tang et al., 1995). However, not all the 
phosphatases which are implicated in regulating components of the MAPK cascade 
necessarily possess SH2 domains. RPTPa is a transmembrane PTP which is tyrosine 
phosphorylated in vivo within the carboxy-terminus of the protein, which subsequently 
creates a binding site for Grb2. den Hertog and colleagues (1994) have demonstrated 
that RPTPa associates with Grb2 in immunoprecipitates from fibroblast cells, 
however, Sos is not detected in these complexes. The absence of Sos means that Grb2 
cannot activate the Ras pathway, suggesting that RPTPa may play a negative role in 
Ras signalling by sequestering Grb2. The mechanism by which RPTPa is constitudvely 
phosphorylated on tyrosine is at present, not fully understood. Interestingly, RPTPa 
can show oncogenic potential, as demonstrated by its ability to catalyse the activation 
of c-Src, which in the same cell system has the effect of inducing the activation of 
MAPK and c-Jun transcription, illustrated in figure 1.6, (Zheng and Pallen, 1994). The 
corollary is that PTPs can apparently function as both negative and positive growth
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stimulators, thus a critical balance must exist in the cell between these activities, and 
those of protein kinases, if a cell is to maintain essential growth control
1.7.6 A novel subfamily: The dual specific protein phosphatases
A increasing number of proteins have recently been identified which are able to 
dephosphorylate both phospho-serine/threonine and -tyrosine residues (reviewed in 
Keyse, 1995). The prototype for these "dual specific" phosphatases is encoded by the 
HI gene of the vaccinia virus, which expresses a protein during the late stage of viral 
infection. VH1 is a small, 20 kDa PTP, which apart from the presence of the PTPase 
active site signature motif, is only distantly related to the eukaryotic tyrosine 
phosphatases. Whilst the precise physiological function of VH1 is unknown, it does 
however efficiently dephosphorylate both phosphotyrosine- and phosphoserine- 
containing substrates in vitro (Guan et a/., 1991). At the present time the rapidly 
expanding VHl-like family of phosphatases includes genes isolated from the budding 
yeast S. cerevisiae, such as YVH1; a gene dramatically induced upon nitrogen 
starvation, and the inactivation of which correlates with a decrease in growth rate 
(Guan et al., 1992). Doi and colleagues, (1994), have also identified MSG5, a dual 
specific phosphatase required for the yeast mating pheromone pathway. Genetic 
studies have placed MSG5 downstream of STE7, a MAPKK homolog, and have 
demonstrated that it directly inactivates the MAP kinase, FUS3. Further VHl-like 
phosphatases have additionally been identified in baculo- and orthopox-viruses (Hakes 
et al., 1993; Sheng and Charbonneau, 1993), and importantly, a number of genes have 
been isolated from mammalian tissues, including VHR, the VH1-related human 
Ser/Tyr phosphatase (Ishibashi et al., 1992). These are discussed more fully below in 
context with the MAPKs. Since the dual specific phosphatases display amino acid 
sequence identity to the PTPases across the active site, it is not surprising that they 
also utilise a titiol phosphate intermediate during the catalytic reaction (Zhou et al.,
1994); however, outside of this region the dual specific phosphatases show limited 
sequence identity with the PTPs.
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A further protein demonstrated to dephosphorylate both tyrosine and threonine 
residues is Cdc25, which is involved in controlling cell entry into mitosis. As 
previously mentioned, passage through successive phases of the cell cycle is controlled 
by Cdks, whose activity is regulated foremost by the association with the ancillary 
proteins, the cyclins, and also by physical association with Cdk inhibitors. Cdk activity 
is additionally regulated by phosphorylation, and Cdc25 phosphatases, although 
weakly related to the main family of protein phosphatases, have been shown to 
specifically dephosphorylate Thr-14 and Tyr-15 of Cdc2/cyclin B (Gautier et al.t 1991; 
Kumagai and Dunphy, 1991). Cdc25 is otherwise rather inefficient against 
phosphotyrosine and -threonine substrates in vitro. Mammalian cells have three related 
Cdc25 genes: Cdc25A, -B, and -C, which appear to interact with different cyclin-Cdk 
complexes (Galaktionov et al., 1995a). Cdc25B and -C are predominantly expressed 
in G2, whilst Cdc25A appears not to be a mitotic regulator, functioning at the Gl/S 
transition of the cell cycle. The catalytic activity of Cdc25C is stimulated 4- to 5-fold 
in the presence of cyclin B at the onset of mitosis, due to an auto-amplification loop. 
Cyclin B possesses a region known as the P box, which is a necessary requirement for 
hypophosphorylated Cdc25C to recognise and bind cyclin B and dephosphorylate 
Cdc2, albeit at a low efficiency (Zheng and Rudderman, 1993). The activated cyclin 
B/Cdc2 complex then phosphorylates Cdc25C, which increases Cdc25C activity 
further activating Cdc2 kinase. Such positive feedback loops are essential to create 
sharp, rapid boundaries between cell cycle phases. Hoffman and co-workers, (1994), 
have demonstrated that Cdc25A plays a  crucial role early in the cell cycle, and is 
phosphorylated by cyclin E/Cdk2, however, in this instance, the involvement of a 
positive feedback loop is as yet unknown. An interesting possibility is that activated 
Cdc25A is the initial phosphatase that activates cyclin B/Cdc2, which then 
subsequendy phosphorylates Cdc25C to establish the hyperactivation of cyclin 
B/Cdc2. It has recently been shown that the carboxyl-terminus of Raf-1 forms a tight 
association with Cdc25 A at the plasma membrane, phosphorylating and stimulating the 
phosphatase activity both in somatic cells, and in Xenopus oocytes (Galaktionov et al., 
1995a). Cdc25 phosphatases also show oncogenic co-operation with either oncogenic
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Ras mutants or pRb deletion mutants, indicating that Cdc25 phosphatases may 
promote transformation (Galaktionov et al., 1995b). In support of this, Cdc25B is 
found to be highly expressed in human primary breast cancers. This provides a strong 
link between mitogenic signalling and the cell cycle, which is further substantiated by 
the demonstration that the 14-3-3 proteins, which function as potential co-activators 
of Raf-1, also physically associate with Cdc25A both in vivo and in vitro (Conklin 
et al., 1995). Withdrawal of growth factors in G1 preceding the "control" point could 
therefore abort the cell cycle via the rapid inactivation of Cdc25A, whilst DNA 
damage and inhibitory factors, such as TGFp, inhibit the cell cycle through the 
induction of the Cdk inhibitors. Studies from two individual groups have identified an 
additional dual specificity phosphatase by virtue of its association with certain Cdks, 
referred to as Cdil (Gyruris et al., 1993) or KAP (Hannon et al., 1994). This enzyme 
contains a single copy of the PTPase active site motif, but does not share sequence 
identity with any known phosphatase beyond this catalytic core, a property shared by 
Cdc25. Presumably this phosphatase will play a direct role in cell cycle regulation, and 
may represent yet another subfamily of the duaLspecific phosphatases.
I.7.6.I. The mammalian MAP kinase phosphatases
The first mammalian dual specific phosphatase was isolated from skin 
fibroblasts, as part of a study to identify cDNAs corresponding to genes induced by 
oxidative stress. This led to the characterisation of a novel complementary DNA 
(CL100), which corresponds to a mRNA of approximately 2.4 kb, and is highly 
inducible by both oxidative stress (including hydrogen peroxide, menadione and 
ultraviolet A radiation), and heat shock (Keyse and Emslie, 1992). CL100 shows 
analogous structural features to the non-receptor PTPs, significantly VH1, and indeed, 
recombinant protein expressed in bacteria rapidly hydrolyses p-nitrophenol phosphate 
(pNPP), a chromogenic molecule related to phosphotyrosine. This enzyme activity is 
ablated in the presence of the phosphotyrosine inhibitor sodium vanadate. The 
similarity between CL100 and VH1 is across the catalytic core only, however, a 
database search demonstrated that the amino acid sequence of CL100 is 96.5%
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identical to that of 3GH134, an immediate early gene isolated from the mouse. 
Immediate early genes constitute the primary genomic response to mitogenic 
stimulation, and are rapidly induced even in the presence of protein synthesis 
inhibitors. This superinduction by protein synthesis inhibitors is manifested in at least 
three ways: i) mRNA stabilisation, ii) activation of intracellular signalling cascades, 
iii) interference with transcriptional down-regulation (Mahadevan and Edwards, 1991). 
The mitogenic stimulation of 3CH134 in fibroblasts is rapid and transient, with 
transcription reaching a peak level at 20 minutes, accumulating during the G0/G1 
transition. Consistent with these kinetics, synthesis of 3CH134 protein peaks at 1 hour 
following serum stimulation and is barely detectable by 3 hours, with an estimated 
half-life of 40-60 minutes (Charles et al., 1992). Subsequently, 3CH134 was identified 
as the mouse homolog of CL100, a gene which implicated for the first time the 
involvement of tyrosine phosphorylation in the cellular response to stress. Its isolation 
as an immediate early gene led to the proposal that mitogenic signalling may be linked 
to the stress response in mammalian cells. Further groups also identified the murine 
homolog, and it is now known variously as 3CH134, ERP (externally-regulated 
phosphatase, Noguchi et al., 1993), and MKP1 (MAP kinase phosphatase, Sun et al., 
1993). In contrast to VH1, CL100 protein shows no measurable catalytic activity 
towards several model proteins modified on either tyrosine or serine/threonine (Alessi 
et al., 1993a), whilst 3CH134 protein demonstrates only a weak intrinsic PTPase 
activity towards phosphotyrosine substrates, with no detectable dephosphorylation of 
phosphoserine and -threonine residues (Charles et a/., 1993). However, several studies 
confirm that CL100/MKP-1 potently, and specifically inactivates recombinant ERK2 
in vitro by the concomitant dephosphorylation of both the activating threonine and 
tyrosine residues (Alessi et al.y 1993a; Zheng and Guan, 1993; Sun et al., 1993). 
CL100 is capable of dephosphorylating either phosphorylated residue in the absence of 
the other, and is active towards both the ERK isoforms, -1 and -2, isolated from NGF- 
stimulated PC12 cells. In addition, CL100 suppresses the oncogenic Ras-induced 
activation of MAPK in Xenopus oocytes, a cell-free system where signalling pathways 
are intact. All of the above activities are abolished by mutagenesis of the highly
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conserved cysteine within the phosphatase active site (Alessi et al., 1993a). Sun and 
co-workers (1993), additionally demonstrated that the transient transfection of MKP-1 
in Cos cells leads to the selective dephosphorylation of ERK2, and blocks ERK2 
activation by serum, oncogenic Ras, and activated Raf. In this regard, the kinetics of 
inactivation of ERK2 coincide with the appearance of newly synthesised MKP-1, and 
the protein synthesis inhibitor cycloheximide leads to the persistent activation of 
ERK2. Interestingly, a catalytically inactive mutant of the phosphatase, Cys-258-Ser, 
physically complexes with activated ERK2 and leads to a sustained serum-induced 
phosphorylation of the MAPK. Presumably such a specific association of the MAPK 
with the dominant, negative phosphatase blocks any further dephosphorylation by 
endogenous phosphatases. Additional experiments using actinomycin D and antisense 
oligonucleotides targeted to MKP-1, also demonstrate that MKP-1 regulates ERK 
activity in vascular smooth muscle cells (Duff et al., 1995). These studies suggest that 
the cell maintains control over RTK signalling cascades by the ultimate induction of an 
immediate early gene, CL100, which attenuates the signalling response by 
dephosphoryladng MAPK. Promoter analysis of the CL100 gene indicates that an 
800 bp region flanking the transcriptional initiation site is sufficient to confer 
transcriptional response to serum and TPA stimulation, and located within this region 
are two CREs (cAMP response element, binding CREB/AFT proteins), and one TRE, 
binding AP-1 dimers, (Kwak et al., 1994). In contrast to other immediate early genes, 
an SRE site has not yet been identified. The link between CL100 and cellular 
proliferation is reinforced by the observation that de-regulated expression of ERP in 
NIH 3T3 cells has a negative effect on cell growth (Noguchi et al., 1993).
Following these observations, a focus of research has identified an increasing 
number of dual specific phosphatases (see Table 1, p54), demonstrating absolute 
substrate specificity towards the MAP kinases both in vitro, and in vivo. At present it 
is not known whether each of these phosphatases shows specificity for particular 
MAPK isoforms, however, considering that there are distinct MAPK kinases, it is 
likely that the phosphatases will in turn, be specific for the MAPKs. The dual 
specificity phosphatase family now includes PAC-1, identified as a mitogen-induced
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tyrosine phosphatase isolated from T-cells, which is predominantly expressed in 
hematopoietic tissues (Rohan et al., 1993). PAC-1 is localised to the nucleus, and has 
subsequently been shown to be a physiologically relevant MAPK phosphatase, specific 
for Thr and Tyr residues (Ward et al., 1994). Other more recently identified dual 
specific phosphatases include HVH3 isolated from human placenta (Kwak and Dixon, 
1995), B23 isolated from human epithelial cells (Ishibashi et al., 1994), HVH2 also 
isolated from human placenta (Guan and Butch, 1995), and MKP-2 cloned from rat 
PC12 cells (Misra-Press et al., 1995). These multiple dual specific phosphatases 
exhibit some similar features: that is they are specific Thr/Tyr phosphatases for 
MAPK, and their expression is induced by both mitogenic and stress related pathways. 
However, these phosphatases have distinct tissue distribution profiles, which may 
dictate unique roles for the members of this family in the regulation of MAPKs, and 
might reflect their co-expression with certain MAPK isoforms. For example, PAC-1 is 
predominantly expressed in hematopoietic tissue. Furthermore, MKP-2 has been 
demonstrated to co-localise with ERK1 in specific areas of the brain where MKP-1 is 
not expressed (Misra-Press et al., 1995; Kwak et al., 1994). The precise function of 
MAP kinase in post-mitotic neuronal cells is unclear, however, in situ hybridisation 
has demonstrated that in the adult brain, erp (MKP-1) transcripts are also primarily 
localised in postmitotic, terminally differentiated cells (Carrasco and Bravo, 1993). 
Thus, it would appear that there is a strong correlation for erp expression in cellular 
differentiation. The subcellular compartmentalisation of the MAPK phosphatases will 
also determine their substrate specificity, and immunofluorescence studies have 
demonstrated that CL100, PAC-1, HVH2 and HVH3 all localise to the nucleus 
(Sneddon and Keyse, unpublished; Rohan et al., 1993; Guan and Butch, 1995; Kwak 
and Dixon, 1995). In addition, MAPK also translocates to the nucleus under certain 
conditions (Seth et al., 1992), and it has been suggested that the duration of MAPK 
activation serves to determine the biological response to growth factor stimulation, 
discussed in section 1.6. Perhaps then, it is not so coincident that the MAPK 
phosphatases are differentially regulated in response to mitogens and cellular stress, 
also demonstrating different kinetics of induction. Although all the dual specific
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phosphatases identified to date behave as immediate early genes, HVH3 is 
up-regulated for 6 hours, in contrast to the more transient activation of CL100 (Kwak 
and Dixon, 1995). Misra-Press and co-workers (1995), have also observed that serum 
stimulation of MKP-2 is biphasic, whilst NGF, which sustains the level of active 
MAPK for a longer duration than EGF, results in a prolonged, elevated induction of 
both MKP-2 and-1.
The strict substrate specificity of the CL 100-like phosphatases is reminiscent to 
that of the Cdc25 genes. Besides the PTPase catalytic motif shared by these two 
families, the dual specific phosphatases also contain the GH2 domains (Cdc25 
homology 2), which are regions that flank the Cdc25 catalytic domain (Keyse and 
Ginsburg, 1993). However, in the dual specific phosphatases, the catalytic domain is 
situated at the C-terminus and not at the N-terminus where the CH2 domains are 
found. Whether these CH2 are functional has yet to be proven, but they have been 
speculated to either increase substrate selectivity or to be involved in localising 
proteins to nuclear or cytoskeletal locations (Kwak et al.t 1994).
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Table 1.
Properties of mammalian dual specific protein phosphatases
Gene and Source Size Remarks
References (amino acid ( t  = highest expression)
______________________ _________  k i l o b a s e s ) ______________________
CL100
Keyse and Emslie, '92 
Alessi et al., 1993a 
Zheng and Guan, 1993
Human 367 aa 
2.4 kb 
mRNA
Inducible by cellular stress and growth 
factors, expression fairly ubiquitous and 
independent of protein synthesis. Substrate 
specificity for MAPK both in vivo and in 
vitro.
3CH134/MKP-
1/Erp
Charles et al., 1993 
Sun et al., 1993 
Noguchi eta l., 1993
M ouse 367 aa 
2.4 kb 
mRNA
Mouse CL 100 homolog. Substrate specificity 
towards MAP kinases both in vitro and 
in vivo.
PAC-1
Rohan eta l., 1993 
Ward eta l., 1994
Human
and
M ouse
314 aa 
2.4 kb 
mRNA
Mitogen inducible, localised in the nucleus. 
Hematopoietic cell specific, with activity 
towards MAPK both in vitro and in vivo. 
Closely related to CL 100.
VHR
Ishibashi et al., 1992
Human 185 aa Activity towards Tyr and Ser phosphorylated 
substrates in vitro.
MAPK specificity unknown.
B23
Ishibashi et al., 1994
Human 397 aa 
2.5 kb 
mRNA
Induced by serum and heat shock, with 
similar kinetics to CL 100.
In vitro specificity towards MAPK.
HVH2
Guan and Butch, 1995
Human 394 aa 
2.5- and 6.0- 
kb mRNAs
Localised in nucleus and induced by phorbol 
esters. Specificity towards MAPK in vitro 
and in vivo, t  expression in placenta and 
pancreas
HVH3
Kwak and Dixon, 1995
Human 384 aa 
2.4 kb 
mRNA
Nuclear localisation, serum induction elevated 
for 3 hours, dependent on protein synthesis, 
t  expression in liver and placenta.
Specificity towards MAPK in vitro.
MKP-2
Misra-Press et al., 1995
Rat 393 aa 
6.0 kb 
mRNA
Serum induced bi-phasic stimulation, 
sustained ~6Hrs. T expression in heart and 
lung. Also induced by stress in CNS. 
Specificity for MAPK in vitro and in vivo.
Cdc25A, B, C
Gautier et al., 1991 
Galaktionov et al., '95
Human ~  417 aa -C and -A specifically dephosphorylate Cdc2- 
cyclin B and Cdk2-cyclin E, regulating entry 
into mitosis and G l/S transition respectively.
KAP/Cdil
Gyruis et al., 1993 
Hannon et al., 1994
Human 212 aa Like Cdc25, shows hom ology only across 
PTPase domain. Activity towards Ser and 
Tyr in vitro. Complexes with certain Cdks
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1.8. Switching off MAP Kinases
Only recently has the complexity of the MAP kinase signalling been 
understood, which involves the integration of at least three parallel pathways which 
can be stimulated simultaneously. In contrast to the well characterised activation of 
MAP kinases, much less is understood regarding their inactivation. This can be 
accomplished by dephosphorylation of either the regulatory phosphothreonine or 
phosphotyrosine residue, or both. Evidence from in vitro studies show that ERK1 and 
-2 can be inactivated completely by treatment with either the protein phosphatase 2A, 
specific for Ser/Thr residues, or CD45, a tyrosine phosphatase (Anderson et al.t 
1990). PP2A is also strongly implicated in regulating the MAPK pathway in vivo by 
the finding that expression of SV40 small t antigen in CV1 cells up-regulates MKK 
and ERK1 and -2 activity, without any effect on Raf-1 activity (Sontag et al.t 1993). 
SV40 small t antigen acts as a surrogate inhibitory B-type regulatory subunit for 
PP2A. Such experiments indicate that PP2A is an important negative regulator, but do 
not reveal which components are the target for inactivation by PP2A. Indeed, as 
previously discussed, PP2A dephosphorylates and inactivates both MKK and MAPK 
(Dent et al., 1992; Kyriakis et al., 1992). The recently identified inducible protein 
phosphatases, with dual tyrosine/threonine specificity, and selectivity for MAPK are 
ideal candidates for inactivating MAPKs in vivo, as discussed above, and there is much 
evidence from studies in fibroblasts and Cos cells to suggest that this is indeed the 
case. For example, in NIH 3T3 fibroblasts, the inactivation of ERK2 is initiated 
60 minutes after serum stimulation, the time at which the MKP-1 protein first appears 
(Sun et al., 1993). However, in many cells the activation of MAPKs is a transient 
event, even in the continuing presence of the activating stimulus. For instance, some 
growth factors or hormones, such as insulin in adipocytes, or EGF in PC12 cells, 
produce a rapid and transient activation of MAPK, the inactivation of which is initiated 
after 10 minutes (Ray and Sturgill, 1987; Traverse et al., 1992). In these situations the 
kinetics of inactivation are too rapid to be explained by de novo synthesis of dual 
specificity phosphatases. Recent experiments have now shown that the rapid
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inactivation of ERK2 in endothelial, adipose and PC12 cells after stimulation with 
EGF is not catalysed by CL 100. Protocols for treating cells with actinomycin D and 
cycloheximide were established to eliminate the detection of CL100 mRNA and 
protein, and under such circumstances ERK2 inactivation was not affected (Wu et al., 
1994; Alessi et al., 1995). However, dephosphorylation of the Tyr residue was 
sensitive to sodium vanadate, implicating the involvement of a tyrosine phosphatase 
distinct from CL100. By contrast, dephosphorylation of the Thr residue was elicited by 
a vanadate-insensitive activity, and indeed, biochemical studies have identified PP2A 
activity as a rate-limiting step in the inactivation of ERK2 in PC12 cells (Alessi et al.,
1995). In a number of situations CL100 induction is not accompanied by the 
inactivation of MAPK, for example, the sustained activation of ERK2 in response to 
NGF in PC12 cells (Wu et al., 1994; Alessi et al., 1995). This raises the possibility 
that the MAPKs may be protected from CL 100-like phosphatases, perhaps spatially or 
through a phosphatase-inhibitor. In Xenopus oocytes, there is a rapid inactivation of 
MAPK following fertilisation, and Sarcevic et al. (1993), have purified an as yet 
uncharacterised tyrosine phosphatase from the cytosolic fraction of Xenopus oocytes, 
which targets the regulatory Tyr residue of MAPK. This corroborates the findings of 
Alessi et al. (1995), who identify a tyrosine phosphatase activity in PC12 cells in 
addition to PP2A. However, more recently, Lewis et al. (1995), have cloned the 
Xenopus homolog (XCL100) of the human CL100 phosphatase. Interestingly, 
XCL100 is constitutively expressed in oocytes, whilst in a Xenopus epithelial cell line, 
this enzyme shows similar properties to previously identified dual specific 
phosphatases, such as induction by serum and cellular stress. Thus, further 
investigations are necessary to determine the precise role of XCL100 in the regulation 
of MAPK activity during early development
Based on the studies outlined above, a model for the physiological inactivation 
of MAP kinase has been tentatively proposed (Keyse, 1995). Stimuli which lead to a 
very rapid and transient activation of MAP kinase do not result in significant 
translocation of the kinase to the nucleus. Therefore, the activity of MAP kinase is 
held in balance between the activities of MKK and PP2A in the cytoplasm. A separate
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tyrosine phosphatase is also implicated in the regulation of cytosolic MAPK, however, 
it is the dephosphorylation of the phosphothreonine by PP2A that is the rate-limiting 
step. Hence, class-specific phosphatases that selectively dephosphorylate the Thr or 
Tyr phosphorylation sites of MAPK may control its inactivation under certain 
circumstances. In contrast, sustained activation of MAPKs is accompanied by 
translocation to the nucleus. This separates MAPK from both MKK and PP2A, which 
remain cytosolic. Once in the nucleus, MAPK is subject to regulation by dual 
specificity phosphatases, refer to figure 1.6, p58.
However, this model is only hypothetical. It is possible that the cellular targets 
of the CL100 phosphatase are not the classical p42 and p44 isoforms of MAP kinase. 
Indeed the specificity of the CLIOO-like phosphatases for the MAPK isoforms is yet to 
be determined. It is envisaged that each MAPK isoform will be regulated by both a 
specific MKK and a specific MAPK phosphatase. Will each of the MAPK 
phosphatases then be stimulated in a specific pathway, in a similar fashion to the 
upstream activators of MAPK? Multicyclic enzyme cascades involving protein kinases 
and phosphatases, such as the MAPK pathway, respond to a great number of 
regulators, with a high degree of amplification at each step. Cross-talk between 
parallel signal pathways regulated by protein phosphorylations is inevitable, and 
mechanisms of positive and negative feedback provide a further network of 
complexity. Furthermore, cell-type specific differences have been illustrated in the 
MAPK activation pathway, and subsequently, all these influences are also going to be 
fundamental in the regulation of the MAPK phosphatases. It is of course entirely 
possible that the MAPKs are not the only physiological substrates for the dual specific 
phosphatases.
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Figure 1.6.
Model for the participation of protein phosphatases in the regulation of 
the MAP kinase cascade.
The protein tyrosine phosphatase Syp, binds through its SH2 domains to 
autophosphorylated growth factor receptors, which then phosphorylate Syp such that 
it complexes with Grb2/Sos to activate p21Ras. The receptor tyrosine phosphatase 
RPTPa is also able to potentiate the activation of the MAP kinases through the 
dephosphorylation and activation of c-Src, although the components of this pathway 
are not known. Conversely, RPTPa can sequester Grb2 molecules preventing the 
activation of p21Ras, since RPTPa is constitutively phosphorylated on tyrosine 
residues (by an as yet unknown mechanism), and can therefore bind the SH2 domain 
of Grb2. Sos is not detected in such complexes. See text for details.
The physiological protein phosphatases for Raf-1, MKKs and RSK are not known, 
although the serine/threonine phosphatase PP2A, targets these enzymes in vitro. 
Transient activation of MAPK leads to a subsequent, rapid inactivation of the protein 
in the cytoplasm by PP2A, and an as yet uncharacterised PTP. Sustained activation of 
MAPK mediates translocation to the nucleus, where it remains active until 
dephosphoiylated on both Thr and Tyr by the dual-specific phosphatases, such as 
CL 100. It is not known if PP2A is nuclear. For full details see text
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1.9. Summary and aims.
Cellular proliferation and differentiation is potently stimulated by a variety of 
cytokines and growth factors which specifically interact with receptor tyrosine kinases. 
Pathways have been defined involving cascades of protein kinases capable of inducing 
complex sets of immediate early genes, functionally significant in cell cycle regulation 
and oncogenic transformation. Thus, protein phosphorylation plays a central role in 
these events, and is regulated by the opposing activities of protein kinases and 
phosphatases. An essential kinase cascade is the mitogen-activated protein kinase 
(MAPK) pathway, implicated in the control of many cellular processes. Currently three 
MAPK pathways are known in mammalian cells, the best understood of which 
involves the extracellular signal-regulated kinases (ERKs), and in this regard they have 
been defined as the paradigm for all signalling cascades. Distinct from this classical 
pathway are the two recently identified MAPK subfamilies, the stress-activated protein 
kinases (SAPKs/JNKs) and p38/RK.
In contrast to the well characterised activation of MAP kinases, much less is 
understood regarding their inactivation. This can be accomplished by 
dephosphorylation of either the regulatory phosphothreonine or phosphotyrosine 
residue, or both. The recent identification of a family of phosphatase genes 
demonstrating dual specificity towards threonine/serine and tyrosine residues, 
harbouring a distinct substrate specificity for the MAP kinases, has led to the 
suggestion that these enzymes may be the physiologically functional phosphatases that 
target, and inactivate, the MAP kinases.
This study was designed to isolate further members of this dual specificity 
phosphatase family. At the start of this project only two such phosphatase genes had 
been identified, namely CL100 (Keyse and Emslie, 1992) and PAC-1 (Rohan et al., 
1993). The technique of polymerase chain reaction (PCR) was employed to amplify 
DNA sequences by the simultaneous extension of complementary strands of DNA 
(Mullis and Faloona, 1987). Highly degenerate primers, based on two conserved 
amino acid sequences between GL100 and PAC-1, were used in an attempt to isolate
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further related dual specific phosphatases. The intent was to use the amplified DNA as 
a homologous hybridisation probe, allowing low stringency screening of gene libraries 
to isolate corresponding cDNA clones. The cDNA clones would then be fully 
sequenced, in the hope of deriving full length cDNAs. Five novel, partial cDNAs were 
detected from screening brain and liver cDNA libraries, which were predicted to 
encode protein phosphatases on the basis that the cDNAs showed sequence homology 
to the PTPase catalytic motif. Sequencing of one clone, TYP 1, revealed that it was a 
full length cDNA. Thus, the subsequent aims ofthis thesis were then to assess whether 
TYP 1 demonstrated phosphatase activity towards phosphoproteins, and to 
characterise the gene by investigating its regulation of expression, both at the RNA 
and protein level. The cell lines chosen for this study were derived from squamous cell 
carcinomas (SCC). The EGF receptor is often amplified, and frequently overexpressed 
in squamous cell carcinomas (Stanton et al., 1994; Ozanne et a/., 1986; Cowley et al., 
1984; Ullrich et al., 1984), being a consistent marker of squamous cell malignancies 
in vivo as well as in cell culture. Inhibition of ligand binding to the EGF receptor by 
specific antibodies prevents growth of SCC in culture (Masui et al., 1984), and 
therefore it has been suggested that overexpression of the EGF receptor may enable 
the cells to respond to low levels of ligand giving them a selective growth advantage 
over their neighbours. Interestingly, SCC are growth inhibited by concentrations of 
EGF that are mitogenic for normal keratinocytes or fibroblasts. It is established that 
the EGF receptor is the initiating kinase in a well characterised protein kinase cascade, 
and as such, SCC cells therefore provide an ideal cellular context in which to study 
protein phosphatases, enzymes which presumably play a role in regulating this kinase 
cascade.
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CHAPTER 2 
MATERIALS AND 
METHODS
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2.1 Materials
2.1.1 Tissue Culture
An immortal murine fibroblast cell line.
A gift from Dr. Ken Parkinson, Beatson Institute.
A vulval squamous cell carcinoma cell line, 
obtained from Dr. Brad Ozanne, Beatson Institute.
A cell line derived from squamous cell carcinomas 
of the head and neck by Dr. Kirsten Edington,
Beatson Institute.
A cervical squamous cell derived by 
Dr. Margareta Nikolic, Beatson Institute.
A squamous cell carcinoma cell line.
A gift from Dr. Ken Parkinson.
A human fibroblast cell strain.
A gift from Dr. Ken Parkinson.
A cell line derived from the transformation of Simian 
CV-1 cells with an origin-defective SV40 genome, 
(Gluzman, 1981).
A gift from Dr. Sally Leevers, Chester Beatty Institute 
for Cancer Research, London.
Beatson Institute Central Services
Sterile phosphate buffered saline (PBS)
Sterile glassware and pipettes
Becton Dickinson U. K. Ltd.
Sterile plastic plates
Fisons Scientific Equipment U.K.
Dimethyl sulphoxide (DMSO)
Gibco Europe Life Technologies Ltd., U.K.
Dulbecco's modified Eagles medium (DMEM)
Foetal calf serum (FCS)
Gentamicin
Glutamine
Methionine-free DMEM
Cell Lines
Swiss 3T3 feeders
A431
BICR6
MS-2
SCC12F
HKK
Cosl
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Sodium bicarbonate 
Sodium pyruvate
Nunc, Denmark
Cryotubes 
Sterile plastic flasks
Research and Diagnostic Sytems, Inc. U.S.A.
Transforming growth factor p i (TGFpl), Human platelet derived.
Sigma Chemical Company Ltd., U.K.
Chloroquine, diphosphate salt 
Cycloheximide
Diethylaminoethyl-Dextran (DEAE-Dextran)
Epidermal growth factor (EGF), from mouse submaxillary glands. 
Hydrocortisone
Worthington Biochemical Company, U.K.
Trypsin
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2.1.2. Immunocytochemistry
Antibodies
anti-TYP 1 antibodies were obtained from Affiniti Research Products Ltd.
BDH Analar, U.K.
DPX mountant 
Glass coverslips
Fisons Scientific Equipment, U.K. 
Acetone, HPLC grade. 
Methanol 
Xylene
Nunc, Denmark
Chamber slides (glass)
Sigma Chemical Company Ltd., U.K.
Bovine serum albumin fraction V (BSA)
Diaminobenzoic acid
Hydrogen peroxide
Nickel chloride
Tween 20
Unipath Ltd., U.K.
Phosphate buffered saline (PBS)
Vector Laboratories, U.K.
Vectastain ABC peroxidase kit
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2.1.3. Protein Biochemistry
Antibodies
anti-ERK2 polyclonal antibody, a kind gift of Anne Wyke, Beatson Institute, 
Glasgow.
anti-p54 antibody, a kind gift of Dr. Jim Woodgett, Ontario Cancer Institute, 
Canada.
anti-c-Myc antibody, 9E10, a kind gift of Dr. Sally Cowley, Chester Beatty 
Institute for Cancer Research, London.
Amersham International pic., U.K.
anti-rabbit Ig, horseradish peroxidase linked whole ab (from donkey) 
anti-mouse Ig, horseradish peroxidase linked whole ab (from sheep) 
[7.32P]ATP (5000Ci/mmol)
ECL western detection agent
[L-35s]methionine (lOOOCi/mmol), in vitro cell labelling mix 
Rainbow colour markers (14,300-200,000 Da)
BDH, Analar, U.K.
Butan-2-ol
Ether
Glycerol
Magnesium acetate 
Magnesium chloride 
Sodium azide
Sodium dodecyl sulphate (SDS)
Sodium pyrophosphate 
Trichloracetic acid (TCA)
Boehringer-Mannheim, Germany
EGTA (ethylene glycol tetra-acetic acid)
Eastman Kodak Company, U.S.A.
13255 Cellulose thin layer plate 
X-OMAT AR X-ray film
Fisons Scientific Equipment, U.K.
Acetic acid
Ammonium persulphate (APS)
EDTA, sodium salt (ethylene diamine tetra-acetic acid)
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Glycine
Hydrochloric acid 
Sodium chloride
Gibco Europe Life Technologies Ltd., U.K.
Dithiothreitol (DTT)
Tris base, ultra pure
Merck, Germany
Ninhydrin
Millipore Corporation, U.S.A.
Immobilon P nitrocellulose
Premiere Beverages, U.K.
Marvel, non-fat dried milk
Promega Ltd., U.K.
TNT™ Coupled Reticulocyte Lysate System
Sigma chemical company Ltd., U.K.
Aprotinin
ATP
Bicinchononic acid 
Bromophenol blue 
Copper II Sulphate 
Emetine, dihydrochloride 
Leupeptin
Manganese II chloride 
2-Mercaptoethanol 
Myelin basic protein (MBP)
Phenymethylsulfonyl fluoride (PMSF) 
Phosphoamino acids 
Protein A sepharose 
Pyridine
Sodium deoxycholic acid 
Sodium fluoride 
Sodium orthovanadate
TEMED (N,N,N',N'-tetramethylethylenediamine) 
Triton-X-100
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Severn Biotech Ltd., U.K.
30% Acrylamide: 0.8% bisacrylamide
Whatman International Ltd., U.K.
Whatman 3MM filter paper 
Glass-microfibre filters (100mm)
2.I.3.I. Proteins
c-Jun protein a kind gift of Dr. Elizabeth Black, Beatson Institute, Glasgow. 
GST-ERK2 protein a kind gift of Dr. Sally Cowley, Chester Beatty Institute, 
London.
GST-TYP 1 protein a kind gift of Dr. Alan Ashworth, Chester Beatty Institute. 
MAP kinase kinase, (EE mutant), a kind gift of Dr. Sally Cowley.
32p-labelled ERK2 a kind gift of Dr. Dario Alessi, Biochemistry department, 
University of Dundee.
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2.1.4. Molecular Biology
Amersham International pic., U.K. 
[a-32P]dCTP (3000Ci/mmol) 
[a-35S]ATP (lOOOCi/mmol)
Hybond N+ membrane
Beatson Institute Central services 
L-broth
BDH, Analar, U.K.
Acrylamide
Butan-l-ol
Glucose
N N' Methylenebis-acrylamide 
Potassium chloride 
Xylene cyanol
Bibby-Sterilin Ltd., U.K.
Sterile bacteriological plates
Bio 101 Inc., U.K.
Geneclean II® kit
Boehringer-Mannheim, Germany
Caesium chloride
Calf intestinal alkaline phosphatase
DNAse-free RNAse A
Klenow fragment E.coli DNA polymerase
Mops, (4-Morpholinpropansulfonic acid)
01igod(T)i2
Protease K
Cinna/Biotecx Laboratories Inc., U.S.A.
RNAzol™ B
Cruachem Ltd., U.S.A.
Oligonucleotide purification cartridges 
Triethylammonium acetate (TEAA) 
Trifluoroacetic acid (TFA)
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DuPont Instruments, U.K.
Glass corex tubes
Flowgen Instruments Ltd., U.K.
Agarose
Fisons Scientific Equipment, U.K.
Boric acid
Chloroform, HPLC grade.
Di-potassium hydrogen orthophosphate
Di-sodium hydrogen orthophosphate
Formaldehyde
Formamide
Isopropanol
Magnesium sulphate
Potassium acetate
Potassium dihydrogen orthophosphate 
Sodium acetate 
Sodium citrate
Sodium dihydrogen orthophosphate 
Sodium hydroxide 
Urea, ultra pure.
Gibco Europe Life Technologies Ltd., U.K.
Bactoagar
Bactotryptone
E.coli DH5a competent cells 
OX 174 Hae-III digested DNA marker 
Restriction enzymes 
Yeast Extract
James Burrough Ltd., U.K.
Ethanol
Lab-Scan Ltd., Ireland, U.K.
Acetonitrile
Northumbria Biologicals Ltd., U.K.
T4 DNA ligase 
T4 polynucleotide kinase
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Nunc, Denmark
Sterile square bacteriological plates
Perkin-Elmer Cetus, U.S.A.
AmpliTaq DNA polymerase
Pharmacia AB, Sweden 
Ficoll 400 
dNTPs Ultrapure 
Oligo-labelling kit 
T7 DNA polymerase
Promega Ltd., U.K.
X Hind-III digested DNA marker 
PolyATract™ mRNA Isolation system I
Rathburn Chemicals Ltd., U.K.
Phenol
Sigma Chemical Company, U.K.
Ampicillin 
Ethidium Bromide 
Kanamycin 
Lysozyme
Polyvinylpyrrolidone 
Sephadex G50 
Yeast RNA type IV
Stratagene, U.S.A.
Lambda Zap n® Library
Technical Photo Systems, U.K.
Fuji RX medical X-ray film
United States Biochemical Corporation, U.S.A.
Sequenase® version II kit
Vernon-Carus Ltd., U.K.
Gauze swabs
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2.1.4.1. Vectors
pBluescript®II KS A 2.96kb phagemid, Stratagene, U.S.A.
pCITH-TYP 1 A 3.8kb plasmid containing an Ncol-Xhol fragment of
TYP1 cDNA cloned into an Ncol-Sall fragment of the 
pCITE-1 vector. The Cap-Independent Translation 
Enhancer (CITE) is located immediately downstream 
from a T7 promoter, Novagen, U.S.A. 
pMT-TYP 1 A 5. lkb plasmid containing a Smal-Asp718 fragment
of TYP 1 cDNA cloned into a Smal-Kpnl fragment of 
the pMT2 expression vector, in which transcription is 
directed by the adenovirus major late promoter, 
(Kaufman et al., 1989). 
pMT-Myc-TYP 1 An Ncol-Xhol fragment of TYP 1 cDNA was
Myc-tagged at the amino terminus by ligation to the 
c-Myc epitope containing a 5' half-Notl site, and a 
3' half-Ncol site (see Table 2).
The resulting construct was cloned into an Notl-Xhol 
fragment of the pMT2 vector. 
pMT-CLlOO CL100 cloned into pTZ19R ( a kind gift of Dr. Stephen
Keyse, Ninewells Hospital, Dundee) was subcloned into 
the pMT2 vector as an Nael-EcoRl fragment. 
pSPT19 A 4.2kb plasmid containing an EcoRl fragment of avian
c-Jun cDNA, cloned downstream of a T7 promoter site. 
A kind gift of Dr. Elizabeth Black, Beatson Institute.
2.I.4.2. DNA Probes 
CL100 
EGF receptor 
TYP 1
TYP 2
An EcoRl-Xhol fragment excised from pTZ19R. 
An EcoRl fragment of the 31 end of the EGFR.
A PCR product from pBluescript-TYP 1 using the 
primers 4340 and -20 (see Tables 2 and 3).
A Xhol-Stul fragment excised from 
pBluescript-TYP 2.
2.1.5. Water
Deionised water for solutions was obtained from a Millipore MilliRO 15 system. 
Water for tissue culture, nucleic acid and protein procedures was further purified on a 
Millipore MilliQ system to 18Mf2cm.
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Table 2.
General oligonucleotide sequences
Oligonucleotide Sequence
pBluescript IIK S
Reverse 
M13 -20
KS
SK
see Maniatis et al., 1989.
5' GGA AAC AGC TAT GAC CAT G 3' 
5' GTA AAA CGA CGG CCA GT 3'
5' TCG AGG TCG ACG GTA TC 3'
5’ CGCTCT AGA ACT AGT GGA TC 3'
Myc epitope
4341
4342
Notl M E Q K L I  S E E D  Ncol 
5' GGCCGCC ATG GAG CAG AAA CTT ATC TCC GAG GAA GAT C 3' 
3' CGG TAC CTC GTC TTT GAA TAG AGG CTC CTT CTA GGTA 51
TYP 1 Antibody 5' R S  P R A E S  L R E D S  T V 3' 
CGC AGC CCG CGC GCC GAG AGC CTC CGC GAG GAC AGC ACC GTG
Table 3.
Oligonucleotides for dual specificity protein phosphatases
Oligonucleotide Sequence
Degenerate #
3350
3351
Y D  Q G G P V E  
5’ TA(c/t) GA(c/t) CA( a/g) GGN GGN CCN GTN GA 3' 
5' AT (gct)CC (a/t)GC (c/t)TG (a/g)CA (a/g)TG NAC 3' 
-based on VHCQAGI
Forw ard# TYP 1
3964
4202
4262
4337
4340
4342
5' GCT CAA AAG GCT GAT GAA CC 3' 
5' CAC AGC GGG CTA CAT CCT AG 3’ 
5' CAC CGT GTC GCT GGT GGT G 3'
5' AGG AGG GTC CTG TGG AGA TC 3' 
5' CTT CGA GTT CGT TAA GCA GC 3' 
5' CTG CGG GAG CGG GCA GAC CC 3'
Reverse # TYP 1 
4261 
4263
4338
4339 
4343
5' CAT CTC GTC CCG TTC ATC AGC 3' 
5' ACA GCC ACG TTG ACC GAC CT 3' 
5' ATC TCC ACA GGA CCC TCC TG 3' 
5f CGA TGT ACT CTA TGG CTT CC 3' 
5' ACT CGA ACT GCA GCA GCT GC 3'
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2.2. Methods
2.2.1. Tissue Culture
2.2.1.1. Culture of Swiss mouse 3T3 feeder cells
Swiss 3T3 fibroblasts were grown in Dulbecco's modified Eagle's medium 
(DMEM) containing 10% (v/v) foetal calf serum (FCS), 0.3% (v/v) sodium 
bicarbonate, 2mM glutamine, ImM pyruvate, 150jig/ml gentamicin. Cells were seeded 
at 10^/9cm dish, and incubated at 37°C in an humidified atmosphere containing 7% 
(v/v) CO2. Medium was changed every third day and cells used for feeders upon 
reaching confluency.
For use as feeders, cells were trypsinised with 0.25% (v/v) trypsin in phosphate 
buffered saline (PBS, 0.14M NaCl, 27mM KC1, lOmM Na2HPC>4, 15mM K2HPO4) 
and resuspended in fresh growth medium. Cells were then lethally irradiated by 
exposure to 60Gy of y-irradiation from a ^ C o  source. This prevents further cell 
divisions. The cells were either used immediately or stored for up to 48 hours at 4°C 
without loss of feeding capacity. Feeder cells were plated at a density of 10^/9cm 
plate.
2.2.1.2. Culture of mammalian squamous cell carcinoma cell lines
A431 cells were maintained in DMEM containing 10% (v/v) FCS and 
supplements, as above.
The BICR6 cell line was grown in serum-containing medium in the presence of a 
3T3 feeder layer, as previously described. The 3T3 layer is necessary to initiate colony 
formation (Rheinwald and Becket, 1981). The medium consists of DMEM with 10% 
(v/v) FCS and supplements as above, including 0.4|ig/ml hydrocortisone. 
Hydrocortisone is required to make colony morphology more orderly and maintains an 
increased proliferation rate (Rheinwald and Green, 1975). The same conditions were 
used for the culturing of cell lines MS-2 and SCC12F, except that they did not require 
the presence of a 3T3 feeder layer, and the DMEM contained 2% (v/v) FCS.
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All cells were incubated at 37°C in an humidified atmosphere containing 7% 
(v/v) CO2. Stock cultures were subcloned at a ratio of 1:10 every 3 days. The cells 
were passaged by aspiration of the growth medium from the monolayer, followed by 
two successive exposures to 2.5ml of 0.25% (v/v) trypsin solution in PBS. The 
majority of the trypsin solution was removed and the monolayers incubated at 37°C 
until the cells could be detached by gentle agitation. Trypsin was inactivated by adding 
ten volumes of serum-containing medium to the detached cells, which was removed by 
centrifugation in a Beckman GP centrifuge at lOOOrpm for 5 minutes at room 
temperature. The supernatant was removed and cells resuspended in the appropriate 
media at the required dilution.
Quiescent cultures were prepared as follows. Cells were plated at approximately 
5 x 10^/175cm^ flask in growth medium and grown at 37°C for approximately three 
days. Medium was aspirated, and the sub-confluent monolayers were washed with an 
equivalent volume of serum-free DMEM. Cells were refed DMEM containing 0.5% 
(v/v) FCS and appropriate supplements, as above, and incubated for a further 60 hours 
at 37°C. This rendered all cell lines used quiescent
2.2.1.3. Culture of human fibroblasts
Human fibroblasts HKK were grown in DMEM as for the squamous cell line 
BICR6, but containing 15% (v/v) FCS. Stock cultures were maintained, rendered 
quiescent and passaged as for squamous cells.
2.2.1.4. Culture of monkey Cosl kidney cells
Cosl cells were grown in DMEM containing 10% (v/v) FCS and supplements as 
for Swiss 3T3 cells. Stock cultures were maintained and passaged as for squamous 
cells.
2.2.1.5. Frozen cell stocks
Stocks of all cells were kept frozen in liquid nitrogen. Cells trypsinized as above 
were resuspended at a concentration of 10^ cells/ml in ice-cold medium containing
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20% (v/v) FCS plus 10% (v/v) dimethyl sulphoxide (DMSO), (DMSO is toxic to cells 
at room temperature). Cells were aliquoted into 1.5ml Nunc cryotubes and frozen at 
-70°C overnight, where they were subsequently placed into liquid nitrogen for long 
term storage. Cells were thawed by transferring the ampoule directly from liquid 
nitrogen to water at 37°C. Once thawed cells were added to a large volume of 
pre-warmed growth medium.
2.2.1.6. Transient transfection of COS cells
For transient transfection, COS-1 cells were seeded at a density of 4 x 10^ 
cells/lOcm plate in DMEM containing 10% (v/v) FCS and grown for 20 hours prior to 
a 4 hour incubation at 37°C with 5ml/10cm plate of DMEM containing 10% (v/v) 
FCS, 0.04% (w/v) DEAE-dextran, 100|iM chloroquine phosphate, and 0.5|Xg 
expression plasmid, either pMT-Myc-TYP 1, pMT-TYP 1 or parental pMT. After 
4 hours, the medium was removed and the cells were incubated for precisely 2 minutes 
with 5ml of PBS containing 10% (v/v) DMSO. This was removed and replaced with 
DMEM, 10% (v/v) FCS for 24 hours. The cells were then treated and harvested as 
required.
For cycloheximide treatment, transfected COS cells were treated with lOjig/ml 
cycloheximide for the indicated times, in the presence or absence of 30ng/ml EGF 
which was added 15 minutes prior to cycloheximide addition.
2.2.1.7. Stimulation of cells with growth factors and heat shock
A431 cells maintained in DMEM supplemented with 10% (v/v) FCS were 
grown to subconfluency in 175cm^ flasks and mitogen stimulated with 30ng/ml EGF 
for the indicated periods of time. For serum stimulation of all squamous cell lines and 
human fibroblasts, medium was aspirated from subconfluent quiescent cultures grown 
in flasks, and replaced with DMEM containing 10% (v/v) FCS for the indicated times. 
Note for manipulation of BICR6 cells, cells were grown in the absence of Swiss 3T3 
feeders for two passages before any treatment. Heat shock was administered by 
immersing flasks containing subconfluent cells into a 44°C water bath for 30 minutes.
75
Following treatment, flasks were returned to 37°C and incubated for the indicated 
periods of time. For TGFp treatment, growing subconfluent cells plated in flasks were 
stimulated with lOng/ml TGFp for the indicated times.
2.2.2. Immunocytochemistry
2.2.2.1. Staining for TYP 1
COS1 cells transfected with TYP 1 as described in section 2.2.1.6, were 
transferred to glass chamber slides 24 hours post-transfection, and grown for a further 
24 hours prior to fixation. Non-transfected COS cells and COS cells transfected with 
parental pMT vector were used as negative controls. Slides were washed twice in 
ice-cold PBS, once in a 1:1 mix of methanol: acetone, and fixed for 10 minutes in 1:1 
methanol: acetone. The slides were air-dried for 30 minutes and used immediately or 
stored at -20°C in airtight conditions. Cells were incubated with goat blocking serum 
from the rabbit peroxidase Vectastain kit at 1:10 dilution in PBS/BSA (0.5% (w/v) 
bovine serum albumin fraction V in PBS) overnight at 4°C in a humid box. Rabbit 
anti-TYP 1 antibodies (1:4000 dilution in PBS/BSA) or normal rabbit sera were added 
for 1 hour at room temperature, and the slides rinsed in a high salt solution (PBS 
containing 0.15M NaCl, 0.05% (v/v) Tween 20), three times for 10 minutes each. The 
secondary anti-rabbit biotinylated antibody from the kit (1:100 in PBS/BSA) was 
incubated for 1 hour at room temperature, cells washed as previously described and 
then exposed to a streptavidin-horseradish peroxidase amplification mix (solutions A 
and B from the kit) for 1 hour. The PBS/salt rinses were repeated again and the colour 
developed using a Ni-DAB solution (PBS containing 0.012% (v/v) hydrogen peroxide, 
0.2% (w/v) NiCl2, 0.6mg/ml diaminobenzoic acid) for 10 minutes. The cells were 
dehydrated by sequential immersion into 70% (v/v) ethanol, 90% (v/v) ethanol, 
2X 100% ethanol and 100% xylene, overlaid with DPX mountant and a glass 
coverslip.
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2.2.3. Protein Biochemistry
2.2.3.1. SDS-polyacrylamide gel electrophoresis
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
employed to resolve proteins according to their apparent molecular weight. The 
acrylamide concentration in the gels varied depending on the technique being used. For 
most applications gels were 10% with respect to acrylamide, whereas for in vitro 
MAP kinase activity assays, the gels used were 15%.
A 10% or 15% SDS-PAGE gel (10% or 15% aciylamide:&w-acrylamide {stock 
is 30% (w/v) acrylamide, 0.8% (w/v) Z?w-acrylamide}, 375mM Tris pH 8.8, 0.1% 
(w/v) SDS, 0.1% (v/v) ammonium persulphate (APS), 0.04% (v/v) TEMED) was 
poured between glass plates, overlaid with H20 -saturated butan-2-ol, and allowed to 
polymerise for 1 hour. The gel front was washed with H2O to remove the butanol 
and blotted dry with Whatman 3MM paper. The stacking gel (4.8% 
acrylamide : fc/s-acrylamide, 125mM Tris pH 6.8, 0.1% (w/v) SDS, 0.1% (v/v) APS, 
0.04% (v/v) TEMED) was poured on top of the resolving gel, a comb inserted and 
allowed to polymerise. Due to the difference in pH between the stacking and resolving 
gel, the stacking gel should only be poured 1 hour before using the gel to minimise 
merging of the pH's. The gel was assembled in the tank and the wells were flushed 
extensively with running buffer (25mM Tris pH 8.3, 191mM glycine, 3.5mM SDS) 
and bubbles removed from the lower surface of the gel plates before the samples were 
loaded.
Protein samples (50jig) were denatured in sample buffer (62.5mM Tris pH 6.8, 
10% (v/v) glycerol, 2.3% (w/v) SDS, 5mM EDTA, lOOmM DTT, 0.002% (w/v) 
bromophenol blue) by heating at 95-100°C for 5 minutes. Proteins purified by 
immunoprecipitation were resuspended and denatured in an equivalent volume of 
sample buffer. Rainbow™ markers (Amersham) were included on all gels. 
Electrophoresis was carried out at 120V for 4-5 hours.
77
2.2.3.2. Preparation of TYP 1 antiserum
A synthetic oligonucleotide corresponding to amino acids 55 to 68 of TYP 1 
(see Table 2, p72), was conjugated to keyhole limpet haemocyanin and used for 
immunisation of New Zealand White rabbits by conventional protocols (Affiniti 
Research Products Ltd., U.K.). The specificity of the antiserum was tested by both 
western blot analysis (see 2.23.1) and immunoprecipitation of transiendy transfected 
COS cells with TYP 1 expression plasmids (see 2.2.3.5).
2.2.3.3. Protein extraction from mammalian cell lines
Cell cultures growing on 9cm plates were washed twice in ice-cold PBS, 
scraped off the plate in 200|il PBS and pelleted in pre-chilled eppendorf tubes by 
microcentrifugation at 4°C, 6000g for 2 minutes. The cell pellet was resuspended in 
50|il P buffer (20mM Tris pH 8.0,40mM Na2?20,50mM NaF, 5mM MgCl2, 100|i.M 
Na3V04 , lOmM EGTA), 50)0.1 S buffer was added (P buffer including 1% (v/v) Triton 
X-100, 0.5% (w/v) sodium deoxycholate, 20pl/ml aprotinin, 20|ig/ml leupeptin, 3mM 
phenylmethylsulfonyl fluoride (PMSF)), and the lysate incubated on ice for 15 minutes. 
The suspensions were centrifuged at 4°C, 12,000g for 10 minutes. The supernatant 
was stored at -70°C.
Protein concentration was determined by analysis of the sample and 1:10 
dilutions using a bicinchoninic acid assay. 10|il of each sample was aliquoted into 
specific positions on a 96 well plate, 200pi of reaction mix (1 volume CUSO4 and 
50 volumes bicinchoninic acid) was added to each sample, and the colour allowed to 
develop at 37°C for 40 minutes. Spectrophotometric analysis was at A590nm using a 
Dynatech MR7000 spectrophotometer. Calibration was carried out using a range of 
BSA standards.
2.2.3.4. Immunoprecipitation and assay of MAP kinase activity
In an eppendorf tube, 200|il S buffer (see 2.2.3.3) was incubated with 50pl 
protein A-sepharose beads and 2|il anti-ERK2 antibody, or ljil anti-p54 antibody (as 
indicated), and rotamixed for 1 hour at 4°C. For controls, pre-immune sera was used.
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Following a brief centrifugation, the supernatant was removed and the cell lysates (one 
9cm plate per immunoprecipitate) from transfected COS cells (see section 2.2.1.6) 
were incubated with the pre-bound antibody/protein A-sepharose beads overnight at 
4°C with rotation. After brief centrifugation, the supernatant was removed and the 
beads washed three times in S buffer, not containing PMSF, once in 30mM Tris pH 
8.0, and once in kinase buffer (30mM Tris pH 8.0,20mM MgCl2,2mM MnCl2).
Each immunoprecipitate was stored on ice and resuspended in a total of 30pl 
kinase buffer containing either 7.5|ig myelin basic protein (MBP for ERK2 assay), or 
2|ig recombinant c-Jun protein (for p54 assay), lpM ATP and 0.5|iCi [y-32p]ATP. 
The kinase assay was initiated by incubation at 30°C for 30 minutes. The reactions 
were terminated by the addition of SDS loading buffer, and samples resolved on 15% 
SDS-PAGE gel. To reduce background radioactivity the proteins were transferred to 
nitrocellulose (see 2.2.3.7), the filters were wrapped in Saranwrap™ and exposed to 
Kodak X-Omat AR film with intensifying screens at -70°C.
2.2.3.5. Methionine labelling and immunoprecipitation of TYP 1
COS cells, 24 hours post-transfection (see section 2.2.1.6), were labelled in 
90mm plates with [L-^^S] methionine as follows. Culture medium was aspirated and 
transfected cells washed once with serum-free DMEM lacking methionine. Cultures 
were then incubated for 1 hour in 3ml/plate of the same medium containing 300|iCi of 
[^^S]-methionine. For some applications, the cells were stimulated for 15 minutes with 
30ng/ml EGF in methionine free medium prior to [^^SJ-methionine addition. After 
1 hour of cell labelling, the medium was aspirated, and the cultures washed with 
DMEM containing 10% (v/v) FCS and supplements (see section 2.2.1.4). The cultures 
were then incubated in 5ml/plate of the same medium for the indicated periods of time 
prior to harvesting, as described in section 2.2.3.3.
Immunoprecipitates were prepared essentially as described in section 2.2.3.4, 
with the following changes. The lysates were first pre-cleared by incubation with 50pl 
protein A-sepharose beads and 20|il of rabbit pre-immune sera for 1 hour at 4°C with 
rotation. After a brief centrifugation, the supernatant was incubated with 20|il
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anti-TYP 1 antibody overnight, at 4°C with rotation. Following this, 50|il protein 
A-sepharose beads was added and incubated for a further hour at 4°C with rotation. 
The immunoprecipitates were washed with S buffer as described in 2.2.3.4, and 
resuspended in SDS-loading buffer, denatured and loaded onto a 10% SDS-PAGE 
gel. After electrophoresis, the gel was fixed in 10% (v/v) acetic acid, 15% (v/v) 
methanol for 40 minutes, and dried under vacuum at 70°C for 1.5 hours. The gel was 
exposed to X-ray film overnight at room temperature.
2.2.3.6. TC A-precipitation of labelled proteins
To ensure that cycloheximide treatment of COS cells inhibited protein synthesis, 
growing COS cells were treated with 10jig/ml cycloheximide for 30 minutes (see 
section 2.2.1.6). Cultures were then washed with serum-free DMEM, lacking 
methionine, and labelled with 35s-methionine for 1 hour as described in section
2.2.3.5. Control cultures were not treated with cycloheximide. Cell lysates were then 
prepared as described in 2.2.3.3. A lOpl sample of a 10-fold dilution of labelled lysate 
was mixed with 1ml of ice-cold 20% (w/v) trichloracetic acid, and incubated on ice for 
30 minutes. The precipitate was collected on a Whatman GF-C filter and washed 
extensively with cold 5% (w/v) TCA. Filters were washed with 95% (v/v) ethanol, 
air-dried and counted in 10ml Ecoscint.
2.2.3.7. Western blotting
For western blot analysis, 50|ig protein samples were resolved on 10% 
SDS-PAGE gels (see section 2.2.3.1). After electrophoresis, the gel was carefully 
removed from the glass plates, discarding the stacking gel, and soaked in transfer 
buffer (25mM Tris, 191mM glycine, 3.5mM SDS, 20% (v/v) methanol) for 
30 minutes. The protein was transferred in the above buffer onto immobilon-P 
nitrocellulose using a Bio-rad wet trans-blot apparatus run at 30V, 4°C overnight
The filter was blocked overnight at 4°C in TBST (20mM Tris pH 7.5, 150mM 
NaCl, 0.05% (v/v) Tween 20) containing 5% (w/v) non-fat dried milk and 0.025% 
(w/v) sodium azide, and incubated with the primary antibody for 3 hours at room
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temperature, typically TYP 1 antisera diluted 1:1000 in blocking buffer, or monoclonal 
antibody 9E10 diluted 1:1000, which specifically recognises the c-Myc epitope. The 
filter was subsequently washed 3 times for 5 minutes each in TBST, and incubated 
with the secondary antibody for 1 hour at room temperature, anti-rabbit IgG 
conjugated to horseradish peroxidase (1:3000) for TYP 1 antisera, or anti-mouse IgG 
conjugated to horseradish peroxidase (1:15,000) for c-Myc antisera. The filter was 
washed extensively in TBST and immersed in ECL detection reagent for 1 minute. 
Following which the filter was lightly blotted, wrapped in Saranwrap™ and exposed to 
Kodak X-Omat AR for 30 seconds-3 minutes.
2.2.3.8. In vitro protein phosphatase assay
In vitro phosphatase activity of recombinant TYP 1 protein was assayed against 
activated, ERK2 kinase. Recombinant GST-ERK2 MAP kinase (2|ig) was incubated 
on ice with lOOng activated MAP kinase kinase (EE mutant, Alessi et al., 1993a), 
100|iM ATP, and lOmM magnesium acetate in a total volume 20pl buffer B (lOOmM 
Tris pH 7.5, 0.2mM EGTA, 0.1% (v/v) 2-mercaptoethanol). The reaction was 
initiated by incubation at 30°C for 30 minutes. After which, the reaction was diluted 
5-fold with ice-cold BSA buffer (50mM Tris pH 7.5, O.lmM EGTA, 0.1% (v/v) 
2-mercaptoethanol, lmg/ml BSA). The activated, labelled ERK2 kinase was stored at 
-70°C.
The phosphatase activity of TYP 1 protein was assayed indirectly by determining 
the activity of ERK2 against MBP. lOpl of the above activated ERK2 substrate was 
preincubated with 20ng recombinant purified TYP 1 protein for 10 minutes at 30°C, 
and placed on ice. The activity of the ERK2 protein was assayed for by the 
incorporation of phosphate into MBP, exactly as described in section 2.2.3.4. The 
reactions were resolved by gel-electrophoresis as described in section 2.2.3.1. Fixed, 
dried gels were exposed to X-ray film at -70°C overnight.
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2.2.3.9. In vitro dephosphorylation of recombinant ERK2
Recombinant GST-ERK2 MAP kinase was ^ P - l a b e l l e d  ^  activated with 
MAP kinase kinase, purified from rabbit skeletal muscle, in the presence of 
[y-32p]ATP exactly as described in Nakielny et al. (1992). On ice, activated ERK2 
(20U/ml, 125jig) was mixed with recombinant, purified TYP 1 protein (0-12.5jig/ml) 
in a final volume of 10pl B buffer (see 2.2.3.8), in the presence or absence of 2mM 
sodium vanadate. The reaction was initiated by incubation at 30°C for 10 minutes. 
After which, 2|il aliquots of each reaction were mixed with SDS-loading buffer and 
analysed by 10% SDS-PAGE gel (see section 2.2.3.1). The gel was fixed, dried and 
exposed to X-ray film with intensifying screens at -70°C overnight
2.2.3.10. One dimensional phosphoamino acid analysis
The ^pqabeiied ERK2 from above (10p.l samples) was precipitated with 160|il 
of 20% (w/v) TCA (see section 2.2.3.6). After incubation on ice for 30 minutes, the 
protein precipitate was collected by centrifugation for 5 minutes at 14,000g. The 
pellets were washed once with 5% (w/v) TCA, followed with ether, and dried under 
vacuum. The eppendorf tubes containing the dried pellets were transferred to Wheaton 
vials, and 600|il 6M HCL added to the vial (not the eppendorf tube). The vials were 
sealed under vacuum and hydrolysis carried out for 1.5 hours at 90°C, using a Waters 
PICOTAG system. Samples were allowed to cool to room temperature, and re-dried 
under vacuum. Finally the samples were redissolved in 3|il of PAA buffer (4.5% (v/v) 
acetic acid, 0.5% (w/v) pyridine in H2O) containing 20mM of each unlabelled 
phosphoamino acid (phosphoserine, threonine, tyrosine) to serve as markers following 
electrophoresis.
Aliquots (0.5pl) were spotted at a point 2cm away from one edge of a 20cm x 
20cm cellulose thin layer plate (Kodak, 13255 cellulose), keeping more than 1.5cm 
between each sample point. A further two 0.5|il aliquots were applied, allowing the 
plate to dry between applications. Wicks of Whatman paper were placed on opposite 
sides of the plate and wetted with PAA buffer, such that the buffer permeated across 
the plate, the two buffer fronts meeting at the area containing the samples.
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Hydrolysates were resolved using a flat bed electrophoresis unit precoated with 
glycerol to allow thermal conduction, run at 1000V for 50 minutes. The plate was 
maintained below 10°C during electrophoresis using a block cooled with tap water. 
Following electrophoresis, the plate was dried using a hair dryer and immersed for a 
few seconds in 0.5% (w/v) ninhydrin in acetone to visualise the standards. Dried plates 
were exposed to X-ray film overnight at -70°C.
2.2.3.11. In vitro translation
In vitro translation was carried out using the TNT™ Coupled Reticulocyte 
Lysate System from Promega, essentially as described by Promega instructions. This 
system incorporates transcription from SP6, T3 or T7 RNA polymerase promoters 
directly in the translation mix, which uses standard rabbit reticulocyte lysates.
Reagents were removed from storage at -70°C and thawed on ice. To an 
eppendorf tube placed on ice, 25|il rabbit reticulocyte lysate was added together with 
2|il reaction buffer, ljxl amino acid mix minus methionine (ImM), l|il RNasin 
ribonuclease inhibitor (40 units), 4pl [L-^^Sjmethionine (lOOOCi/mmol, Amersham), 
ljxg DNA template (pCITE-TYP 1 and/or pSPT19-c-Jun) and ljil RNA polymerase 
(T7) in a total volume 50jil. The components were gently mixed and incubated at 
30°C for 2 hours. For non-radioactive control reactions, a complete amino acid mix 
was used. After translation, the reactions were terminated by the addition of 
O.lmM emetine. To determine TYP 1 phosphatase activity towards c-Jun, 10|il 
samples of translated TYP 1 and c-Jun, treated with O.lmM emetine, were mixed and 
incubated at 30°C for 30 minutes. All samples (20jil) were mixed with SDS-loading 
buffer, denatured and loaded onto 10% SDS-PAGE gel, as described in 2.2.3.1. 
Following electrophoresis, the gel was fixed for 30 minutes in (v/v) 10% acetic acid, 
15% (v/v) methanol, and dried under vacuum at 70°C for 1.5 hours. The gel was 
exposed to X-ray film at room temperature.
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2.2.4. Molecular Biology
2.2.4.1. Preparation of genomic DNA from cell lines.
DNA was prepared using the salting out method as described by Miller et al.
(1988). Cells were lysed in 3ml lysis buffer (lOmM Tris-HCL, 400mM NaCl, 2mM 
EDTA, pH 8.2) and digested overnight at 37°C with 0.2ml 10% (w/v) SDS and 0.5ml 
protease K solution (lmg protease K in 1% (w/v) SDS, 2mM EDTA). After digestion, 
lml saturated NaCl (approximately 6M) was added and the tube shaken vigorously for 
15 seconds, followed by centrifugation (Beckman J2-21) at 3000g for 5 minutes to 
pellet the protein. Exactly two volumes of room temperature ethanol was added to 
precipitate the DNA strands, which were spooled out on a glass pipette, air-dried and 
resuspended in 100-200pl TE (lOmM Tris-HCL, 0.2mM EDTA, pH 7.5). DNA 
concentrations were determined by measuring absorbance at 260nm and using the 
conversion of 10D unit at 260nm is equivalent to a concentration of 50pg/ml. The 
ratios 260nm/280nm should be 1.8-2.0 showing good deproteinization of the DNA 
sample. Genomic DNA was stored at 4°C.
2.2.4.2. Total RNA extraction from mammalian cell lines.
Extraction of total RNA from mammalian cell lines was carried out following the 
manufacturer’s protocol for RNAzol™ B (Cinna/Biotecx). Sub-confluent cells grown 
in 1 7 5 cm 2  flasks were washed twice in ice-cold PBS which was completely removed 
by aspiration. Cells were subsequently lysed directly in the culture flask by the addition 
of 6ml RNAzol™ B (lml/3.5cm dish). A disposable cell scraper was implemented to 
homogenise the cells, and the RNA was solubilised by passing the lysate a few times 
through the pipette. Chloroform was added (0.2ml per 2ml lysate) and the glass corex 
tubes vigorously shaken for 15 seconds, then incubated on ice for 5 minutes. The 
samples were centrifuged at 12,000g, 4°C for 15 minutes after which the upper, 
colourless aqueous phase was transferred to a fresh corex tube and an equal volume of 
isopropanol added. The samples were stored overnight at -20°C. The RNA precipitate 
was pelleted by centrifugation at 12,000g, 4°C for 25 minutes. The RNA pellet was 
washed once with 2ml ice-cold 75% (v/v) ethanol by vortexing and centrifugation at
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7,500g, 4°C for 8 minutes. The RNA was air-dried and redissolved in 500|il 
diethylpyrocarbonate (DEPC) RNase-free water. Note, all solutions and tubes should 
be pre-treated with DEPC to prevent RNase contamination. The RNA concentration 
was determined by measuring the absorbance at 260nm and using the conversion of 
10D unit being equivalent to 40(ig/ml. RNA was stored at -20°C.
2.2.4.3. Preparation of poly (A)+ RNA
Poly (A)+ RNA was prepared using the PolyATtract® mRNA Isolation System 
I from Promega. The system uses a biotinylated oligo (dT) primer to hybridise at high 
efficiency in solution to the 3' poly A region present in eukaryotic mRNA species. The 
hybrids are captured and washed at high stringency using streptavidin coupled to 
paramagnetic particles and a magnetic separation stand.
In a sterile, RNase-free eppendorf, lmg of total RNA was combined with 
RNase-free H2O to a final volume of 500pl, and placed in a 65°C heating block for 
10 minutes. After which 13j l l 1 20X SSC and 3|il biotinylated-oligo (dT) probe (both 
reagents supplied) was added, mixed gently and incubated at room temperature until 
completely cooled. Streptavidin-paramagnetic particles (supplied) were resuspended 
gently using a pipette and 0.6ml aliquoted per lmg total RNA into a screw top 
eppendorf. The beads were captured by placing in a magnetic stand and washed three 
times with 0.5X SSC (0.3ml per wash). Washed beads were resuspended in 0.5ml of 
0.5X SSC, and the entire contents of the annealing reaction added. This was incubated 
at room temperature for 10 minutes. The beads were then captured using the magnetic 
stand and washed four times with 0.1X SSC (0.3ml per wash). After the final wash, as 
much of the aqueous phase as possible was removed using an aspirator. The mRNA 
was eluted from the solid phase by two successive washes with RNase-free deionized 
H2O (lOOjil and 150jil). The pooled eluate (0.25ml total) was frozen at -20°C and 
then freeze-dried to a volume of approximately lOp.1 for northern analysis. The mRNA 
was stored at -20°C, and typically yielded 10|ig.
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2.2.4.4. First strand cDNA synthesis
For cDNA preparation, poly (A)+ RNA (10|ig) was converted into first strand 
cDNA using 500 U Mo-MLV reverse transcriptase in a buffered solution (50mM Tris- 
HC1 pH 8.3, 75mM KC1, 3mM MgCl2) containing lOmM DTT, O.lmM Oligo (dT)i2 
and 0.25mM each dNTP in a total volume of 50jil, incubated for 1 hour at 37°C. The 
cDNA synthesis reactions were terminated by heating at 65°C for 10 minutes and 
then stored at 4°C. For PCR applications, cDNA was purified using Geneclean (see 
2.2.4.9) and eluted in 50|il TE.
2.2.43. Minipreparations of plasmid DNA
Small amounts of plasmid DNA were prepared using the alkaline lysis method as 
described by Maniatis et al. (1989). Single colonies of bacteria carrying the required 
plasmid were picked from agar plates using a sterile loop and grown in 5ml L-broth 
(1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, pH 7.0) 
supplemented with the appropriate antibiotic (50|ig/ml ampicillin) at 37°C in a shaking 
incubator. Bacteria were pelleted from 5ml of the overnight culture at low speed for 
1 minute in a bench top centrifuge. The drained pellet was resuspended in 200|il of 
solution I (50mM Glucose, 25mM Tris-HCL pH 8.0, lOmM EDTA pH 8.0) and 
transferred to an eppendorf. After incubation for 5 minutes at room temperature, 
alkaline lysis was effected by the addition of 400|xl of freshly made, ice-cold solution II 
(0.2M NaOH, 1% (w/v) SDS). The samples were mixed by inversion and placed on 
ice for 5 minutes. Lysis was terminated by the addition of 300pl ice-cold solution III 
(3M KAc pH 4.8), vortexed and incubated on ice for a further 5 minutes. The 
precipitated cell debris was pelleted in a bench top microcentrifuge for 2 minutes and 
the supernatant removed to a fresh eppendorf tube. At this point RNase treatment was 
employed, which involved incubation with lOmg/ml RNase for 10 minutes at 60°C. 
The nucleic acids were precipitated by adding two volumes of ice-cold ethanol to the 
supernatant, standing at room temperature for 5 minutes and microcentrifuged for 
10 minutes. The pellet was washed in 1ml -20°C 70% (v/v) ethanol, microcentrifuged 
for 10 minutes and all ethanol removed using an aspirator. The pellet was air-dried and
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dissolved in 25jil TE. Plasmid DNA was stored at -20°C. Typically, 2|il of this 
minipreparation was digested for mapping purposes.
2.2.4.6. Large scale preparation of plasmid DNA
A 10ml overnight culture was transferred to 500ml L broth containing antibiotic 
(50|ig/ml ampicillin) and shaken at 37°C overnight. Cells were pelleted from the 
overnight culture in polypropylene botdes at 5000rpm, 4°C for 10 minutes, rinsed 
with 50mM Tris-HCL pH 8.0 and resuspended in 25ml lysozyme solution (25mM 
Tris-HCL pH 8.0, lOmM EDTA, 50mM glucose containing 5mg/ml lysozyme) for 
30 minutes at room temperature. Following this, 40ml solution II (0.2M NaOH, 
1% (w/v) SDS) was added, mixed well and placed on ice for 15 minutes. Protein and 
detergent was then precipitated by adding 20ml solution III (3M KAc pH 4.8), mixed 
by inversion and kept on ice for a further 15 minutes. The flocculates were centrifuged 
at 10,8lOg, for 5 minutes at 4°C. The supernatant was filtered through a gauze, and 
the DNA precipitated by adding 0.6 volumes of -20°C isopropanol and immediately 
centrifuged at 10,8 lOg, room temperature for 5 minutes. After discarding the 
supernatant, the pellet was drained thoroughly and then resuspended in 5ml TE, 
pH 8.0.
Plasmid DNA was purified on a CsCl gradient. Precisely 7.5g CsCl was 
dissolved in the 5ml DNA solution in a plastic universal, and 5mg ethidium bromide 
added. The refractory index was adjusted to 1.3860-1.3900 with TE pH 8.0 or CsCl. 
The CsCl solution was balanced in Beckman polycarbonate tubes and centrifuged in a 
Beckman TL-100 ultracentrifuge (rotor TLA-100) at 40,000 rpm for 40 hours at 
20°C.
The plasmid band was removed from the gradient using a syringe with a 19 
gauge needle and extracted with an equal volume of water-saturated isobutanol until 
all the ethidium bromide had been removed. The DNA was precipitated by adding an 
equal volume of water and 2 volumes of room temperature ethanol, and left standing 
at room temperature for 15 minutes. The DNA was pelleted in glass corex tubes by 
centrifugation at ll,950g, 4°C for 15 minutes. The pellet was resuspended in
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lml deionised H2O and re-precipitated with 0.1 volumes 3M NaOAc pH 5.0 and 
2 volumes ethanol at -20°C for 1 hour. DNA used for transfection of cells in culture 
was phenol/chloroform extracted before precipitation. The DNA pelleted as above, 
was rinsed with 70% (v/v) -20°C ethanol, freeze-dried and dissolved in TE, pH 8.0. 
The DNA concentration was measured as described in section 2.2.4.1.
2.2.4.7. Restriction enzyme digest of DNA
Plasmid DNA (<2jig) was incubated with 5-10 units enzyme in a buffered 
solution as specified and supplied by the manufacturer for 1-2 hours at 37°C. Larger, 
preparative digests were carried out in proportionally larger volumes. For double 
digests, manufacturer's information was consulted and the appropriate buffer used.
Digestion of genomic DNA (30-50|ig) was carried out essentially as described 
except digestion was continued overnight. Following this, a 5pl sample was analysed 
by gel electrophoresis (see below) to determine the extent of digestion. Where 
necessary a further aliquot of enzyme was added and incubation continued. Due to the 
inhibitory effects of high glycerol concentrations, the volume of enzyme used never 
exceeded 1/10th of the total volume.
All reactions were terminated by the addition of DNA loading buffer and 
digestion fragments were analysed by agarose gel electrophoresis as described below.
2.2.4.8. Agarose gel electrophoresis
Flat bed electrophoresis apparatus was used. Non-denaturing agarose gels 
(0.8%-1.5% (w/v) agarose) were cast in IX TAE buffer (40mM Tris base, 
16mM acetic acid, ImM EDTA, pH 8.0) containing 0.5|ig/ml ethidium bromide. The 
gel was submerged in IX Tae buffer. Samples for electrophoresis, and molecular 
weight standards (bacteriophage X Hind-III digested or 0X174 Hae-in digested) were 
mixed with one tenth volume of gel loading buffer (0.25% (w/v) bromophenol blue, 
30% (v/v) glycerol in TE), loaded and resolved by electrophoresis towards the anode 
at 100V for 30-60 minutes. The separated DNA was visualised by illumination with
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short wave (312nm) UV light and photographed through a red filter using polaroid 
type 57 high speed film or using an appligene imager.
2.2.4.9. Elution of DNA fragments from agarose gels
Geneclean II® (BIO 101) was used according to manufacturer's instructions. 
The required DNA fragment was excised from the gel and the agarose block 
containing the fragment was weighed and volume calculated (lg = 1ml). 2.5 volumes 
of 6M Nal was added and the agarose incubated at 55°C for 5 minutes to induce gel 
melting. Following this, 5pl glassmilk®, a suspension of silica matrix in water which 
binds single and double-stranded DNA without binding contaminants, was added for 
every 5pg or less DNA. This was mixed and left at room temperature for 5 minutes to 
allow binding. The glassmilk was pelleted by brief centrifugation and washed 3 times 
by mixing with 300|il NEW wash ( a Tris and EDTA-buffered solution of NaCl, 
ethanol and H2O), pelleting the glassmilk and removing the supernatant. Finally, half 
the desired volume of TE was added to the cleaned pellet and heated to 55°C for 
5 minutes. The glassmilk was pelleted and the TE containing DNA removed to a fresh 
eppendorf. This was repeated to elute all the DNA. Typically for most applications 
DNA was eluted in 20pl final.
2.2.4.10. Ligation of DNA/PCR fragments
Vector DNA was digested as described in section 2.2.4.7. The DNA fragment to 
be inserted was also digested as above and then isolated by gel electrophoresis and 
purified as described in section 2.2.4.9.
To prevent the vector DNA from ligating back to itself without an insert, it was 
first dephosphorylated. The vector DNA was digested with the required enzyme as 
directed by the manufacturer and an aliquot removed to check that digestion was 
complete. The linearized plasmid DNA was dephosphorylated using calf intestinal 
alkaline phosphatase (5 units) essentially according to Maniatis et al. (1989), except 
that reactions were carried out in restriction buffer. The final volume (twice the 
digestion volume) was made up with H2O and the reaction incubated at 37°C for
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1 hour. The digested, dephosphorylated DNA was then isolated by electrophoresis and 
purified using Geneclean II® (see section 2.2.4.9).
PCR products were cloned by blunt-end ligation as described by Ashworth, 
(1993). PCR products electrophoresed in agarose and purified using Geneclean II® 
(eluted in 13|il water) were mixed with kinase buffer (70mM Tris-HCl pH 7.5, lOmM 
MgCl2), lmM ATP, lOmM DTT and T4 polynucleotide kinase (5 units) in a total of 
20|il, and incubated at 37°C for 30 minutes. After which 0.5mM each dNTP and 
Klenow polymerase (5 units) were added, mixed and incubated 15 minutes at room 
temperature. The DNA was purified using Geneclean n® and eluted into 16fil H2O.
Ligations were effected in a minimum volume (20|il). The insert was ligated to 
the dephosphorylated vector (10-20ng) at a ratio 3:1 respectively, (for PCR products 
the total 16jil was used). The vector and insert DNA were mixed on ice in a reaction 
containing ligase buffer (66mM Tris-HCl pH 7.5, 5mM MgCl2, lmM ATP, 
lmM DTT) and T4 DNA ligase (5-10 units), and incubated at room temperature for a 
minimum of 2 hours.
2.2.4.11. Transformation of competent bacterial cells
Competent E.coli DH5a cells were thawed on ice and to each 200|il aliquot, the 
appropriate amount of plasmid DNA or ligation mix (lOjil) was gently added. After 
incubation on ice for 30 minutes, the cells were heat shocked for 5 minutes at 37°C, 
and then returned to ice. 0.5ml of SOC medium (2% (w/v) bactotryptone, 0.5% (w/v) 
yeast extract, lOmM NaCl, 2.5mM KC1, lOmM MgCl2, lOmM MgS04 , 
20mM glucose) was added to the cells, which were returned to 37°C for 40 minutes 
to allow expression of the antibiotic resistance marker. Cells were then pelleted by 
brief centrifugation and resuspended in 50|il of L-broth. All cells were spread onto an 
L-broth agar plate (15g Bacto-Agar/litre L-broth) containing antibiotic and incubated 
overnight at 42°C. Plasmid DNA was prepared from transformed colonies as 
described in section 2.2.4.5, or amplified by PCR as in section 2.2.4.16b.
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2.2.4.12. Radioactive labelling and purification of DNA probes
DNA fragments were 32P labelled using an oligolabelling kit (Pharmacia) as per 
manufacturer's instructions. DNA (50ng-100ng) in a volume of no more than 34(il was 
denatured by heating for 2 minutes at 100°C, and then placed on ice prior to the 
addition of 10|il reagent mix (buffered aqueous solution containing dATP, dGTP, 
dTTP and random hexadeoxy-ribonucleotides), 50|iG [a-32P]dCTP and 10 units 
Klenow fragment. The reaction mix was incubated at 37°C for 1 hour.
The labelled probe was purified on a sephadex-G50 column. Eppendorf tubes 
pierced at the bottom were packed with sephadex-G50 equilibrated in TE buffer 
(pH 8.0), excess liquid was removed by centrifugation at 2000rpm for 3 minutes. 
Samples were subsequently spun at 2000rpm for 5 minutes, and the unincorporated 
nucleotides retained in the beads. Radioisotope incorporation in the probe was 
monitored using a scintillation counter.
2.2.4.13. Southern analysis
30|ig of digested genomic DNA samples (see section 2.2.4.7) were 
electrophoresed on a 0.8% (w/v) agarose gel together with Hind-III digested X DNA 
to serve as markers. Electrophoresis was overnight at 30V in IX TAE buffer. The 
DNA was photographed and the gel depurinated by soaking in 0.25M HC1 until the 
dye front changed to a yellow colour. The gel was rinsed in deionised H2O and the 
DNA transferred overnight onto Hybond N+ membrane by upward capillary blotting 
using 0.4M NaOH, essentially as described in Maniatis et al. (1989). The blot may be 
stored wrapped in Saranwrap™ at 4°C.
The detection of specific DNA species was carried out using the method of 
Church and Gilbert, (1984). Membranes were pre-hybridised at 65°C for 1 hour in 
sealed plastic bags containing approximately 25ml aqueous hybridisation solution 
(0.5M Na2HPC>4 pH 7.2, lmM EDTA, 7% (w/v) SDS). Probes, labelled by the 
random priming method above, were denatured at 100°C for 2 minutes and incubated 
with the membranes in a minimal volume of fresh hybridisation solution (5 x 
l O ^ c p m / m l ) .  Membranes were hybridised overnight at 65°C in a shaking water bath.
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To remove non-specific binding the membranes were washed at high stringency 
(40mM Na2HPC>4, 1% (w/v) SDS), with multiple quick washes at room temperature 
followed by a final wash at 65°C for 20 minutes. Excess liquid was removed and the 
membrane wrapped in Saranwrap™ and exposed to photographic film (either Kodak 
X-OMAT AR or Fuji RX) with intensifying screens at -70°C.
2.2.4.14. Northern Analysis
Northern analysis was carried out essentially as described by Maniatis et al.
(1989). Poly (A)+ RNA samples (10|ig) were mixed with 3 volumes RNA loading 
buffer (2ml contains 350jil formaldehyde, 1ml formamide, 150jil RNA loading dye 
{50% (v/v) glycerol, O.lmM EDTA, 0.6% (w/v) bromophenol blue, 0.6% (w/v) 
xylene cyanol) 30|il ethidium bromide - lOmg/ml stock, 200(il 5X Mops buffer 
containing 0.1M Mops, 40mM sodium acetate, 5mM EDTA, pH 7.0) and heated for 
10 minutes at 65°C. The samples were loaded onto a 1% (w/v) agarose gel containing 
20% (v/v) 5X Mops, 17.5% (v/v) formaldehyde. Electrophoresis was overnight at 
30V in IX Mops buffer which was constantly recirculated. The RNA was 
photographed and the gel soaked in deionised H2O for 10 minutes to leach out the 
formaldehyde. Transfer of the RNA to Hybond N+ membrane was the same as for 
southerns, except that the buffer used was 20X SSC (3M NaCl, 0.3M sodium citrate, 
pH 7.0). The membrane was UV-crosslinked using a UV Stratalinker 1800 
(Stratagene).
Membranes were prehybridised in 10ml of hybridisation solution (50% (v/v) 
deionised formamide, 10X Denhardt's solution {100X stock contains lOg ficoll, 
lOg polyvinylpyrrolidone, lOg BSA in 500ml H2O}, 5X SSPE {20X stock contains 
3M NaCl, 0.2M NaH2P04 .H20 , 20mM EDTA, pH 7.4) 2% (w/v) SDS, lmg/ml 
yeast RNA) at 42°C for a minimum 5 hours, using Hybaid™ bottles in a Mini oven 
MK II (as per manufacturer's instructions, rotation speed 7). The hybridisation 
solution was replaced with fresh solution containing the radiolabelled probe (prepared 
as in section 2.2.4.12) at a concentration of 5 x 10^cpm/ml, and hybridised at 42°C 
overnight. The membrane was washed at low stringency (2X SSC, 0.05% (w/v) SDS)
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several times at room temperature, and then at high stringency (O.IX SSC, 0.1% (w/v) 
SDS) at 50°C for 40 minutes with one change of fresh wash solution. Excess solution 
was shaken from the membrane, and the blot covered in Saranwrap™ and exposed to 
X-ray film (as above) at -70°C with intensifying screens.
Radioactive probe was stripped from the membrane by gentle agitation of the 
blot for 10 minutes in sterile H2O containing 0.5% (w/v) SDS which had been heated 
to 100°C. The solution was allowed to cool before the membrane was removed. The 
membrane can be stored wrapped at -20°C.
2.2.4.15. Oligonucleotide synthesis and purification
Oligonucleotides were synthesised on an Applied Biosystems 381A DNA 
synthesiser or 392 DNA/RNA Synthesiser using the manufacturer's protocols and 
Cruachem reagents. Primers were synthesised with or without trityl group protection. 
All these primers were firstly deprotected by incubation overnight at 55°C.
"Trityl on" primers were detritylated using an Applied Biosystems 
oligonucleotide purification cartridge. 5ml acetonitrile was passed through the column 
to waste at a rate of 1 drop/sec using a syringe. This was followed by 5ml 
2M triethylammonium acetate. The deprotected oligonucleotide ammonium solution 
was diluted with an equal volume of distilled H2O and passed through the column the 
same way. The eluate was collected and passed through a second time. The cartridge 
was then flushed through with 5ml 10% (v/v) ammonia and 10ml distilled H2O. The 
oligonucleotide was detritylated while bound to the support by passing 2.5ml 2% (v/v) 
trifluoroacetic acid through the column, allowing it to stand for 5 minutes and 
repeating. The cartridge was then flushed with 10ml distilled H2O. The 
oligonucleotide was eluted drop-by-drop with 3 ml 20% (v/v) acetonitrile, freeze-dried 
overnight and dissolved in 250ml TE pH 8.0. Primer concentration was determined by 
measuring absorbance at 260nm and using the conversion that 33OD260 equivalent 
to lmg/ml. Primers were stored at -20°C.
"Trityl o ff  primers were purified by desalting by precipitation with butan-l-ol. 
lml butan-l-ol was added per 150jil primer solution and microcentrifuged at 13,000g
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for 20 minutes at room temperature. Excess butanol was removed by centrifugation 
under vacuum and the primer dissolved in 150|il TE pH 8.0. Primer concentrations 
were calculated as above.
2.2.4.16. Polymerase chain reaction (PCR)
a) Generation of novel phosphatase probes
Approximately lOng A431 cDNA (see section 2.2.4.4) was used as a template in 
conjunction with 50pmol of each degenerate oligonucleotide primer (see Table 3, p72) 
in a PCR reaction, essentially as described in Ashworth, (1993). A master mix 
comprising of 200|iM of each dATP, dCTP, dTTP, and dGTP, IX PCR buffer 
(15mM Tris-HCl pH 8.8, 60mM KC1, 2.25mM MgCl2), 50pmol of each 
oligonucleotide and 2.5 units Taq polymerase (a themolabile DNA polymerase from 
Thermus aquatic us), was aliquoted into 0.5ml polypropylene microcentrifuge tubes to 
a volume of 49|il. The template (l|il) was added last to reduce the chances of cross 
contamination, thorough mixing is unnecessary, and the reactions were overlaid with 
lOOjil of light mineral oil. DNA amplification was performed using a Techne PHC-1 
thermal cycler for 30 cycles of denaturation (94°C, 20 seconds), annealing (52°C, 
20 seconds), and extension (72°C, 45 seconds), with a final extension (72°C, 
10 minutes). Samples were stored at 4°C. The reaction products (5|il of each sample), 
were resolved by agarose gel electrophoresis (see section 2.2.4.8) and fragments of the 
expected size, 260bp, were excised and purified using the Geneclean kit (eluted in 
15pl as described in section 2.2.4.9). The PCR products were cloned into 
pBluescript® II KS (Stratagene) by blunt-end ligation (see section 2.2.4.10) and 
sequenced directly from bacterial colonies (see below).
b) Amplification of DNA from bacterial colonies
It is most convenient to sequence directly from bacterial colonies harbouring 
plasmids containing the subcloned PCR product. This is done by PCR on the bacterial 
colonies, whereby the PCR product can then be sequenced. PCR was carried out 
essentially as described in the previous section. Primers were complementary to
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regions flanking the restriction site used for subcloning, namely Reverse and M l3-20 
(see Table 2, p72). Using a disposable microbiological loop, bacterial colonies were 
picked and the loop twirled in the PCR master mix for 2-3 seconds. The loop was then 
used to innoculate 5ml L-broth cultures such that a stock of the bacterial colony was 
made, as described in section 2.2.4.5. Mineral oil was then added to the PCR tubes 
and DNA amplification continued as described above in section a). PCR products were 
analysed by agarose gel electrophoresis, bands were excised, the DNA purified by the 
Geneclean procedure and sequenced directly by the method described below.
If further sequencing of the bacterial clone was required, PCR analysis was 
performed on the bacterial culture after overnight growth as follows. 100|il bacterial 
culture was centrifuged for 1 minute in a microfuge, and the supernatant discarded. 
The pellet was resuspended in 50|il H2O and the tube boiled for 5 minutes, 
centrifuged for 1 minute, and lfil of the supernatant used in the PCR reaction, as 
described above in section a).
2.2.4.17. Sequencing
a) Direct sequencing of PCR products
Sequencing was carried out according to the chain termination reaction of 
Sanger et al. (1977), essentially as described in Ashworth, (1993). The PCR product 
was purified using Geneclean and eluted in 15|il H2O. In a flip-top eppendorf, 7|il 
(0.25-l.OjJ.g) PCR product was mixed with ljxl (lOpmol) of the appropriate 
sequencing primer, (see Tables 2 and 3, p72) and placed in a heating block at 
95-100°C for 5 minutes. Typically the primers used were internal to the primers used 
in the PCR reaction. The tube was placed on dry ice for 1 minute to freeze, and then 
centrifuged briefly (2-3 seconds) in a microcentrifuge. The annealed DNA was labelled 
by adding 7.5|il of a previously prepared reaction mix composed of 2|il 5X sequencing 
buffer (5X is 200mM Tris-HCl pH 7.5, lOOmM MgCl2, 250mM NaCl), lp l DTT 
(lOOmM), 2|il labelling mix (7.5pM dCTP, dGTP, and dTTP diluted 1:4 in H2O), 
0.5|il [a-35S]ATP, and 2|il (2 units) T7 DNA polymerase (Pharmacia; diluted 8 fold 
in lOmM Tris-HCl pH 7.5, 5mM DTT, 0.5mg/ml BSA). This was centrifuged briefly
95
and incubated at room temperature for 2 minutes. During this time, 3.5pl of this 
labelling mix was added to the lip of each of the four eppendorf tubes containing T, C, 
G, A termination mixes. The termination reaction was initiated by brief centrifugation, 
and the tubes then placed in a 37°C water bath and incubated for 5 minutes. The 
reactions were stopped by addition 4jil formamide/dye mix (95% (v/v) formamide, 
20mM EDTA, 0.05% (w/v) bromophenol blue), and the samples heated to 95°C for 
2 minutes prior to loading onto a polyacrylamide gel as described below in section c).
b) Preparation and sequencing of double-stranded plasmid DNA
Minipreparation plasmid DNA was prepared as in section 2.2.4.5, and 
12pl DNA used for sequencing for each primer. The DNA was denatured by adding 
0.1 volumes of 2M NaOH, 2mM EDTA and incubating at 37°C for 30 minutes. The 
mix was neutralised by the addition 0.1 volume 3M sodium acetate pH 4.5-5.5, and 
the DNA precipitated using 2X volume ethanol at -70°C for 15 minutes. The DNA 
precipitate was microcentrifuged for 10 minutes, washed with 70% (v/v) ethanol, 
air-dried and redissolved in 7pl H2O.
Sequencing was carried out essentially as described in the sequenase® kit 
(United State Biochemicals). 7pi denatured DNA was added to 2fil 5X sequencing 
buffer (as above) and lpl (lOpmol) appropriate primer (see Table 3). The primer was 
annealed by incubation at 65°C for 2 minutes followed by a slow cool to room 
temperature. The annealed DNA was labelled using the same method as described in 
section a).
c) Analysis of sequencing reactions
Sequencing reactions were analysed by denaturing gel electrophoresis. A 6% 
polyacrylamide gel (acrylamide to bisacrylamide 19:1) in TBE (lx TBE is 90mM Tris, 
90mM boric acid, 2mM EDTA) containing 42% (w/v) urea was polymerised with 
0.08% (v/v) APS and 0.8% (v/v) TEMED and immediately poured between gel plates 
separated by wedged (0.4- 1.0mm) spacers. The gel was then placed in a vertical 
apparatus (BRL Life Technologies, model S2) with both ends submerged in IX TBE
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buffer. Samples were heated to 95°C for 2 minutes and 4pl loaded onto the gel using a 
sharks-tooth comb. The gel was run at 85W for approximately 3.5 hours. The gel was 
fixed in a solution of 10% (v/v) acetic acid for 45 minutes and transferred to 3MM 
Whatman paper, covered with Saranwrap™ and dried under vacuum at 80°C for 
2 hours. The gel was exposed direcdy onto Kodak X-OMAT AR film at room 
temperature. Autoradiographs were read from the bottom (5' end of DNA) upwards.
2.2.4.18. cDNA library screening
A custom human brain, and rodent liver library constructed in the ZAP II vector 
was acquired from Stratagene, and plating and screening was carried out essentially as 
described in the Stratagene instruction manual, outlined briefly below.
a) Preparation of plating cultures
E.coli XL 1-Blue carry the F  episome, which is required for both colour 
selection (not utilised in this case), and the in vivo excision process (see section 
2.2.4.19). The TnlO tetracycline gene is also located on the F  episome, therefore, in 
the presence tetracycline, the episome is selectively maintained.
XLl-blue cells were streaked onto an L-broth agar plate containing 12.5pg/ml 
tetracycline, and grown at 37°C until colonies appeared. A colony was used to 
innoculate 50ml L-broth supplemented with 0.2% (w/v) maltose and lOmM MgSC>4 
and grown overnight with shaking at 30°C. This temperature ensures that cells will 
not overgrow since phage can adhere to dead cells. The culture was centrifuged at 
2000rpm for 10 minutes, and the pelleted cells gently resuspended in 15ml of 
lOmM MgSC>4. The cells were diluted to OD500 = 0.5 with lOmM MgS04  and 
stored at 4°C for 3 days maximum. Approximately 1ml of OD500 -  0-5 was needed 
for each 245mm square plate and 200jil of OD500 = 0-5 cells for each 100mm plate.
b) Titering phage
The Lambda ZAP n  phage was diluted in 4 serial, 10-fold dilutions in TM buffer 
(lOmM MgSC>4, 50mM Tris-HCl pH 7.5). In a 15ml sterile tube, 200|il of XLl-blue
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cells diluted to OD500 = 0-5 were mixed with l|il of each Lambda phage dilution and 
incubated at 37°C for 15 minutes to allow the phage to attach to the cells. 3ml molten 
top agar (0.7% (w/v) agarose in L-broth cooled to 48°C) was added to the 
culture/phage mix and poured immediately onto warmed (42°C) 100mm L-broth 
plates. The plates were left to harden at room temperature and then incubated at 42°C 
overnight The number of plaques per plate were counted and the titre calculated using 
the formula:
titer = (no. plaques x 1000 x dilution factor) pfu/ml.
c) Screening cDNA library
For both the human brain and rodent liver library, approximately 7.5 x 10^ 
pfu/plate were plated on four large 245mm square L-broth plates with 1ml of OD600 
= 0.5 XL 1-Blue cells/plate and 30ml top agar/plate. These were incubated overnight at 
42°C. The plates were refrigerated for 2 hours at 4°C prior to taking lifts, as this 
prevents the top agar from sticking to the nitrocellulose filter.
For each plate, Hybond N+ membrane (Amersham) was layered onto the plate 
and left for 1 minute. Five orientation marks were made with a needle through the 
membrane into the agar. After transfer, the filter was carefully lifted ensuring not to 
drag the membrane across the plate, and inverted over 3-4ml denaturation solution 
(1.5M NaCl, 0.5M NaOH) placed on a piece of Saranwrap™, and left for 2 minutes. 
After which the filter was transferred to 3-4ml neutralisation solution (1.5M NaCl, 
0.5M Tris-HCl pH 8.0) for 5 minutes. The filter was rinsed in 50mM Na2HPC>4, 
briefly blotted with 3MM Whatman paper, and UV-crosslinked using a UV 
Stratalinker 1800 (Stratagene). The agar plates were stored at 4°C.
The filters were prehybridised, hybridised and washed using the method of 
Church and Gilbert, (1984), as described in section 2.2.4.13. The probe was a mixed 
product of two PCR reactions, each using the degenerate oligonucleotides with 
l|il culture supernatant from the two most frequently isolated novel phosphatase 
clones, which had been subcloned into pBluescript (see section 2.2.4.16b). The 
degenerate primers were used in the PCR instead of internal pBluescript primers,
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because the library cDNA was also cloned into a pBluescript vector. Each PCR 
product was purified using Geneclean, and approximately lOng DNA from each was 
mixed and radiolabelled as described in section 2.2.4.12. The filters were wrapped in 
Saranwrap™ and exposed overnight onto Kodak X-OMAT AR film with intensifying 
screens at -70°C.
The films were orientated against the filters using the needle marks, and positive 
clones determined using the strongest signals on the film. The end of an inverted 
pasteur pipet was used to "core" the putative clones from the stock agar plates, and 
the agar plug placed into an eppendorf tube with 500|il TM buffer and 20|il 
chloroform. The tube was briefly vortexed and incubated overnight at 4°C to elute the 
phage. The phage stock is stable for 1 year at 4°C.
For each positive clone, lOOjil of a 200-fold dilution of eluted phage in TM 
buffer was added to 200|il XLl-Blue cells at OD500 = 0-5* incubated at 37°C for 
15 minutes, mixed with 3.5ml molten top agar, and poured onto 100mm L-broth 
plates. Transfer to nitrocellulose filters and screening was carried out as previously 
described above. This procedure was repeated for a total of four platings, such that 
single, positive plaques were isolated.
d) In vivo excision of the pBluescript phagemid
In vivo excision of the cloned insert is dependent upon the simultaneous 
infection of XLl-blue cells with both the lambda vector (containing cloned insert) and 
the M13 helper phage (ExAssist™). The F  episome is required for pili formation, 
necessary for superinfection with the ExAssist helper phage. The M l3 phage proteins 
recognise the sites of initiation and termination for DNA synthesis, which have been 
subcloned separately into the Lambda ZAP II vector. The newly synthesised phagemid 
is secreted from the E.coli, and rescued by transformation into SOLR cells. 
Subsequent bacterial colonies contain the pBluescript double-stranded phagemid with 
the cloned DNA insert. Helper phage will not grow, since they are unable to replicate 
in Su“ (non-suppressing) SOLR strains and do not contain ampicillin-resistance genes.
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SOLR cells are also resistant to lambda phage infection, preventing lambda DNA 
contamination.
Single plaques, isolated as described above, were placed in 500|il TM buffer 
with 20pl chloroform and incubated overnight at 4°C. In a 50ml conical tube 200p.l of 
OD600 = 1-0 XLl-Blue cells, prepared as in section 2.2.4.18a), were combined with 
lOOp.1 eluted phage stock and l|il ExAssist helper phage, and incubated at 37°C for 
15 minutes. After which, 3ml of terrific broth (for 1 litre: 12g bacto tryptone, 
24g bacto yeast extract, 4ml glycerol. After autoclaving add 100ml solution B {0.17M 
KH2PO4, 0.72M K2HPO4}) was added and incubated at 37°C with shaking for 
2.5 hours. The tube was heated at 70°C for 15 minutes, and centrifuged for 5 minutes 
at 4000g. The supernatant containing the pBluescript phagemid, packaged as phage 
particles, was stored at 4°C.
To rescue the phagemid, l|il supernatant from above was added to 200|ll 
ODboo =1-0 SOLR host cells, and incubated at 37°C for 15 minutes. The SOLR cells 
were prepared as described for XL 1-Blue cells, see section 2.2.4.18a, with the 
following changes: SOLR cells were streaked on L-broth agar plates containing 
50p.g/ml kanamycin. Overnight cultures were grown in L-broth with no supplements. 
Following incubation, 10|il and 100}il of the phage/S OLR mix was spread onto 
L-broth plates containing 50|ig/ml ampicillin, and incubated overnight at 42°C. 
Minipreparations of plasmid DNA were prepared as described in section 2.2.4.5.
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RESULTS
Isolation of Novel Protein Phosphatases
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3. Isolation of novel protein phosphatases
3.1. Degenerate PCR and analysis of resulting clones
The human gene CL100, its murine homolog 3CH134, and PAC-1 show 
significant sequence identity to the vaccinia virus protein VH1, which has been 
demonstrated to dephosphorylate both phospho-serine and -tyrosine residues in vitro, 
as discussed in section 1.7.6. In order to isolate related cDNAs to this potentially 
novel, dual specificity phosphatase subfamily, degenerate PCR primers were designed 
based on the amino acid sequences conserved between CL 100, 3CH134 and PAC-1, 
see table 3, p72 (Keyse and Emslie, 1992; Rohan et al., 1993). The 3' primer spans the 
PTPase catalytic motif, a region highly conserved in all protein tyrosine phosphatases, 
inclusive of the VHl-like enzymes, whilst the 5' primer corresponds to a region only 
identified in | the CL100 and PAC-1 genes. These primers were used to amplify 
related sequences from cDNA made from poly (A)+ RNA isolated from the human 
squamous cell line, A431. PCR fragments of the predicted size, 270 base pairs, were 
purified by gel electrophoresis and subcloned by blunt-end ligation into the EcoRV site 
of pBluescript KS I I , as described in the Methods.
The cloned inserts were amplified by PCR using the universal Reverse and 
M l3-20 primers, and subsequently sequenced, in both 5' and 3' directions, using the 
more internal, universal primers for pBluescript, KS and SK. Fifty individual bacterial 
clones were analysed in this way. Sequence analysis identified six of these to be 
identical to the CL100 gene, and have been designated PCR group A. A further twelve 
clones were found to be homologous to, but distinguishable from CL 100, and within 
this twelve were divided into groups B-E. The predicted amino acid sequences of 
these five groups of PCR clones are illustrated in figure 3.1, pl03. The nucleotide 
sequences are presented in the appendix, figure A. Of the residual clones that were 
analysed, eight showed sequence identity to the Na/K ATPase beta subunit, whilst the 
remainder proved to be PCR artifacts, or PCR products that were not sequenced, due 
to their being much smaller, or larger than the predicted 270 base pair product.
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Figure 3.1.
Alignment of the predicted amino acid sequence of the five groups of 
clones isolated by degenerative PCR.
The residues underlined and in bold represent the degenerate PCR primers, amino acid 
sequences that are completely conserved are overlined, and "..." indicates sequence 
data not obtained. * denotes a stop codon.
Group A (CL100): Y G O G G P V E I L P F L Y L G S A Y H A S
Group B : E I L P F L Y L G S A Y H A S
Group C : £ I L P F L Y H A S A Y H A A
Group D : £ p I R F L Y L L K L Y S P R
Group E : £ I L H S L F L G S C S H G S
Grp A: R K D M L D A L G I T A L I N V s A N C P N H F E G
Grp B: K C E F L A N L H I T A L L N V s R R T S E A C M T
Grp C: R R D M L D A L G I T A L L N V s S D C P N H F E G
Grp D: K V L Y R S S A R L L G L K T p R L D Q T R Q L L K
Grp E: D L R G C R P V R S Q P V L N V S A S C P N H F . .
GipA: H Y Q Y K S I  P V E D N H K A D I  S S W F N E A I  D
Grp B: H L H Y K W I P V E D S H T A D I  S S H F Q E A I  D
GrpC: H Y Q Y K C I  P V E D N H K A D I  S S W F M E A I  E
GrpD: D * ............................................................................................................
Grp E : ......................................................................................................................
Grp A: S I  K N A G G R V F  V H C O A G 
GrpB: C V R E K G G K V L I  
GrpC: C V K D C R G R V L I
Grp D : ...........................................
Grp E : ...........................................
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Clones from groups D and E were only isolated once, and sequence data for these two 
clones could not be obtained using the 3' primer. However, these clones do show 
limited sequence homology to the CL100 gene, suggesting that they may be partial 
sequences of a miss-cloned cDNA, or perhaps more distandy related phosphatase 
genes, rather than PCR artifacts. In view of this, a mixed probe from groups B and C 
only, was used to screen the cDNA libraries.
3.2. Library screening and sequence analysis of partial cDNA clones
From the five groups of clones isolated by degenerative PCR, probes from 
groups B and C were chosen to screen the cDNA libraries, since these were the most 
complete and frequently isolated novel sequences, with six individual clones making up 
group B, and four clones in group C. Thus, a mixed hybridisation probe was used to 
screen 30 x 10^ plaques from both a human brain, and a rodent liver cDNA library, 
plated at approximately 7.5 x 10^ pfu/plate as described in the Methods. Low 
stringency screening of the libraries was performed for four separate platings of 
positive plaques, such that single plaques could then be identified. Six final hybridising 
clones were isolated in this way. These were analysed in more detail by using 
restriction mapping and partial DNA sequencing, using both pBluescript primers and 
the degenerate primers. The four clones from the liver cDNA library ranged between 
the sizes of 1 kb to 2.4 kb, and sequence data revealed that two of these were 
identical, overlapping clones. The clones isolated from the brain cDNA library yielded 
much larger cDNA products. All of the clones were found to encompass the PTPase 
catalytic motif, which typifies Tyr, and Ser/Thr phosphatase activity. The predicted 
amino acid sequences of these partial clones are shown in figure 3.2, pl05, and are 
compared to CL 100. The sequences designated TYP 1 and 2 refer to the clones 
isolated from the brain cDNA library, whilst TYP 3-5 represent the liver cDNA clones. 
The nucleotide sequences are presented in the appendix, figure B. (TYP represents the 
amino acid single letter code for threonine, tyrosine phosphatase).
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Figure 3.2.
Sequence alignment of CL100 and the predicted amino acid 
sequences corresponding to the TYP partial cDNAfs.
The residues underlined and in bold represent the regions corresponding to the 
degenerate oligonucleotides, the second region corresponding to the PTPase catalytic 
motif. Amino acid sequences that are completely conserved between CL100 and the 
various TYP cDNA's are overlined, and indicates sequence data not obtained.
CL100 Y G O G G P Y E I L P F L Y L G A s Y H A s R K D M
TYP 1 H D Q E G P V E I L P F L Y L G S A Y H A A R R D M
TYP 2 V E I L S s L Y L G G A Y H A s K C K F
TYP 3 V E I L P Y L F L G S C S H S s D L 0  G
TYP 4 ....................... # # 9 m 9 # 9 9 . .
TYP 5 V E I L H s L Y L G S A Y H A s K C E F
CL100: L D A L G I T A L I N V s A N C P N H F E G H Y Q Y
TYP 1: L D A L G I T A L L N V s S D C P N H F E G H Y Q Y
TYP 2: L D K L Y I T A Q L N V p # 9 9 9 . .
TYP 3: L Q A C G I T A V L N V s A s c P N H F E G L F R Y
TYP 4: . , # # # 9 9 # 9 9 9 . .
TYP 5: L A N L H I T A L L N V s Q R T s E A C M T H L H Y
CL100: K s I p V E D N H K A D I s s W F N E A I D F I D S
TYP 1: K C I p V E D N H K A D I s s W F M E A I E Y I D A
TYP 2: • « • L V E E G H M A D I s s H F Q E A I D F I D C
TYP 3: K s I P V E D N Q M V E I s A W F Q E A I G F I D W
TYP 4: • • • • , # * A D I s s H F Q E A I D F I D C
TYP 5: K W I P V E D s H T A D I s s H F Q E A I D F I D C
CL100: S K N A G G R V F Y H C 0 A G I S R s A T I C L A Y
TYP 1: V K D C R G R V L Y H C 0 A G I S R E A T I C L A Y
TYP 2: V R E K K G K V L Y H c Ft A G F s c S P T
TYP 3: V K N S G G R V L Y H C 9 .
TYP 4: V R E G G G K V L Y H c E A G Y R S P T I c M A Y
TYP 5: V R E K G G K V L Y H c . • # 9 9
CL 100: I M R T N R V K L D E A F E F V K Q R R s I I s P N
TYP 1: L M M K K R V R L E E A F E F V K Q R R s I I s P N
TYP 4: L M K T K Q F R L K E A F D I V K Q R R S V I s P N
CL100: F S F M
TYP 1: F S F M
TYP 4: F G F M
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Since the initiation of this work, many research groups have also identified further 
CLIOO-like protein phosphatases, as previously discussed in the introduction, section 
1.7.6.1. One of these genes VH3, was isolated by Kwak and Dixon (1995) through the 
screening of a human placental library. VH3 shows the highest level of expression in 
both the liver and the placenta, and encodes a cDNA of 2.1 kb. Interestingly, TYP 5, a 
2.1 kb clone isolated from the liver demonstrates sequence identity to VH3, albeit one 
amino acid change from a phenylalanine (TTt/c) in VH3, to a serine (TCC) in TYP 5. 
This C for T substitution may be due to a PCR error, or simply that TYP 5 was 
isolated from a rat liver cDNA library, whilst VH3 is a human placental clone. VH3 
also shows high sequence similarity to a further gene, B23, isolated from a mammalian 
epithelial cDNA library by Ishibashi et al. (1994). Both B23 and VH3 exhibit a greater 
degree of homology to each other, than either gene shows with CL100. TYP 5 is also 
one of the initial clones, group B, identified by PCR using the degenerative primers, 
whilst TYP 1 shows sequence identity with PCR group C.
3.3. Complete sequence analysis of TYP 1
To attempt to gain complete sequence for all the cDNAs above would have 
been very time consuming, particularly considering that some of the cDNAs indicated 
to be only partial clones at 1.0 kb, hence necessitating further screening in order to 
obtain full length clones. The sequencing of these clones was also technically difficult, 
as it became clear that they were extremely GC rich in places, causing a great number 
of compressions between these residues, making it difficult to decipher the true 
sequence. In this regard, efforts were concentrated on sequencing TYP 1 (2.7 kb), and 
TYP 2 (3.0 kb), the two largest clones isolated from the human brain cDNA library. 
Disappointingly, although much sequence data was obtained for TYP 2, it was 
problematic in interpreting an open reading frame running through the entire sequence. 
The complete nucleotide sequence of TYP 1 is shown in figure 3.3, pl07. The 
positions of the oligonucleotides used in the sequence analysis are also illustrated in 
figure 3.3, and shown in table 3, p72.
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Figure 3.3.
Positioning of the oligonucleotides used for sequencing TYP 1.
KS ->
1 CCCGGGTTCTCTTCTCTTCCTCGCGCGCCCAGCCGCCTCGGTTCCCGGCGACCATGGTGA
GGGCCCAAGAGAAGAGAAGGAGCGCGCGGGTCGGCGGAGCCAAGGGCCGCTGGTACCACT
* * *  3964
6 1  CGATGGAGGAGCTGCGGGAGATGGACTGCAGTGTGCTCAAAAGGCTGATGAACCGGGACG 
GCTACCTCCTCGACGCCCTCTACCTGACGTCACACGAGTTTTCCGACTACTTGGCCCTGC
1 2 1  AGAATGGCGGCGGCGCGGGCGGCAGCGGCAGCCACGGCACCCTGGGGCTGCCGAGCGGCG 
TCTTACCGCCGCCGCGCCCGCCGTCGCCGTCGGTGCCGTGGGACCCCGACGGCTCGCCGC
< -  4261
4202
1 8 1  GCAAGTGCCTGCTGCTGGACTGCAGACCGTTCCTGGCGCACAGCGCGGGCTACATCCTAG 
CGTTCACGGACGACGACCTGACGTCTGGCAAGGACCGCGTGTCGCGCCCGATGTAGGAIC
2 4 1  GTTCGGTCAACGTGCGCTGTAACACCATCGTGCGGCGGCGGCCTAAGGGCTCCGTGAGCC 
GAAGCGAGTTGGACGGGACATTGTGGTAGCACGCCGCCGCCGGATTCCCGAGGCACTCGG
< -  4263
3 0 1  TGGAGCAGATCCTGCCCGCCGAGGAGGAGGTACGCGCCCGCTTGCGCTCCGGCCTCTACT 
ACCTCGTCTAGGACGGGCGGCTCCTCCTCCATGCGCGGGCGAACGCGAGGCCGGAGATGA
3 6 1  CGGCGGTCATCGTCTACGACGAGCGCAGCCCGCGCGCCGAGAGCCTCCGCGAGGACAGCA 
GCCGCCAGTAGCAGATGCTCGTCGCGTCGGGCGCGCGGCTCTCGGAGGCGGTCCTGTCGT
-> 4262
4 2 1  CCGTGTCGCTGGTGGTGCAGGCGCTGCGCCGCAACGCCGAGCGCAACCACATCTGCCTGC 
GGCACAGCGACCACCACGTCCGCGACGCGGCGTTGCGGCTCGCGTTGGTGTAGACGGACG
4 8 1  TCAAAGGCGGCTATGAGAGGTTTTCCTCCGAGTACCCAGAATTCTGTTCTAAAACCAAGG 
AGTTTCCGCCGATACTCTCCAAAAGGAGGCTCATGGGTCTTAAGACAAGATTTTGGTTCC
5 4 1  CCCTGGCAGCCATCCCACCCCCGGTTCCCCCCAGCGCCACAGAGCCCTTGGACCTGGACT 
GGGAGGCTCGGTAGGGTGGGGGCCAAGGGGGGTCGCGGTGTCTCGGGAACCTGGACCTGA
- >  4337
6 0 1  GCAGCTCCTGTGGGACCCCACTACACGACCAGGAGGGTCCTGTGGAGATCCTTCCCTTCC 
CGTCGAGGACACCCTGGGGTGATGTGCTGGTCCTCCCAGGACACCTCTAGGAAGGGAAGG
< -  4338
6 6 1  TCTACCTCGGCAGTGCCTACCATGCTGCCCGGAGAGACATGCTGGACGCCCTGGGCATCA 
AGATGGAGCCGTCACGGATGGTACGACGGGCCTGTGTGTACGACCTGCGGGACCCGTAGT
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7 2 1  £GGCTCTGTTGAATGTCTCCTCGGACTGCCCAAACCACTTTGAAGGACACTATCAGTACA 
GCCGAGACAACTTACAGAGGAGCCTGACGGGTTTGGTGAAACTTCCTGTGATAGTCATGT
781
841
901
961
1021
1081
1141
1201
***
—>
<—
>__<
*
AGTGCATCCCAGTGGAAGATAACCACAAGGCCGACATCAGCTCCTGGTTCATGGAAGCCA
TCACGTAGGGTCACCTTCTATTGGTGTTCCGGCTGTAGTCGAGGACCAAGTACCTTCGGT
>
TAGAGTACATCGATGCCGTGAAGGACTGCCGTGGGCGCGTGCTGGTGCACTGCCAGGCGG
ATCTCATGTAGCTACGGCACTTCCTGACGGCACCCGCGCACGACCACGTGACGGTCCGCC
< -  4339
<
E'c a t c t c g c g g t c g g c c a c c a t c t g c c t g g c c t a c c t g a t g a t g a a g a a a c g g g t g a g g c
CGTAGAGCGCCAGCCGGTGGTAGACGGACCGGATGGACTACTACTTCTTTGCCCACTCCG
-> 4340
TGGAGGAGGCCTTCGAGTTCGTTAAGCAGCGCCGCAGCATCATCTCGCCCAACTTCAGCT
ACCTCCTCCGGAAGCTCAAGCAATTCGTCGCGGCGTCGTAGTAGAGCGGGTTGAAGTCGA
TCATGGGGCAGCTGCTGCAGTTCGAGTCCCAGGTGCTGGCCACGTCCTGTGCTGCGGAGG
AGTACCCCGTCGACGACGTCAAGCTCAGGGTCCACGACCGGTGCAGGACACGACGCCTCC
< -  4345
4342
CTGCTAGCCCCTCGGGACCCCTGCGGGAGCGGGGCAAGACCCCCGCCACCCCCACCTCGC
GACGATCGGGGAGCCCTGGGGACGCCCTCGCCCCGTTCTGGGGGCGGTGGGGGTGGAGCG
AGTTCGTCTTCAGCTTTCCGGTCTCCGTGGGCGTGCACTCGGCCCCCAGCAGCCTGCCCT
TCAAGCAGAAGTCGAAAGGCCAGAGGCACCCGCACGTGAGCCGGGGGTCGTCGGACGGGA
ACCTGCACAGCCCCATCACCACCTCTCCCAGCTGTTAG* 
TGGACGTGTCGGGGTAGTGGTGGAGAGGGTCGACAATC* ____  < -  SK
denotes first methionine 
indicates forward primer 
indicates reverse primer 
PTPase catalytic motif 
denotes termination codon
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Initially the technique of "shot-gun" cloning was used with frequent cutting restriction 
enzymes, such as Asp 718. Sequence data was pieced together using the Contig 
algorithm, GCG version 7.0. Oligonucleotides were then designed based on the 
sequence obtained, such that TYP 1 was sequenced in both 5' and 3’ directions across 
the whole length of the|cDNA.Nucleotide sequence analysis, see figure 3.4, pi 10, 
revealed an ATG at position 52, located within a consensus translation initiation site 
(Kozak, 1987), and therefore this is predicted to be the first methionine. The coding 
region (1182 bp) is flanked by a GC rich 5' untranslated region and a 3' untranslated 
region containing a polyadenylation signal, not shown. The TYP 1 cDNA encodes a 
predicted polypeptide of 394 amino acids with an estimated molecular mass of 
approximately 43 kDa. Consistent with this, the translation initiation site was verified 
by performing in vitro transcription and translation, and a single band of 43 kDa was 
observed, see section 5.3. The amino acid sequence is also illustrated in figure 3.4. 
This sequence does not contain the model seven-amino acid nuclear targeting 
sequence, as exemplified by the SV40 large T antigen. However, there are presently 
several examples of a newly emerging bipartite nuclear targeting sequence, comprising 
two basic amino acid elements, close together but not actually contiguous, in the 
primary sequence (Dingwall and Laskey, 1991). It would seem that there is no 
consensus sequence for the intervening spacer region. Although the bipartite sequence 
is defined as two basic amino acids, followed by a second cluster in which three out of 
the next five are basic, it is possible that the two regions marked "NLS" in figure 3.4, 
may impart nuclear localisation properties on the TYP 1 protein, which has been 
demonstrated to be nuclear, discussed later in section 5.6. Interestingly, these 
sequences, or variations of, are also present in the CLIOO-like phosphatase family, and 
indeed CL 100, PAC-1, HVH2 and HVH3 have been demonstrated to localise to the 
nucleus, see section 1.7.6.1. The TYP 1 protein does not contain characteristic 
transmembrane sequences. However, there are MAP kinase phosphorylation sites at 
the extreme carboxy-terminus of the protein (Figure 3.4, region 3), which may be 
involved in the regulation of TYP 1.
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Figure 3.4.
Nucleotide- and predicted amino acid sequence of TYP 1 cDNA.
Nucleotides are numbered on the left beginning at the first nucleotide of the cDNA. 
Amino acids are indicated in single letter code with the first predicted methionine in 
bold, marked by an asterisk. This is located within a consensus translation initiation 
site C C A /G C C A TG G  (Kozak, 1 9 8 7 ). The termination codon is also denoted by an 
asterisk. The PTPase domain is indicated in bold italics, and the bracketed regions 1 
and 2 show homology to the CH2 domains in Cdc25. The bracketed region 3 indicates 
potential MAP kinase phosphorylation sites, and NLS marks the two putative nuclear 
localisation signals. See text for details.
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The deduced TYP 1 amino acid sequence was used to search the Genbank/EMBL data 
base using the FASTA algorithm of the GCG programme, and throughout its entire 
length exhibits the highest degree of similarity to CL100, 62.8% identity, and its 
murine counterpart 3CH134, 62.5% identity, (Keyse and Emslie, 1992; Charles et al., 
1992). The TYP 1 sequence displays 50.8% identity with human PAC-1, whilst 
demonstrating 27.5% identity with VH1. Across the putative catalytic region, which 
includes the signature motif (I/V)HCXAGXGR(S/T)G, TYP 1 shares significant 
homology with VH1 and other VHl-like family members. In addition, two regions 
conserved between CL100 and Cdc25, a phosphatase whose activity is necessary for 
cell cycle regulation, are also present in TYP 1, and other CLIOO-like phosphatases. 
The functional significance of these regions is as yet unknown, but they may be 
involved in substrate recognition (Keyse and Ginsburg, 1993), or localising proteins to 
nuclear or cytoskeletal locations (Kwak and Dixon, 1994). These regions of homology 
are illustrated in figure 3.5, pi 12.
The pharmaceutical use of the nucleotide and amino acid sequences of the PCR 
groups, the partial TYP cDNA clones, and the full length sequence of TYP 1 as MAP 
kinase phosphatases are protected by an international patent application: 
no. PCT/GB94/00694
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Figure 3.5.
A. Alignment of the CH2 domains of CL100, TYP 1 and 
human Cdc25A.
' ■  "  ' □  ■  -- v
r
HCdc25A
U C L 1 0 0
W ■ J T Y P  1
F V I I DCRYPYEYEGGHIKGAVNLHM. . . PELYVLKGGYKEFF hCdc25A
C L L L D C R S F F A F N A G H I A G S V N V R F . . . A QV F FLK GG YEA FS  CL100
C L L L D C R P F L A H S A G Y IL G S V N V R C . . . T D I C L LKGGYFRFS TYP 1
B. Alignment of the PTPase domains of human C dc25A  
and the CL 100-like phosphatases.
( j i : ■ "p -  —
L J L ^
V V F H C E F S S E R G P R M C  hCdc25A 
VLVHCA A GV N RSG A M I VH1 
V F V H C Q A G I S R S A T I C  CL100 
V L V H C Q A G I S R S A T I C  T Y P 1 
V L V H C Q A G I S R S A T I C  PAC-1 
VLVHC E A G I S R S  P T I C  VH3
hCdc25a
VH1
pCLlOO
T Y P  1
In each figure, the catalytic phosphatase dom ain  is show n in dark blue, and 
the CH2 dom ains in light blue. Identical residue motiffs are show n in bold.
CHAPTER 4 
RESULTS
Regulation of TYP 1 and TYP 2 expression
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4. Regulation of TYP 1 and TYP 2 expression
4.1. Genomic DNA analysis
The activity of protein kinases is significantly associated with an increase in 
cellular proliferation, which can frequently lead to neoplastic transformation under 
certain circumstances. Conversely, in this regard the protein phosphatases, which 
antagonise the kinases, have been viewed as potential tumour suppressor genes. 
Hence, the expression levels of TYP 1 and 2 were investigated across a panel of 
various squamous carcinoma cell lines, to establish if these genes are lost, or perhaps 
amplified in such tumours.
Southern analysis was performed on restriction enzyme-treated genomic DNA 
samples from various cancer cell lines, with the aim to investigate the gene dosage and 
amplification levels of TYP 1 and 2. The panel of cell lines include the squamous cell 
carcinomas A431, SCC12F, and BICR6, and a cell line isolated from a young girl with 
acute lymphoblastic leukemia, SMS-SB cells (genomic DNA was kindly supplied by 
Joe Winnie). SMS-SB cells were chosen as the control cell line, since both TYP 1 and 
TYP 2 are not expressed in these cells, as determined by northern analysis (data not 
shown), indicating that there is, presumably, no need for any genetic loss or 
amplification of the TYP phosphatase genes. As demonstrated in figure 4.1, pi 15 and 
figure 4.2, pi 16, there appears to be no significant loss, amplification or 
rearrangement of the TYP 1 and TYP 2 genes in the squamous cell lines studied, as 
judged by the expression levels in the SMS-SB cells.
114
Figure 4.1.
Detection of TYP 1 DNA sequences in various cell lines
&  so 4^ so <£? Vo <0 ^
(Vs ^  C5 (Vs cj &  cj
ct v  J ?  C7 ^  ^  r r  v  ^
EcoRl Digest Hindlll Digest EcoRl + Hindlll
* I < —  23 kb
< —  9.0 kb
< —  6.6 kb
< —  4.4 kb
Southern Analysis: 30|ig  samples of genomic DNA. isolated from 
various cell lines (as labelled), were digested overnight with the indicated 
restriction enzymes. Electrophoresis was carried out overnight through a 
0.87c agarose gel. DNA transferred onto Hybond N+. and the membrane 
hybridised using a probe specific for TYP 1 (as detailed in Methods). 
Arrows indicate the Hind-III digested X DNA markers.
Figure 4.2.
Detection of TYP 2 DNA sequences in various cell lines
VC <S? O <£?
/y  -V  C v  ^  J ?  r y  V ' v k  i ?
EcoRl Digest Hindlll Digest EcoRl + Hindlll
< —  23 kb
« m
< —  9.0 kb 
< —  6.6 kb
< —  4.4 kb
Southern Analysis: The membrane that was used in figure 4.1 for 
TYP 1 DNA detection was stripped from radioactivity, and 
re-hybridised with a TYP 2 DNA probe, as described in Methods. 
The arrows indicate the Hind-III digested y DNA markers.
4.2. Tissue expression of TYP 1 and TYP 2
Initially, the expression of TYP 1 and 2 was investigated by northern analysis 
across a panel of multiple human tissues, and compared to the expression of CL100. 
Whilst TYP 1 and 2 are expressed at low, but detectable levels in all the tissues tested, 
their expression is most abundant in the placenta. TYP 1 additionally shows a slightly 
higher expression level in pancreatic tissue, whilst TYP 2 demonstrates a small 
increase in expression in the heart and kidney, as illustrated in figure 4.3, pi 18. The 
expression of CL100 is also ubiquitous across the tissues tested, but would appear to 
be less specific than TYP 1 and 2, with high mRNA levels seen in placenta, lung, liver 
and skeletal muscle. This data provides evidence that TYP 1 and 2, and CL100 may be 
regulated in a tissue-specific manner, and this is supported by the findings that other 
family members also show a differential pattern of tissue expression. For example, 
PAC-1 is strictly expressed in cells of hematopoetic origin (Rohan et al., 1993), VH3 
(Kwak and Dixon, 1995), and B23 (Ishibashi et al., 1994) demonstrate a high 
expression in liver cell lines, whilst MKP-2 shows an increased expression in the 
central nervous system (Misra-Press et al., 1995). Two mRNA species (2.4 and 
7.0 kb) were detected by the TYP 1 probe; the 2.4 kb mRNA is consistent with the 
cloned cDNA, the larger 7.0 kb mRNA (not shown) may represent an alternative 
splice variant of TYP 1, or a closely related transcript. However, at present there is no 
evidence to distinguish between these two possibilities.
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Figure 4.3.
N o rth e rn  blot analysis of TY P 1, TY P 2, a n d  C L 100 
m RN A  d is tr ibu tion  against poly (A) m R N A  from  
h u m an  m ultip le  tissues , (C lontech \1 T N  blot).
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Each lane contains approximately 2 itg of highly pure poly (A) RNA 
isolated from human tissues as indicated. The membrane was initially 
hybridised with the TYP 1 probe, and then with TYP 2 and CL 100 
respectively, being stripped from radioactivity between each hybridisation, 
as detailed in the Methods.
4.3. Induction of TYP phosphatase mRNA by mitogens
One striking feature of the CLIOO-like dual specific phosphatases is that they 
are rapidly induced upon mitogenic stimulation. Consequently, the expression of TYP 
1 and TYP 2 was investigated in two squamous carcinoma cell lines after stimulation 
with either the growth factor EGF, or serum, and compared to the mitogenic induction 
of CL100. As shown in figure 4.4, pl20, TYP 1 expression in growing A431 cells is 
low, but shows an increased stimulation by 1 hour after EGF treatment, with a peak at 
4 hours representing a 12-fold induction over untreated cells (as determined by laser 
densitometry using PDI image software analysis). Thereafter, the mRNA transcript 
declines, returning to base line by 8 hours. This is in contrast to CL100 and TYP 2, 
whose expression levels are rapidly induced, at least 50-fold over control levels by 
30 minutes following EGF stimulation, with a slow return to base line by 12 hours. 
Placenta poly (A)+ RNA is included as an internal control for the detection of the TYP 
phosphatases, since the expression of both TYP 1 and 2 is particularly high in this 
tissue, as determined by northern analysis using the MTN tissue blot, figure 4.3. The 
EGF receptor is used as a loading control, and is encoded by a 5.8 kb mRNA. A 
transcriptional variant, possibly carrying a longer 3' untranslated region, is also 
detected at 10.5 kb. A431 cells also synthesise a 2.8 kb mRNA, a secreted polypeptide 
representing almost the entire extracellular EGF-binding domain of the receptor. 
However, this transcript is not recognised by the EGF receptor probe, which consists 
of a restriction fragment of the 3' end of the gene, inclusive of the kinase domain.
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Figure 4.4.
Induction of TYPs and CL100 by EGF in A431
squamous cell carcinomas.
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Northern analysis: Growing A431 cells were stimulated for 15 min 
with 30ng/ml EGF and incubated for the indicated periods of time 
before isolation of total RNA. 1 mg/ml total RNA was used to prepare 
poly (A) mRNA. and 10 pg samples were electrophoresed overnight 
through a 1 °7c agarose gel. RNA was transferred to Hybond N+. and the 
membranes sequentially probed with T Y P E  TY P 2. CL 100 and the EGF 
receptor as a loading control: the membranes were stripped from 
radioactivity between each hybridisation. See Methods for details.
The squamous carcinoma cell line, A431, cannot be rendered quiescent, thus cells 
harvested at each time point are an asynchronous population within the cell cycle. To 
ensure that the mRNA induction observed was not due to cell cycle variations, but a 
true response to mitogen exposure, expression levels of TYP 1 and 2 were also 
investigated in the cell line SCC12F,| rendered quiescent 1 after plating in 0.5% 
serum for 60 hours. Equivalent results were also obtained with quiescent SCC12F 
cells, as demonstrated in figure 4.5, pl22. Stimulation with serum for 1 hour induced 
TYP 1 mRNA levels, which peak approximately 10-fold compared to starved cells by 
2 hours. The expression of CL 100 was induced in response to serum by 30 minutes, 
with a 20-fold greater stimulation than detected in quiescent cells within 1 hour. The 
time course of TYP 2 response to serum in quiescent SCC12F is not as immediate as 
CL100, peaking at 2 hours. However, both TYP 2 and CL100 mRNA levels decline 
by 4 hours, and have returned to basal levels by 8 hours. Whilst TYP 1 mRNA 
transcript, although also declining by 4 hours, is still significantly expressed at 8 hours.
Thus, CL 100 and TYP 2 are similarly activated in an immediate-early manner 
upon mitogenic stimulation. However, there are clear differences in the kinetics of 
induction of TYP 1, which appears to be induced slightly later in SCC12F squamous 
carcinoma cells, and remains up-regulated for a longer period of time than both TYP 2 
and CL 100.
4.4. Regulation of TYP phosphatase mRNA by cellular stress
The differential response between TYP 1 and CL100 mRNA expression upon 
mitogenic stimulation prompted the investigation into the effects of heat shock on the 
expression of TYP 1 and TYP 2, since Keyse and Emslie (1992) first isolated CL100 
as a stress-induced gene. These studies confirm that CL100 expression is markedly 
induced by 30 minutes in SCC12F cells following heat shock, returning to basal levels 
after 2 hours treatment, consistent with previous reports. This is shown in figure 4.6, 
p i23. TYP 2 expression follows the same profile as CL 100, although induction is 
slower peaking at 1 hour rather than 30 minutes.
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Figure 4.5.
Induction of TYPs and CL100 mRNA by serum in
SCC12F squamous cell carcinomas.
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Northern analysis: SCC12F cells were grown in 0.5% serum for 60 hours to 
induced quiescence, and then were stimulated with 10% serum. Total RNA 
was isolated at indicated times after stimulation. 1 mg/ml total RNA was used 
to prepare poly (A) mRNA. and lOpg samples were electrophoresed ovemig 
through a 1% agarose gel. The RNA was transferred onto Hybond N+. and 
the membranes sequentially probed with TYP 1, TY P 2. CL100 and the EGF 
receptor as a loading control. Membranes were stripped from radioactivity 
between each hybridisation. See Methods for details.
Figure 4.6.
Induction of TYPs and CL100 by heat shock in
SCC12F squamous cell carcinomas.
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Northern analysis: Growing SCC12F cells were heat shocked by 
placing the flasks for 30 min in a 44°C water bath. The flasks were 
then returned to 37°C for the indicated times prior to RNA isolation.
1 mg/ml total RNA was used to prepare poly (A) mRNA. and lOpg 
samples were loaded onto a 17c agarose gel and electrophoresed 
overnight. RNA was transferred to Hybond N+. and membranes were 
sequentially probed with TYP 1, TYP 2 and CL 100. The membranes 
were stripped of radioactivity between each hybridisation. For details 
refer to Methods.
The expression level of TYP 2 in SCC12F cells after heat shock is also significantly 
lower compared to CL100 mRNA induction. However, TYP 1 mRNA is not induced 
upon heat shock in SCC12F cells, illustrated in figure 4.6. Indeed, the expression level 
of TYP 1 would appear to be slightly down-regulated by 2 hours compared to 
untreated growing cells, returning to near basal levels after 8 hours. Under these 
conditions, expression of TYP 1 mRNA in growing cells is much higher than that 
observed for TYP 2 and CL 100, and interestingly, whilst the basal expression of 
TYP 1 is increased in growing, in comparison to quiescent SCC12F cells, as expected, 
TYP 2 and CL100 mRNA levels are equally low in both quiescent and growing cells, 
refer to figures 4.5 and 4.6.
4.5. TYP phosphatase expression in fibroblast cells
To further examine the expression of these genes in different cell types, the 
induction of TYP 1 and 2 in response to mitogens was subsequently investigated in 
human fibroblasts, on the basis that CL100 was initially cloned from a fibroblastic cell 
line (Keyse and Emslie, 1992). However, this data demonstrates that TYP 1 is not 
expressed in HKK fibroblasts, even following mitogenic stimulation, shown if figure 
4.7, pl25. Expression of CL100 is detected 30 minutes following serum stimulation, 
which increases approximately 15-fold compared to quiescent cells by 1 hour. 
Elevated levels of the transcript persist for at least 8 hours, although there is a 
significant decline after 1 hour. TYP 2 expression is also induced within 30 minutes, 
approximately 10-fold in comparison to quiescent cells, and is reminiscent of CL100 
showing a slight decrease in mRNA levels after 1 hour, remaining fairly constant over 
the next 6 hours.
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Figure 4.7.
Induction of TYPs and CL100 mRNA by serum in
HKK fibroblast cells.
HKK fibroblasts
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between each hybridisation, refer to methods for details.
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4.6. Effects of TGFp treatment on TYP and CL100 mRNA expression
In many mammalian cell types, transforming growth factor-p treatment 
promotes growth arrest in G1 (Massague, 1990), by inhibiting G1 cyclins and then- 
associated kinase activities, thereby suppressing Rb phosphorylation, as introduced in 
section 1.1.2. This inhibition is mediated in part by the activities of cyclin-dependent 
kinase inhibitors (Li et al., 1995, Reynisdottir et al., 1995). However, protein 
phosphatases have also been demonstrated to play a role in cell-cycle regulation, such 
as Cdc25 (Kumagai and Dunphy, 1991), and possibly Kap/Cdil (Hannon et al., 1994; 
Gyruris et al., 1993).
The expression levels of TYP 1 and 2, and CXI00 as a consequence of TGFp 
treatment, were therefore investigated in SCC cell lines known to be sensitive to this 
growth factor (Mailliri, A. et al., submitted). After treating the cell lines BICR6 and 
MS2 with TGFP for 24 hours, both TYP 1 and CL100 transcripts are induced 
compared to the control levels in growing cells, although the induction of CL100 
mRNA is greater than that seen for TYP 1, shown in figure 4.8, pl28. The levels of 
TYP 2 mRNA are extremely low in BICR6 cells, however, evidence demonstrates that 
TYP 2 mRNA levels decrease as a consequence of TGFP treatment in MS2 cells.
Following this preliminary result, phosphatase expression levels were 
investigated in MS2 cells treated with TGFp over a 24 hour period. TGFP induces and 
represses the transcription of a variety of genes, and whilst there is a rapid decrease in 
c-Myc expression (Pietenpol et al., 1990), there is a much slower reduction, between 
12 and 24 hours, in the hyperphosphorylated form of pRb (Laiho et al., 1990), 
cyclin E (Geng and Weinberg, 1993) and CDK4 (Ewen et al., 1993). Figure 4.9, pl29 
demonstrates that TYP 1 mRNA levels substantially increase between 8 and 12 hours, 
and remain elevated for at least 24 hours following TGFp treatment. The expression of 
CL100 is possibly biphasic following treatment of MS2 cells with TGFp, with a 
significant increase after 1 hour, which declines to below the basal level seen in 
growing cells by 2 hours. The CL100 mRNA levels then increase a second time, 
returning to basal levels by 8 hours. It is difficult to interpret whether the CL100
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message increases above the basal level between 8 and 24 hours, as the poly (A)+ 
RNA on the membrane would appear to be slightly under loaded for the last four time 
points, as shown by the EGF receptor mRNA expression level. However, this does 
suggest that the increase seen in TYP 1 message after 8 hours, is more exaggerated 
than the figure would suggest. TYP 2 mRNA levels could not be detected by northern 
analysis using this membrane.
The squamous cell line SCC12F, is resistant to the anti-proliferative effects of 
TGFp. The loss of sensitivity to TGFp has been reported to occur late during the 
development of carcinomas, but in most cases, the mechanisms of resistance to TGFp 
remain unclear. As demonstrated in figure 4.10, p i30, the mRNA levels of TYP 1, 
TYP 2 and CL100 remain unchanged following TGFp treatment over 24 hours. This 
confirms that the changes in mRNA expression levels seen in MS2 and BICR6 cell 
lines is a true response to the growth factor TGFp.
In summary, the above expression studies demonstrate that whilst TYP 2 is 
regulated in an immediate-early fashion reminiscent of CL 100, and other documented 
CLIOO-like phosphatase genes, TYP 1 is unusual, showing a differential pattern of 
expression from CL100 and other family members, suggesting that TYP 1 is unique in 
terms of its regulation and cell-type specificity.
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Figure 4.8.
Induction of TYPs and CL100 in response to TGFb
treatment in BICR6 and MS2 squamous cell lines.
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1 mg/ml samples were used to prepare poly (A) mRNA. 10 ,ug of 
poly (A) mRNA was loaded onto a 19c agarose gel and 
electrophoresed overnight. RNA was transferred to Hybond N+, 
and probed with TYP 1, TYP 2 and CL100 as indicated. 
Membranes were stripped from radioactivity between each 
hybridisation.
Figure 4.9.
Induction of TYPs and CL100 in response to TGFp
treatment of MS2 squamous carcinoma cells.
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N o rth e rn  an a ly s is :G row ing  M S2 cells  w ere  incubated  in 10% serum  
su p p lem en ted  w ith  lO ng/m l T G F p  for the indicated times, prior to total 
RNA isolation. 1 mg/ml total RNA was used to prepare poly (A) mRNA. 
and lOpg samples were loaded onto a 1% agarose gel and electrophoresed 
overnight. RNA was transferred onto Flybond N+. and the membranes were 
sequentially probed with TYP 1, TYP 2, CL 100, and the EGF receptor as a 
loading control. Membranes were stripped from radioactivity between each 
hybridisation. See Methods for details.
Figure 4.10.
Induction of TYPs and CL100 in response to TGF(3 in
SCC12F squamous carcinoma cells.
SCC12F squamous cells
5.8kb
50C
i
1 Ong/ml TGF|3
0  8h 12h 24h
TYP 1 
—>  
2.4kb
TYP 2 ____
s . o k T *  “  ■  M U
CL100
2 .4 k b *  W
EGF-R
N o r th e rn  analysis:G row ing S C C 1 2 F  cells  w ere  trea ted  w ith  
10% se ru m  su p p lem en ted  w ith  1 Ong/ml T G F  (3 for the indicated 
periods of time prior to total RNA isolation. Poly (A) mRNA samples 
were prepared from 1 mg/ml total RNA. and electrophoresed overnight 
through a 1% agarose gel. RNA was transferred onto Hybond N+. and 
the membrane sequentially probed with TY P 1, TY P 2. CL100. and the 
EGF receptor as a loading control. Membranes were stripped from 
radioactivity between hybridisations, refer to Methods for details.
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5. Characterisation of TYP 1 activity
5.1. TYP 1 can inactivate MAP kinase
The TYP 1 catalytic domain shows extremely high sequence identity to the 
VHl-like dual specificity phosphatases, and furthermore, CL100 has been 
demonstrated to specifically dephosphorylate and inactivate ERK 1 and 2 MAP kinase 
isoforms (Alessi et al., 1993a). More recently, other family members have also shown 
substrate specificity towards the ERK MAPK isoform both in vitro and in vivo, such 
as PAC-1 (Ward et a l, 1994), HVH2 (Guan and Butch, 1995), and MKP-2 
(Misra-Press et al., 1995).
In order to establish whether TYP 1 exhibits a similar phosphatase activity 
towards the MAP kinases, a transient expression system was used. Cos cells were 
transfected with either 0.5pg pMT-TYP 1 or pMT-CLlOO. The activation state of 
endogenous ERK2 was examined by immunoprecipitation with a polyclonal ERK2 
antibody, from cells that were either serum deprived or re-stimulated with EGF. The 
immunoprecipitates were then tested for MAP kinase activity by an in vitro assay 
which utilises myelin basic protein (MBP) as a substrate for ERK2 in the presence of 
[y-32p]ATP. As shown in figure 5.1, p i33, the first two lanes demonstrate that under 
control conditions where cells are transfected with parental vector only, the 
phosphorylation of MBP by immunoprecipitated ERK2 is dependent upon EGF 
stimulation (+). However, EGF stimulation of cells which are constitutively expressing 
TYP 1, reduces the phosphorylation status of MBP by 73% compared to the control 
cells. As previously reported, constitutive expression of CL100 reduces the 
phosphorylation status of MBP by 87% compared to the control levels. The 
percentage figures are calculated on the basis that the control shows 100% MBP 
phosphorylation, and relative percentages are estimated using densitometry. Extensive 
TYP 1 inactivation of ERK2 also occurs when a sample of cell lysate from TYP 1 
transfected Cos cells (i.e. lane 3) is pre-incubated with immunoprecipitated ERK2 
from stimulated cells (lane 2), and then assayed for activity towards MBP, data not 
shown.
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Figure 5.1.
Effect of transient transfection of TYP 1 and 
CL100 on ERK2 MAP kinase activity.
pMT pMT-TYP 1 pMT-CLlOO
—  _|_ —  —  _|_ 30ng/ml EGF
21.5kDa - >
14.3kDa - >
Cos cells were transfected with 0.5 jag of pM T-TYP 1, pMT-CLlOO 
or control pMT vector, and treated with 30ng/ml EGF. Lysates were 
prepared as described in the Methods. The activation state of ERK2 was 
examined by immunoprecipitation. Cell lysates (either serum deprived 
or stimulated with EGF for 5 min. as indicated) were incubated overnight 
at 4°C  with 2 pi of anti-ERK2 antibody, pre-bound to protein A-sepharose. 
The antibody/protein complex was pelleted, washed and incubated with 
MBP in the presence of [ y-32P] ATP for 20 min at 30 CC. The reactions 
were terminated with SDS loading buffer and proteins resolved on a 15% 
SDS-polyacrylamide gel. Molecular mass markers (bio-rad) are indicated. 
See methods for more detail. M BP runs at 21.5 kDa as indicated, with 
degradation products running below.
CL 100 was initially identified as a gene whose mRNA was rapidly induced in 
response to cellular stress (Keyse and Emslie, 1992). It has also been demonstrated 
that CL100 inactivates the stress-induced MAP kinase isoform, p38, (Rouse et al., 
1994). Further stress-activated protein kinases which are involved in the 
phosphorylation of c-Jun include the SAPK, and the JNK family members, see section 
1.2.1. To establish if stress-activated protein kinase activity is compromised in the 
presence of TYP 1, Cos cells were transfected with TYP 1, and subjected to heat 
shock at 44°C in order to induce the stimulation of endogenous SAPKs/JNKs. The 
activation state of endogenous, immunoprecipitated p54JNK was then assayed against 
recombinant c-Jun protein in the presence of [y-32P]ATP. As illustrated in figure 5.2, 
p i35, heat shock for 30 minutes at 44°C is sufficient to activate endogenous p54JNK, 
as demonstrated by the ability of immunoprecipitated p54JNK to phosphorylate 
recombinant c-Jun, see lane 2. However, constitutive expression of TYP 1 inhibits the 
phosphorylation of recombinant c-Jun protein by activated p54JNK, by more than 
90%, as compared to the mock-transfectants. Identical results were obtained for 
CL100 expression, which similarly inhibits c-Jun phosphorylation more than 90% 
compared to control levels. These results indicate that MAP kinase activity is 
compromised in the presence of TYP 1.
To demonstrate that MAP kinase inactivation was a direct consequence of 
TYP 1, the ability of TYP 1 protein to inactivate recombinant ERK2 was examined. 
TYP 1 cDNA was cloned into | baculovirus in order to express a GST fusion 
protein, and purified by Alan Ashworth. For this assay, recombinant ERK2 protein 
was activated and 32P-labelled by phosphorylation with purified MAP kinase kinase 
(EE mutant, Alessi et al., 1993a), and then incubated for 20 minutes at 30°C with 
20ng purified TYP 1 protein. As demonstrated in figure 5.3, p i36, loss of ERK2 
activity was observed, as analysed by the reduced ability of ERK2 to phosphorylate 
MBP in the presence of [7-32P]ATP, lanes 3 and 4. As an internal control, activated 
ERK2 was also incubated with recombinant Myb protein, lanes 5 and 6, and as 
expected, ERK2 remains active, phosphorylating MBP as efficiently as active ERK2 
alone. These three reactions were performed in duplicate.
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Figure 5.2.
Effect of transient transfection of TYP 1 and CL100 
on stress-activated MAP kinase activity.
pMT pMT-TYP 1 pMT-CLlOO
+ + _j_ heat-shock
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Cos cells transfected with 0.5 jug of pM T-TYP 1, pMT-CLlOO or control 
pMT vector were heat shocked at 44 °C. and lysates prepared as 
described in the Methods. The activation state of p54JNK was examined 
by immunoprecipitation. Cell lysates were incubated overnight at 4°C  
with 1 pi anti-p54 antibody, pre-bound with protein A sepharose beads. 
The antibody/protein complex was pelleted, washed, and incubated with 
recombinant c-Jun protein in the presence of [ y-32P]A TP for 20 min at 
3 0 °C. The reactions were terminated by the addition of SDS loading 
buffer and the proteins resolved on a 15% SDS-polyacrylamide gels. 
Although the translation of recombinant c-Jun yields a full length protein, 
in this assay system a truncated c-Jun protein, running at 21kDa. is 
preferentially phosphorylated.
Figure 5.3.
Inactivation of recombinant ERK2 by TYP 1.
Active MAPK MAPK + TYP 1 MAPK + MYB
Baculovirus expressed TYP 1 (20 ng) was incubated with activated, 
phosphorylated recombinant GST-ERK2 protein (200ng) as described 
in the Methods. The activity of ERK2 towards MBP was assayed in 
the presence of [ y-32P]ATP for 20 min at 30° C. The reactions were 
terminated by the addition of SDS loading buffer, and the proteins 
resolved on a 15% SDS polyacrlamide gel. Recombinant Myb protein 
was used as a control, and each reaction is shown in duplicate. 
Molecular mass markers (Bio-rad) are indicated by the arrows.
5.2. TYP 1 is a dual specificity Tyr/Thr protein phosphatase
ERK2 autophosphorylates on serine and threonine residues, while 
phosphorylation of both threonine 183 and tyrosine 185 by MAP kinase kinase is 
required for its activation. It has been demonstrated previously that CL100 inactivates 
MAP kinase by a parallel dephosphorylation of both tyrosine and threonine residues 
(Alessi et al., 1993a).
To determine the molecular mechanism of TYP 1 inactivation of ERK2, 
increasing concentrations of TYP 1 protein were incubated for 10 minutes at 30°C 
with activated, 32P-labelled ERK2, and the reaction products were analysed on an 
SDS-PAGE gel, see figure 5.4a, pl38. Consistent with the previous observation that 
TYP 1 can directly inactivate ERK2, TYP 1, like CL 100, is capable of 
dephosphorylating MAPKK-activated ERK2 in a concentration dependent manner. 
Indeed, incubation of activated ERK2 with 3.0|ig TYP 1 results in almost all the 
labelled phosphate being removed from ERK2. At this particular concentration of TYP 
1, co-incubation with sodium vanadate, an inhibitor of protein tyrosine phosphatases 
and CLIOO-like phosphatases, effectively blocks dephosphorylation of ERK2. 
Furthermore, aliquots of 32P-labelled ERK2 treated with TYP 1 protein, and subjected 
to one dimensional phosphoamino analysis, demonstrates that both threonine and 
tyrosine residues are effectively dephosphorylated, illustrated in figure 5.4b. As 
expected, no loss of phosphate is seen in the presence of sodium vanadate. Analysis of 
the autoradiograph by densitometry shows that TYP 1 inactivates ERK2 with 50% 
dephosphorylation occurring in 10 minutes (the incubation time), with a concentration 
of approximately 14nm TYP 1. This is comparable to CL100 which has been shown to 
inactivate ERK2 at a concentration of approximately 7nm (Alessi et al., 1993a).
In conclusion, these studies demonstrate that TYP 1 acts as a dual specific 
threonine/tyrosine phosphatase, rapidly inactivating and dephosphorylating ERK2. 
Phosphoamino acid analysis suggests that TYP 1 dephosphorylates the tyrosine 
residue more efficiendy than the threonine.
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Figure 5.4.
Dephosphorylation of recombinant ERK2 by TYP 1
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5.3. TYP 1 phosphatase activity towards c-Jun
The proto-oncogene c-Jun is phosphorylated at a number of sites at both the 
amino- and carboxyl-termini of the protein, which alters both DNA binding and 
transcriptional activity of the gene. Many research groups have demonstrated that the 
phosphorylation at the amino-terminus of c-Jun is carried out by a family of MAP 
kinases, known as the JNK/SAPKs subfamily, see section 1.5.2.1. The enzymes which 
are involved with phosphorylating the carboxy-terminus of the c-Jun protein are 
presently not known. As demonstrated in figure 5.5, pl40, when c-Jun is translated 
in vitro using a reticulocyte lysate containing 35s-labelled methionine, there are a 
minimum of four sites which are differentially phosphorylated, therefore conferring 
different mobilities of these phospho-proteins through an SDS-PAGE gel, lane 1. It 
was therefore investigated whether it was possible to co-translate TYP 1 and c-Jun, 
and alter the pattern of c-Jun phosphorylation. Translation of TYP 1 results in a 
protein running at the predicted molecular mass of 43 kDa, lane 2. However, although 
co-translation of TYP 1 and c-Jun appears to inhibit the phosphorylation states of 
c-Jun, as demonstrated by the loss of some of the c-Jun phospho-proteins, lane 3, both 
TYP 1 and c-Jun proteins run at approximately the same size, and consequendy the 
TYP 1 protein masks the four phosphorylation products of c-Jun. In view of this, 
TYP 1 was translated in the absence of radioactive label, lane 6. An aliquot of 
translated -^S-labelled c-Jun protein was then incubated with cold-translated TYP 1 
protein, and this clearly results in the inhibition of the upper phosphorylation states of 
c-Jun, lane 10. However, the protein kinase and phosphatase activities in the lysate are 
undefined, and therefore this assay does not determine whether TYP 1 inactivates a 
c-Jun kinase, or activates a c-Jun phosphatase, which may be present in the lysate, or 
indeed directly dephosphorylates c-Jun. Prior to incubation, the protein products were 
treated with emetine, to prevent any further translation. The luciferase gene, lane 4, 
was used as a control for the translation reaction, and reticulocyte lysate alone, lane 5, 
was used to demonstrate that the protein products visualised are due totranscriptiorof 
the DNA added, and not a component of the lysate itself. Reticulocyte lysate was also 
used as an incubation control. I (see Black et al. 1991. Oncogene 6: 1949-58)
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Figure 5.5.
TYP 1 phosphatase activity towards c-Jun.
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In vitro translation was carried out using the TNT Coupled Reticulocyte 
Lysate System from Promega. 1 pg DNA template (pCITE-TYP 1 and/or 
pSPT19-c-Jun) was used for each translation reaction, and incubated for 
2 hours at 30 °C. The control (retie lysate alone) and cold TYP-1 were 
non-radioactive. Following translation, the reactions were terminated by 
the addition of O.lmM emetine. To determine TYP 1 phosphatase activity 
towards c-Jun. 10 pi samples of translated TYP-1 and c-Jun were mixed 
and incubated at 30°C for 10 min. All samples were mixed with SDS 
loading buffer, and proteins resolved on 107c SDS polyacrylamide gel, 
as indicated. The gel was dried under vacuum and exposed to Kodak film. 
Molecular mass markers are shown. See Methods for details.
5.4. Expression of the TYP 1 protein
In order to investigate the regulation of TYP 1 protein expression, several 
peptides were designed to the amino-terminal sequence of TYP 1. This region is 
preferable for raising antibodies against, considering that the amino-terminal sequences 
in TYP 1, and indeed the other CLIOO-like phosphatases, are the most divergent 
Several polyclonal rabbit antisera were raised against the TYP 1 peptides, and 
sequentially screened for the detection of TYP 1 protein using lysates from Cos cells 
transfected with pMT-TYP 1. One antibody (B) specifically recognises a 43 kDa 
protein, and the corresponding peptide is illustrated in table 2, p72. The TYP 1 cDNA 
has also been tagged at the amino-terminus with the c-Myc epitope, see table 2. This 
was so that TYP 1 protein could be detected and immunoprecipitated with a c-Myc 
antibody, prior to the TYP 1 antisera having been produced. However, all the 
applications utilising the c-Myc antibody have since been repeated using TYP 1 
antisera, and are therefore not presented in this thesis. However, the Myc-tagged 
TYP 1 construct is used as an additional control for the detection of TYP 1 protein, 
and is recognised by the antisera as a 46 kDa protein. The 43 and 46 kDa single 
protein bands are identified as TYP 1 based on mobility and competition by the 
addition of excess peptide, as shown in figure 5.6, p i42.
Since TYP 1 mRNA is induced upon mitogenic stimulation of squamous 
carcinoma cell lines, the protein expression was investigated in the SCC line A431, 
following induction by EGF. As demonstrated in figure 5.7, pl43, TYP 1 protein in 
growing A431 cells is barely detectable, time point 0. However, after | 
stimulation the protein is induced at 4 hours, and peaks at 8 hours. This is consistent 
with the kinetics of mRNA accumulation, which show an induction after 1 hour and 
peak at 4 hours, see section 4.3. In A431 cells, unlike transfected Cos cells, 
background protein bands are also detected by the TYP 1 antisera, however, the 
TYP 1 protein can be clearly recognised due to the positioning of the control protein 
bands from transfected Cos cells. Additionally, the TYP 1 protein detected in A431 
cells can be entirely competed by an excess of peptide, lower diagram shown in 
figure 5.7.
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Figure 5.6.
Immunoblot analysis of TYP 1 protein.
50jug samples of extracts from Cos cells transfected with either 
0 .5pg parental pMT vector, pMT-Myc-TYP 1 or pMT-TYP 1 
were resolved by electrophoresis on a 10% SDS polyacrylamide 
gel, and protein transferred to nitrocellulose as described in the 
Methods. The filters were probed with rabbit anti-TYP 1 antibody 
(1:1000) in the presence and absence of excess competitor peptide, 
as indicated, and proteins detected by immersing the filters in ECL 
reagent for 1 min. followed by exposure to Kodak film. The positions 
of Myc-TYP 1 and TYP 1 are indicated by arrow heads, the molecular 
mass marker (Bio-rad) is indicated on the left.
Figure 5.7.
Immunoblot analysis of a mitogen induced 
time course of TYP 1 protein.
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G row ing  A431 cells  w ere  s tim ula ted  w ith  3 0 n g /m l E G F  for the 
ind ica ted  periods  o f  t im e prior to cell lysis, as d escribed  in the 
M ethods. 50 |ig  lysate samples were resolved on a 10% SDS-PAGE gel. 
and proteins transferred to nitrocellulose overnight. The filters were probed 
with rabbit anti-TYP 1 antibody (1:1000) in the presence and absence of an 
excess of competitior peptide, and proteins were detected by immersing the 
filters in ECL reagent for 1 min, followed by exposure to Kodak fim. 
Transfected Cos cell extracts were used as internal markers, and the TYP 1 
protein is indicated by the the arrow heads. The position of the molecular 
mass marker (Bio-rad) is shown on the left.
5.5. Analysis of the stability of TYP 1 protein
Following the detection, and the induction of TYP 1 protein upon mitogenic 
stimulation by western analysis, the stability of the protein was investigated using the 
technique of pulse-chase, where cells are initially pulsed with [35S]methionine for a 
period of time sufficient to radioactively label proteins during their synthesis. The cells 
are then chased for a longer period of time in cold-methionine media, such that newly 
synthesised proteins, which are not labelled, gradually compete out the radiolabelled- 
proteins, thus enabling the stability of the radiolabelled proteins to be determined.
The TYP 1 antibody was initially tested for the ability to immunoprecipitate 
protein from extracts of [35S]methionine-labelled A431 cells. Since the level of TYP 1 
protein is too low to be detected in growing cells, see figure 5.7, the cells were 
stimulated for 4 hours with EGF prior to labelling with [35S]methionine for one hour. 
Cell lysates were prepared, and the TYP 1 protein immunoprecipitated using two 
different antibodies: A and B, (although antibody A is not able to detect TYP 1 protein 
by western analysis). As demonstrated in figure 5.8a, pl45, TYP 1 protein was 
immunoprecipitated by antibody B only, lane 3. Pre-immune sera was used a control. 
Immunoprecipitation analysis of TYP 1 protein was then performed using A431 cells 
which had been stimulated with EGF for 4 hours prior to labelling with 
[35S]methionine, and then chased over a period of 6 hours. However, no specific 
protein signal for TYP 1 could be detected, due to the high number of non-specific 
proteins which also immunoprecipitate with the TYP 1 antibody B in A431 cells, data 
not shown. Therefore, the stability of the TYP 1 protein cannot be investigated by this 
method.
Since TYP 1 protein is detectable in transfected Cos cells, with little 
background interference, pulse-chase labelling was repeated in Cos cells which were 
transfected with 0.5|ig pMT-TYP 1. Post-transfection, the cells were labelled with 
[35S]methionine for one hour, and chased over a 6 hour period. As indicated in figure 
5.8b, TYP 1 protein is readily detectable by immunoprecipitation with antibody B.
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Figure 5.8.
Immunoprecipitation of TYP 1 protein following 
35S-methionine labelling
A
46 kDa — >
M 43 kDa
A: Growing A431 cells were stimulated with EGF for 4 hours prior to 
labelling with [35S]methionine for 1 hour. Cell lysates, which had been 
pre-cleared. were incubated overnight at 4°C  with 20pl TYP 1 antibody. 
50 (li1 protein A-sepharose beads were added and incubated for a further 
hour at 4 0C. The immunoprecipitates were washed, mixed with SDS- 
loading buffer and TYP 1 protein resolved on a 107c SDS-PAGE gel. The 
gel was then fixed in acetic acid/methanol, dried under vacuum and exposed 
to Kodal film. The control antibody is pre-immune sera. See Methods for 
more detail.
B: Cos cells were transfected with 0.5 jag pMT-TYP 1. Post-transfection 
cells were labelled with [35S]methionine for 1 hour, and then chased in 
media with cold methinine for the indicated times prior to cell lysis. 
Immunoprecipitation was carried out exactly as described above using 
20jal antibody B. Samples were resolved on a 107c SDS-PAGE gel. 
the gel dried and exposed to Kodak film.
B Chased for the indicated times 
0 lh 2h 4h 6h
—  —  -
A decrease in protein is detected by 2 hours, and by 6 hours TYP 1 protein is barely 
detectable, indicating that the protein is relatively unstable.
This experiment was approached in a different way by using cycloheximide, 
which inhibits protein synthesis. Cos cells were transfected with TYP 1 and grown for 
24 hours prior to treatment with lOpg/ml cycloheximide at time 0. Cell lysates were 
then harvested over a period of 6 hours. In this instance, a decrease in TYP 1 protein 
was detected in the first hour, confirming that the protein is considerably unstable, as 
shown in figure 5.9a, pl47. Interestingly, treatment of the cells with EGF prior to 
cycloheximide addition appears to stabilise the TYP 1 protein, with protein still 
detected 6 hours after cycloheximide treatment. However, in cells not treated with 
EGF, TYP 1 protein is barely detectable at 6 hours. In this regard, the density of each 
band in the figure was measured by molecular dynamics laser densitometry using the 
PDI image analysis software. The density is measured in pixel units (OD x MM^) 
which is a function of spot intensity and the number of pixels covered. These 
measurements, which are a composite from three separate experiments, were then 
converted into a percentage of the control, with the control showing 100%, and 
plotted against time, see figure 5.9b. The graph demonstrates that EGF treatment 
stabilises the TYP 1 protein considerably. The half-life of TYP 1 is estimated to be 
90 minutes, which is similar to that reported for CL100 (Noguchi et al., 1993). Upon 
stimulation with EGF, the half-life of TYP 1 protein is extended to just over 3 hours. 
Although cycloheximide has been shown to prolong the half-life of many immediate 
early genes, the previous pulse chase experiment results in a similar calculated half-life 
forTYPl.
To ensure that cycloheximide treatment of Cos cells inhibited protein synthesis, 
growing Cos cells were treated with 10|ig/ml cycloheximide for 30 minutes, and then 
labelled with [35S]methionine for 1 hour. Cell lysates were then prepared and 
precipitated with TCA as described in the Methods. The precipitate was collected on a 
Whatman GF-C filter, the filter was then washed, dried and counts per minute 
calculated. The control cells were not treated with cycloheximide. Protein synthesis in 
cells treated with cycloheximide is inhibited by more than 96%.
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Figure 5.9.
Effect of cycloheximide on TYP 1 protein levels.
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Cos cells were transfected with 0.5jug pMT-TYP 1. and stimulated 
with 30ng/ml EGF for 15 min as indicated. Cells were then treated 
with 10jLtg/ml cycloheximide for the indicated periods of time prior 
cell lysis, see Methods. 50pg protein samples were resolved by 
electrophoresis on a 10% SDS polyacrylamide gel, and proteins 
transferred to nitrocellulose overnight. The filter was probed with 
anti-TYP 1 antibodies (1:1000), and protein detected by immersing 
the filter in ECL reagent for 1 min, followed by exposure to Kodak 
film. The position of the TYP 1 protein is indicated.
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Bands from the above gel were quantitated using a densitometer, 
and plotted as a percentage of the control, ie. growing cells without 
cycloheximide treatment.
Cos cells 5.6 x 10 ^ cpm 100 % protein synthesis
Cos cells + cycloheximide 2.2 x 10 5 cpm 3.9% protein synthesis
5.6. Subcellular localisation of TYP 1 protein
The subcellular localisation of TYP 1 was investigated using a biotin-labelled 
secondary antibody and a streptavidin-horseradish peroxidase conjugate, see Methods 
for details. Cos cells were transiently transfected with either pMT-TYP 1 or parental 
vector, and 24 hours post-transfection were transferred onto glass slides, and grown 
for a further 24 hours. The slides were then stained with TYP 1 antibody B, or rabbit 
pre-immune sera as a control. Figure 5.10, p i49 panel A demonstrates that cells 
transfected with TYP 1 show a strong positive staining in the nucleus. A few cells 
show a slighdy higher than background staining in the cytoplasm, presumably due to 
TYP 1 being transfected in these cells, and consequently overexpressed. The control 
cells, panels B and C, do not show any nuclear staining above background levels. 
These results are in agreement with data demonstrating that PAC-1 (Rohan et al.,
1993), CL100 and HVH3 (Kwak and Dixon, 1995), HVH2 (Guan and Butch, 1995) 
and MKP-2 (Misra-Press et al., 1995) also show nuclear staining, suggesting that this 
phosphatase family functions primarily in the nucleus. The implications of this are 
discussed later.
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Figure 5.10.
Subcellular localisation of TYP 1
A
TYP 1 Antibody
B
Negative Control
Antibody
C
Negative Control 
Transfection
~s~
Cos cells were transfected with either 0.5jag pM T-TYP 1 (Panel A
and B) or 0.5 jag parental pM T (Panel C), transferred to glass chamber 
slides and grown for a further 24 hours. Slides were washed, fixed 
and stained with anti-TYP 1 antibody (1:4000), and a secondary 
antibody conjugated to biotin, as described in the Methods. Control 
antibodies were pre-bleed normal rabbit serum. The thick arrow heads 
indicate TYP 1, which is localised primarily in the nucleus. The thin 
arrows indicate cells with background staining only.
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6. Discussion
Protein phosphatases are generally classified according to their phosphoamino 
acid specificity, and as such, until presently, have been divided as tyrosine or 
serine/threonine phosphatases. Unlike the protein kinases, the serine/threonine 
phosphatases share no sequence identity with the tyrosine phosphatases. However, 
recently a newly identified group of proteins have been demonstrated to function as 
dual specific phosphatases, showing activity towards both phosphoserine/threonine 
and -tyrosine residues. The prototype for this new subfamily of phosphatases is the 
vaccinia virus protein VH1 (Guan et al., 1991), and interestingly, all the novel proteins 
which have been identified in this group show sequence homology to the protein 
tyrosine phosphatases across the PTPase catalytic motif: (I/V)HCXAGXGR(S/T)G.
6.1. Sequence analysis of novel dual specific phosphatases
The results presented in this thesis describe the isolation of further members of 
this subfamily of dual specific phosphatases, and specifically the characterisation of 
one protein, TYP 1 (threonine-tyrosine phosphatase 1). Using the technique of 
degenerative PCR with primers designed across two conserved regions found in the 
dual specific phosphatase genes CL100 (Keyse and Emslie, 1992), and PAC-1 (Rohan 
et al., 1993), related DNA sequences were amplified from the squamous cell line 
A431. Sub-cloning and sequencing resulted in the identification of five groups of 
clones that show sequence homology to the PTPase catalytic motif. This would 
suggest that the clones are phosphatase genes, and indeed PCR group A was identified 
as CL 100. The remaining four clones proved to be novel sequences, and of these, the 
two most frequently isolated sequences were used as a mixed hybridisation probe to 
screen two cDNA libraries. This resulted in the identification of five cDNA clones 
which show sequence homology both to the PTPase catalytic motif, and a region 
conserved only in the CLIOO-like phosphatases, see figure 3.2. As such, it is proposed 
that these genes encode proteins with similar functions to CL 100, and have therefore
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been designated threonine/tyrosine phosphatases (TYP 1-5). The three clones isolated 
from the liver cDNA library range between 1-2.4 kb in length, the smaller of which 
possibly represent only partial cDNA clones. The two largest clones were isolated 
from the brain cDNA library, and are more than 2.7 kb in length. With the knowledge 
that CL 100 mRNA is approximately 2 kb long, it was reasonable to assume that these 
two clones were more than likely full length. Efforts were concentrated on obtaining 
full sequence data from these clones, TYP 1 and TYP 2. Full sequence analysis of 
TYP 1 was completed, and demonstrates that TYP 1 encodes a 394 amino acid, 
non-transmembrane protein, figure 3.4. Although a great deal of sequence information 
was collected for TYP 2, an open reading frame running through the entire sequence 
could not be determined. The occurrence of stop codons throughout the sequence 
leads to the conclusion that the TYP 2 clone is in fact a pseudogene, a non-functional 
sequence which is highly homologous to the normal gene. There is no strong selective 
pressure to eliminate pseudogenes, since at least one copy of the functional gene 
remains in the genome. However, over time the pseudogene accumulates additional 
mutations. Consequently, only some regions of the pseudogene are recognised as 
"normal". However, the PTPase domain and a region upstream of this, which is highly 
conserved in the CLIOO-like phosphatases, are clearly present in TYP 2, figure 3.2. 
Other regions in the sequence of TYP 2 also show similarity, but are not identical to 
the CL100 gene, therefore suggesting that TYP 2 is a novel gene belonging to the 
class of dual specific phosphatases. Since the sequence of TYP 2 could be identified 
as homologous to, but distinct from CL 100, the regulation of expression of TYP 2 
was investigated by northern analysis. A specific probe for TYP 2 was chosen from the 
5' end of the gene, as this region demonstrates near sequence homology to CL100 
without including the PTPase motif. As can be seen from the northern analysis, TYP 2 
is not hybridising to the CL100 transcript, confirming that there is presumably, a novel 
functional gene represented by TYP 2.
At the time of isolation, the clones TYP 1-5, were used to search the 
Genbank/EMBL database, and whilst showing significant homology to conserved 
regions in CL 100 and PAC-1, and the PTPase domain of protein tyrosine
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phosphatases, they proved to be novel sequences. The full length of TYP 1 exhibits the 
highest degree of homology to CL100, 62.8%, confirming that this gene is most likely 
a member of the dual specific phosphatases rather than the tyrosine phosphatases. 
More recently, a number of research groups have identified further members of this 
novel subfamily of phosphatases, and at present the mammalian genes include B23 
(Ishibashi et al., 1994), HVH3 (Kwak and Dixon, 1995), HVH2 (Guan and Butch, 
1995), and MKP-2 (Misra-Press et al., 1995). TYP 5, which was isolated from the 
liver cDNA library, shows sequence identity with HVH3. In addition, HVH2, which 
was cloned from human placenta, shows sequence identity with TYP 1. Misra-Press 
and colleagues (1995) have also reported the cloning of MKP-2 from PC 12 cells 
which, excluding a few amino acid changes, is extremely homologous to TYP 1 and 
HVH2. Interestingly the mRNA transcript of MKP-2 is 6.0 kb, and could represent the 
larger mRNA species which Guan and Butch (1995) identify during northern analysis, 
using an HVH2 probe. Additionally, expression studies performed in this thesis using a 
probe for TYP 1, also identify an approximate 7.0 kb transcript, which presumably 
represents this same larger species of mRNA.
A common evolutionary origin of this family is demonstrated by the presence 
within each isoform of the PTPase motif, a defining feature of the protein tyrosine 
phosphatases. The dual specific phosphatases are also highly conserved between 
species, having been identified in vertebrates, yeast, and baculo- and orthopox viruses, 
indicating that these phosphatases play an important regulatory role within the cell. 
Indeed, the dual specific phosphatase Cdc25, is implicated in cell cycle control by 
virtue of its interaction with the cyclin-dependent kinases, and more recently 
Galaktionov and co-workers (1995b), have suggested that Cdc25 may function as an 
oncogene. Two domains present in Cdc25 known as the CH2 domains are also present 
in TYP 1, and the CLIOO-like phosphatases. It is thought that these domains are 
involved in substrate specificity in vivo, although presumably they do not confer the 
property of dual specificity, since the VH1 protein demonstrates activity towards 
tyrosine and serine residues, but lacks these CH2 domains.
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6.2. Regulation of TYP 1 and TYP 2 expression
Analysis of the regulation of TYP 1 and CL100 mRNA levels in squamous 
cells, demonstrated a difference in expression between CL100 and TYP 1. Whilst 
CL100 and TYP 2 are significantly induced by 30 minutes upon mitogenic exposure of 
the squamous cell line A431, TYP 1 mRNA expression is not maximal until 4 hours 
following mitogen stimulation, figure 4.4. This difference in induction is also seen 
when quiescent SCC12F squamous cells are stimulated with serum. Although in 
SCC12F cells, TYP 1 expression is maximal at 2 hours, as opposed to 4 hours as seen 
in A431 cells. However, the TYP 1 transcript remains up-regulated for a longer period 
of time in SCC12F cells. Indeed, by 8 hours, when both CL100 and TYP 2 expression 
have returned to basal levels, TYP 1 mRNA is still induced, figure 4.5. Thus, under all 
conditions tested here, the temporal difference in mRNA expression between TYP 1 
and CL100 is maintained. Interestingly, Guan and Butch (1995) find that HVH2, 
which is identical to TYP 1, is not significantly induced in a liver cell line upon 
stimulation with EGF. However, in these experiments cells were treated with EGF for 
1 hour, which is perhaps too short a period for TYP 1 induction. Evidence presented 
here would suggest that TYP 1 does not behave as an immediate early gene, unlike 
TYP 2, CL 100 and other family members identified so far. The late functioning of 
TYP 1 is further substantiated by the finding that protein expression is not maximal 
until 8 hours following mitogenic stimulation, and in fact is not detected at all until 
4 hours after stimulation, figure 5.7, consistent with the induction of mRNA 
expression.
A further difference between TYP 1 and previously isolated CLIOO-like 
phosphatases, is that TYP 1 is not induced by heat shock. Thus, it would seem that the 
dual specific phosphatase genes are differentially regulated, demonstrating varying 
kinetics in mRNA expression. This is clearly shown with TYP 1, and also the 
phosphatase HVH3, which behaves as an immediate early gene being induced by 
30 minutes, but is up-regulated for 6 hours (Kwak and Dixon, 1995). Presumably the 
discriminate regulation demonstrated by the dual specific phosphatases will impart
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unique roles on their function, reflecting their co-expression with specific substrates, 
such as the particular isoforms of the MAP kinase family. Indeed, evidence presented 
here demonstrates that the dual specific phosphatases are differentially regulated in 
response to cellular stress, mitogens such as EGF, and the growth factor TGF(3, 
suggesting these genes may have distinct roles in separate signal transduction 
pathways. Although physiologically, as recognised with MAP kinase regulation, it is 
almost impossible to define "separate pathways" in signal transduction. Rather, there is 
a co-ordination of "cross-talk" between the signalling cascades.
It is becoming evident that these phosphatases are not only differentially 
regulated as a consequence of specific stimuli, but they are also expressed in a tissue 
specific manner. Results in this thesis demonstrate that TYP 1 expression appears to 
be both tissue and cell-type specific. In particular, TYP 1 is not expressed in human 
fibroblasts, even upon mitogenic stimulation, figure 4.7. Whilst both TYP 1 and 2 are 
highly expressed in placenta, CL100 appears to be equally expressed in placenta, lung, 
liver and skeletal muscle. It was also noticed that TYP 1 mRNA was expressed at a 
level significantly lower than CL100 and TYP 2. As previously mentioned, PAC-1 is 
specifically hematopoietic (Rohan et al., 1993), whilst MKP-2 is strongly expressed in 
the central nervous system (Misra-Press et al., 1995). Interestingly, ERK3 tissue 
expression is restricted to neuronal cells (L’Allemain, 1994). These subtle differences 
will undoubtedly be important in determining the precise function and specificity of 
these phosphatases within the cell.
6.3. The involvement of TYP 1 in the MAP kinase cascade
It has been established from both in vitro and in vivo experiments that the 
dual specific phosphatases specifically dephosphorylate and inactivate the 
extracellular-regulated MAP kinases (Alessi et al., 1993a; Sun et al., 1993; Zheng and 
Guan, 1993; Ishibashi et al., 1994; Ward et al., 1994; Kwak and Dixon, 1995, Guan 
and Butch, 1995). Using a transient expression system, results presented in this thesis 
demonstrate that TYP 1 is capable of inhibiting both growth factor-stimulated ERK2
155
activity, and heat shock-induced p54JNK activity, figures 5.1. and 5.2. In these 
experiments, TYP 1 activity is comparable and equivalent to CL 100. In spite of TYP 1 
and CL100 being over expressed, these observations strongly suggest that TYP 1 is 
likely to be a component of the MAP kinase signal transduction pathways. This is 
further substantiated by the findings that TYP 1 directly inactivates and 
dephosphorylates ERK2 in a concentration dependent manner, and that this is due to 
the concomitant dephosphorylation of both the threonine and tyrosine residues, which 
are phosphorylated by MAPK kinase, figures 5.3. and 5.4. These results are in 
agreement with previous studies that other phosphatase family members also 
demonstrate substrate specificity towards the MAP kinase isoforms. Such substrate 
specificity is further demonstrated by the fact that CL100 fails to dephosphorylate and 
activate p34cc^ c^, the cyclin dependent kinase which is the in vivo substrate for Cdc25, 
although both Cdc25 and CL100 share sequence identity across the catalytic domain 
(Alessi et al., 1993a). It would be interesting to investigate whether TYP 1 
demonstrates activity towards other substrates, such as p34C(*c2.
It was observed that TYP 1 appears to dephosphorylate the phosphotyrosine 
residue more efficiently than the phosphothreonine, as demonstrated in the 
phosphoamino acid analysis, figure 5.4b. This preferential dephosphorylation of the 
tyrosine residue over the threonine has also been confirmed by studies with PAC-1 
(Ward et al., 1994) and HVH2 (Guan and Butch, 1995). Despite the growing number 
of dual specific phosphates identified, little is known about the biochemical 
mechanisms employed by this family of enzymes. Denu and co-workers (1995) 
investigated the catalytic properties of the dual specific phosphatases, using the 
prototypic human VHR protein. In order to explore substrate specificity, 
diphosphorylated peptides were used as substrates. This is because phosphorylation of 
MAP kinase by MAPK kinase is not stoichiometric on both the tyrosine and threonine 
residues, thus making comparative determination of the rates of dephosphorylation 
ambiguous. Their results confirm that phosphothreonine hydrolysis is approximately 
three orders of magnitude slower than the hydrolysis of phosphotyrosine. Perhaps this 
is not so surprising, since the dual specific phosphatases contain the PTPase catalytic
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motif. This raises questions as to the mechanism that confers the function of dual 
specificty on these phosphatases.
It will be interesting to explore whether the potentially different MAP kinase 
proteins of a cell regulate their own specific phosphatase for their inactivation. Indeed, 
the question of specificity of these phosphatases for the various isoforms of MAP 
kinase still remains. It is worth noting that CL100 was first isolated as a 
stress-inducible gene, and in vitro, CL100 is able to dephosphorylate and inactivate a 
stress-induced MAP kinase, p38 (Rouse et al., 1994). In some cell-types, the 
physiological targets of CL100 may not be the classical ERK1 and ERK2 isoforms. 
This may explain why in PC12 cells, CL 100 induction is not accompanied by the 
inactivation of ERK2 (Alessi et al., 1995). It is also demonstrated here that TYP 1 can 
alter the phosphorylation pattern of c-Jun, figure 5.5. Although, these translation 
experiments do not distinguish whether TYP 1 dephosphorylates c-Jun directly, or 
inactivates a kinase present in the reticulocyte lysate. It is possible that TYP 1 
activates a serine/threonine phosphatase such as PP2A, which subsequently 
dephosphorylates c-Jun. In this regard, it has been reported that PP2A is inhibited 
in vitro by the phosphorylation of a carboxy-terminal tyrosine residue, catalysed by 
receptor protein tyrosine kinases, or v-src. Furthermore, PP2A is phosphorylated at 
this residue in vivo (Chen et al., 1994c). Could PP2A be activated by removal of this 
inhibitory tyrosine residue by TYP 1? Whether PP2A is responsible for 
dephosphorylating c-Jun could be investigated through the use of specific phosphatase 
inhibitors, such as okadaic acid. However, transient transfection studies show that 
TYP 1 inactivates the stress-induced MAP kinase, p54JNK, suggesting that the 
observed inhibition of c-Jun phosphorylation maybe mediated through the inactivation 
of p54JNK, a kinase which phosphorylates c-Jun at the amino-terminus. Since TYP 1 
is not induced upon heat shock, this is most likely acting through the mitogen 
stimulated pathway. Although other stimulants of cellular stress which may activate 
TYP 1 are yet to be investigated, such as protein synthesis inhibitors, UV irradiation 
and inflammatory cytokines.
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As discussed in the introduction, there is now evidence for parallel MAP kinase 
cascades, and numerous studies support the contention that at least two signal 
transduction cascades exist in mammalian cells, that is the stress-related responsive 
MAP kinases and the mitogenic-mediated MAP kinase response. Whilst there is 
considerable cross-talk between the components of these MAP kinase pathways, it is 
anticipated that the dual specific phosphatases will be able to distinguish between the 
MAP kinase proteins, enabling the differential regulation of these enzymes through the 
existence of both specific MAP kinase kinases and MAP kinase phosphatases. The 
possibility of distinct phosphatase targets is perhaps highlighted by the variant tissue 
and cell-type specificity observed between the immediate early CL 100-like genes and 
TYP 1. Additionally, it has been proposed that the temporal activation of MAP kinases 
is sufficient for cells to enact proliferative or differentiation responses (Cowley et al., 
1994). Therefore, it is possible that the TYP 1 protein may play a more significant role 
in the regulation of MAP kinase activity during cell differentiation. In these situations, 
MAP kinase activity is sustained for several hours, concordant with the delayed 
kinetics of the TYP 1 protein, as opposed to the immediate early induction of the 
CL 100-like phosphatases. It can be envisaged the latter phosphatases are perhaps 
more involved in regulating the transient activation of MAPK, observed during cell 
proliferation. The results in this thesis demonstrate that TYP 1 readily inhibits 
EGF-induced ERK2 activity, and heat shock-induced p54JNK activity. Similar 
comparisons of MKP-1 activity towards MAP kinase isoforms have been investigated, 
and have demonstrated that whilst MKP-1 has the capacity to efficiently inactivate 
ERK2 activity, UV-induced JNK1 activity is largely unaffected (Sun et al., 1994). This 
data indicates that there is a degree of selectivity of MKP-1 for ERK2. However, 
cell-type-specific differences also exist in the relative regulation of the MAP kinase 
pathways, and as such, studies by Zinck et al. (1995), suggest that MKP-1 is more 
efficient towards the stress-activated MAP kinases. Zinck and co-workers demonstrate 
that in Hela cells, under normal conditions, SAPK activity is down-regulated within 
60 minutes, however full inhibition of protein synthesis by treatment with 
cycloheximide blocks the down-regulation of SAPKs, suggesting that the component
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responsible for S APK inactivation seems to be newly synthesised. Conversely, efficient 
down-regulation of ERKs is seen within 60 minutes irrespective of the status of 
cellular protein synthesis. This indicates that the components involved in ERK down- 
regulation are probably pre-existing and do not require de novo synthesis. Concordant 
with this, the rapid down-regulation of ERK activity has been ascribed to the 
inactivation of Raf-1 by protein kinase A (Cook and McCormick, 1993; Hafner et al., 
1994). Furthermore, as discussed in section 1.8, ERK2 inactivation in some cell types 
seems to depend on protein phosphatase 2A and another unidentified tyrosine 
phosphatase (Alessi et al., 1995). Hence, the observations by Zinck et al. (1995), 
would indicate that SAPKs require protein synthesis for down-regulation, raising the 
possibility that in vivo, the dual specific phosphatases such as MKP-1, act more 
efficiently on SAPKs than on ERKs. However, it is worth noting that the immediate 
early genes CL100 and 3CH134 are actually super-induced within the first hour of 
cycloheximide treatment (Sun et al., 1993; Kwak et al., 1994), and it is only after 
prolonged treatment that CL100 protein synthesis is repressed, since CL100 protein 
has a half-life of 40-60 minutes (Alessi et al., 1995). Interestingly, Kwak and Dixon 
(1995) report that regulation of HVH3 during hepatoma cell stimulation differs from 
CL100 in that it has a component that is dependent on protein synthesis, as 
cycloheximide addition does not enhance, but partially blocks the induction of HVH3 
mRNA.
Activation of the MAP kinase signal transduction cascade subsequently results 
in the expression of several immediate early genes. As expected, this rapid rise in 
tyrosine phosphorylation needs to return to normal levels in order to avoid abnormal 
growth. It is not by coincidence that the stimulation of MAP kinases by mitogens and 
cellular stress also leads to the induction of the dual specific phosphatases, which 
specifically inactivate MAP kinase isoforms, and whose patterns of induction are 
consistent with them playing a role in mitogenic cell cycle progression. However, a 
fine balance between the activities of the MAP kinases, and the activities of the dual 
specific phosphatases is crucial, if the same stimuli are to induce and activate both 
enzymes. Perhaps the maintenance of such an antagonistic system is aided through the
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activities of post-translational modification. Considering that so many kinases are 
themselves regulated by phosphorylation, such as the MAP kinases, it is entirely 
feasible that the dual specific phosphatases may also be regulated in a similar manner. 
There is accumulating evidence for the regulation of protein tyrosine phosphatases by 
phosphorylation. For example, the stimulation of cells transiently expressing RPTPa 
with TP A, a direct activator of protein kinase C, increases RPTPa serine 
phosphorylation, concomitant with an enhancement in PTPase activity (den Hertog 
et al., 1995). The finding of putative MAP kinase phosphorylation sites at the 
carboxy-terminus of TYP 1, suggests that MAP kinase may itself regulate the activity 
of the TYP 1 protein. It is interesting that EGF leads to the stabilisation of the protein, 
increasing its half-life from approximately 1 hour, to more than 3 hours, figure 5.9. 
Although extremely hypothetical, it is possible that the TYP 1 protein is indirectly 
stabilised by EGF, as a consequence of EGF stimulating MAP kinase, which in turn 
functions to phosphoiylate TYP 1. It will be exciting to investigate whether MAP 
kinase does indeed phosphorylate TYP 1, and whether this modification alters the 
activity of the TYP 1 protein. Krautwald and colleagues (1995) have observed that the 
stable transfection of activated raf in a macrophage cell line suppresses MAP kinase 
activation, and furthermore, this correlates with the constitutive expression of a 
number of immediate early genes, including the MAP kinase phosphatase, MKP-1. 
Northern blot analysis demonstrated that MKP-1 was constitutively expressed at low 
levels in v-Raf-expressing macrophages, and CSF-1-induced expression of MKP-1 
persisted for longer in these cells compared to the parental macrophages. Importantly, 
a revertant cell line does not express detectable levels of MKP-1 mRNA, and MAPK is 
activated as normal. This raises the intriguing possibility that in macrophages, Raf may 
be feeding-back on the MAP kinase pathway by participating in the control of MKP-1 
expression.
The kinetics of activation and inactivation of MAP kinases appears to be cell 
type-specific. As discussed in the introduction in section 1.8, it has been demonstrated 
that the rapid inactivation of MAP kinase in several cell-types is not catalysed by 
CL100 (Alessi et al., 1995; Wu et al., 1994). In these situations, CL100 is not induced
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until after MAP kinase is completely inactivated, and such a transient activation of 
MAP kinase does not lead to translocation to the nucleus, where CLIOO-like protein 
phosphatases have been localised As previously mentioned, the proposed model for 
MAP kinase inactivation in the cytoplasm is through PP2A and an as yet 
uncharacterised PTP, although such a PTP has been purified and characterised from 
Xenopus (Sarcevic et al., 1993). The potential to dephosphorylate just one residue by 
class specific phosphatases, as in the above model, is sufficient to inactivate MAP 
kinase, and allows the possibility of the rapid reactivation of this enzyme, maybe 
through a route independent of MAPK kinase. In support of this, in certain cell-types 
MAP kinase activity is biphasic, suggesting that there is a reactivation of MAP kinase 
(Seth et al., 1992). It has also been demonstrated that MAP kinase activation in 
chromaffin and endothelial cells, after certain stimuli, is sustained for at least 2 hours 
with a slow inactivation of up to 6 hours, despite an increase in CLIOO-like activity 
after 1 hour. This may be due to a possible regulation exerted on the dual specific 
phosphatases by MAP kinase through the MAPK phosphorylation sites in the carboxy- 
terminal of these phosphatases, or indeed, through the possible interaction with a 
specific phosphatase inhibitor. However, in such a situation the delayed inactivation of 
MAP kinase may be due to TYP 1, or a similarly late-induced phosphatase, since 
results presented in this thesis demonstrate that TYP 1 mRNA and protein expression 
is not maximal until 4 and 8 hours respectively, by which time the immediate early 
CLIOO-like phosphatases have returned to basal levels. Furthermore, it is observed 
that the mitogen, EGF, stabilises the TYP 1 protein in transfected Cos cells. In 
addition, it is also shown that TYP 1 expression is nuclear, figure 5.10, as is MAP 
kinase following sustained activation.
MAPK kinase is a cytosolic protein (Lenormand et al., 1993), therefore, MAP 
kinase activation must be a cytosolic event. However, the site of MAP kinase 
inactivation in some instances must occur in the nucleus, since this is where the dual 
specific phosphatases are localised. The mechanism by which MAP kinase enters the 
nucleus is not understood, as the gene does not contain a classical nuclear localisation 
signal. Whether MAP kinase relies on a chaperone molecule is not clear. It has been
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demonstrated that a single point mutation in the catalytic domain of MKP-1, 
Cys-258-Ser, is sufficient to exclude MKP-1 from the nucleus (Brondello et al., 1995). 
This mutant MKP-1CS, although less potent than wild-type MKP-1, was able to 
partially inhibit MAP kinase sensitive gene induction, presumably through retarding 
the translocation of MAP kinase to the nucleus. It has also been shown that MKP-1CS 
forms a physical complex with the phosphorylated form of MAP kinase, and augments 
MAP kinase phosphorylation. However, the activity of MAP kinase was not tested 
under these conditions (Sun et al., 1993). Thus, mutants of MKP-1 are able to 
associate with MAP kinase, and although MAP kinase may still undergo 
phosphorylation by MAPK kinase, the activity of MAP kinase is abrogated, by virtue 
of the fact that MKP-1CS remains cytosolic, thus preventing MAP kinase from 
activating transcription factors i in the nucleus. Additionally, a mammalian mutant of MAP 
kinase, analogous to the dominant gain of function mutation in Drosophila known as 
sevenmaker (rl^111), shows an increased sensitivity to low levels of signalling in vivo. 
However, this mutation does not lead to an elevated basal kinase activity, but rather 
demonstrates a decreased sensitivity to CL100 (Bott et al., 1994). In relation to the 
above studies, the mutant MAPK may be less sensitive to CL100 due to an alteration 
in the sub-cellular localisation of the protein compared to the wild-type, i.e. an 
inhibition of translocation to the nucleus. Thus, the compartmentalisation of these 
kinases and phosphatases will play an important role in determining their regulation of 
activation and substrate availability. It is intriguing that all the dual specific 
phosphatases identified so far are localised to the nucleus. Whilst there is evidence that 
the ERK isoforms are translocated to the nucleus, it is still to be demonstrated that the 
JNK isoforms are definitively nuclear, even though they have been demonstrated to 
phosphorylate c-Jun.
The dual specific phosphatases may have some involvement in negative cell 
cycle progression. Results presented here demonstrate that CL100 and TYP 1 mRNA 
expression is significantly induced after TGFp treatment, and that this induction is 
clearly sustained over 24 hours as regards TYP 1 expression. The mechanism of TGFp 
signal transduction in cells remains unclear, although there is evidence that TGFp
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inhibition is not a Consequence of one single pathway, but may impinge on several 
co-ordinated pathways, each of which can result in growth inhibition. For example, 
alterations are seen in the expression levels of c-Myc, CDK4, cyclin D and CDK 
inhibitors, and the phosphorylation status of pRb. One or more of these pathways 
tends to be lost in tumour cells. It has been reported that TGFP exerts its 
antiproliferative effects at a level that is distal from those of receptors for growth 
factor-activating factors (Like and Massague, 1986). However, more recent data has 
shown that TGFP addition to proliferating cultures of epithelial cells, which are 
sensitive to the inhibitory effects of TGFp, show a rapid activation of MAP kinase 
which is sustained for at least 90 minutes, although these cells are still growth inhibited 
(Hartsough and Mulder, 1995). It has been reported that in some carcinoma cell lines 
that are sensitive to TGFP inhibition, the early effects of TGFp are the enhancement of 
the expression of both jun proteins (Pertovaara et al., 1989), and c-Fos (Hsu et al., 
1994). An important property of TGFp is its ability to activate its own mRNA 
expression and thereby increase its own secretion. Two distinct regions of the 
promoter of TGFp are responsive to autoregulation, and in both of these regions, 
autoinduction is mediated by the binding of the AP-1 complex (Kim et al., 1990). With 
regard to the observed activation of MAP kinase, in association with an inhibition of 
cell growth (Hartsough and Mulder, 1995), a possible explanation is that activated 
MAP kinase leads to the efficient phosphorylation and activation of both c-Jun and 
c-Fos, via the phosphorylation of transcription factors, see section 1.5.2.1. The 
subsequent AP-1-dependent gene transcription ultimately leads to the autoinduction of 
TGFp. In cell types that have the potential to activate the latent, secreted TGFp, the 
growth inhibitory effects of TGFp would be amplified. The overlap between sets of 
genes stimulated by TGFp and mitogens is interesting. Through jun and fos families of 
proteins, their complexes, and AP-1-binding sites, both mitogens and TGFp could act 
by a similar mechanism, but with different kinetics and magnitudes. Thus, evidence 
would suggest that cells which are sensitive to the inhibitory effects of TGFp, are able 
to stimulate AP-1 induction, but these cells do not progress to the S phase of the cell 
cycle, as demonstrated by growth inhibition. Further evidence for the involvement of
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MAP kinases in the inhibition of the cell cycle has been demonstrated in S. cerevisiae. 
The FAR1 protein, which is an inhibitor of G1 cyclin-dependent kinases, is a direct 
target of the MAP kinase FUS3. Indeed, phosphorylation of FAR1 induces its binding 
to, and consequent inhibition of the CDK-cyclin complexes (Herskowitz, 1995). In 
turn, it would be interesting to investigate if MAP kinases are able to activate CDK- 
inhibitors in a mammalian system, since these cell cycle regulators have been 
implicated as effectors of TGFp-induced cell cycle arrest
Evidence would therefore suggest that the MAP kinases not only play a 
significant role in cellular differentiation and proliferation, but may also be involved in 
an additional pathway which leads to growth inhibition, via TGFp. The induction of 
TYP 1 and CL100 in response to TGFp, in cells sensitive to the growth inhibitory 
effects of TGFp, suggests a role for these phosphatases in the tight regulation of TGF 
p-induced MAP kinase activation. This is substantiated by the finding that expression 
of MKP-1 inhibits serum stimulated transcriptional events, as well as the entry into 
S phase (Brondello et al., 1995). In a similar study, it has also been demonstrated that 
Ras-induced DNA synthesis is inhibited by micro-injection of MKP-1 (Sun et al.,
1994). It is proposed that TYP 1 plays a role in the growth inhibitory effect of TGFp 
by regulating MAP kinase activity in the nucleus, such that cell cycle progression is 
prevented. Agonists which induce the long term induction of dual specific 
phosphatases, such as TGFP, which are distinct from the overlapping mitogenic signals 
that induce both MAP kinases and MAP kinase phosphatases, provide a suitable 
mechanism for the attenuation of MAP kinase activity throughout the phases of the 
cell cycle.
6.4. Future prospects
Experiments are currently underway to generate cell lines stably or 
conditionally expressing wild-type TYP 1, to determine the long term effects of TYP 1 
expression on cell proliferation or transformation. Transfections have been initiated in 
fibroblasts which do not express TYP 1, and in epidermal cells for which the
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expression pattern of TYP 1 has been determined. The expression vector is based on 
pBABEneo, directed by the MLV LTR, which will ensure reasonable constitutive 
expression, and can be introduced either by transfection, or by infection as a 
retrovirus. A further expression vector that will be used is the tetracycline responsive 
promoter vector. This is co-transfected with a plasmid expressing the hybrid 
tetR-VP16 transactivator protein (bacterial tetracycline repressor fused to the 
activation domain of the herpes simplex virus VP16), which regulates expression of 
the test construct. The tight regulation afforded by this system will enable control over 
the level of TYP 1 expression via the concentration of tetracycline in the media. These 
vectors will be of considerable use if continual expression of TYP 1 proves toxic for 
the cells.
It will be interesting to investigate the downstream consequences of TYP 1 
expression on AP-1 DNA binding activity. It has been demonstrated in our laboratory 
that AP-1 DNA binding activity is biphasic in growth factor stimulated fibroblasts 
(Hawker et al., 1993). The DNA binding activity of AP-1 is regulated by 
phosphorylation, at least in part, by a MAPK-like activity. It will be interesting to 
investigate if the expression of TYP 1 effects the DNA binding capacity of AP-1 in 
these cells in response to mitogen activation.
Results in this thesis did not examine whether TYP 1 specifically associates 
with MAP kinase, as has been demonstrated for MKP-1 (Sun et al., 1993). This could 
be judged by GST-fusion experiments, and through the use of the two hybrid yeast 
system, which is currently being investigated by Alan Ashworth in his laboratory.
Site-directed mutagenesis will also be used to replace the cysteine-280 with a 
serine in the TYP 1 catalytic domain, to create a phosphatase dead mutant. This may 
show a dominant negative phenotype, and if so, will allow the inhibition or 
enhancement of TYP 1 activity by expression of the wild-type or mutant protein. It 
will be interesting to determine if the mutant TYP 1 protein displays a different 
subcellular localisation to the wild-type, and/or alters the activity of MAP kinase.
The growth and differentiation of epidermal cells is very much dependent upon 
the activation of the EGF receptor. This is highlighted by the finding that most SCC
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derived cell lines over-express the EGF receptor, and that inhibition of EGF receptor 
inhibits proliferation, and in some cases promotes differentiation (Modjtahedi et al., 
1993). Results in this thesis have shown that EGF and TGFp induce TYP 1 mRNA 
expression. Clearly, the generation of stably transfected cell lines will prove useful in 
ascertaining the role of MAP kinase pathways in regulating the growth and 
differentiation of SCCs. It will be interesting to determine if TYP 1 expression alters 
the antiproliferative response of SCC cells to TGFp, and to investigate the role of 
MAP kinase-like activities in the TGFp response.
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Figure A
Predicted nucleotide sequences of the five groups of clones isolated by 
PCR using the degenerative oligonucleotides.
Group A : 745- CAG GGT GGC CCG GTG GAA ATC CTG CCC TTT CTG 
(CL100) TAC CTG GGC AGT GCG TAT CAC GCT TCC CGC AAG GAC 
ATG CTG GAT GCC TTG GGC ATA ACT GCC TTG ATC AAC 
GTC TCA GCC AAT TGT CCC AAC CAT TTT GAG GGT CAC 
TAC CAG TAC AAG AGC ATC CCT GTG GAG GAC AAC CAC 
AAG GCA GAC ATC AGCTCC TGG TTC AAC GAG GCC ATT 
GAC TTC ATA GAC TCC ATC AAG AAT GCT GGA GGA AGG 
GTG TTT GTC CAC TGC CAG GCA GGC -1018
Group B: GAG ATC CTT CCC TCC CTC TAC CTT GGA AGT GCC TAC 
(TYP 5) CAT GCA TCC AAG TGC GAG TTC CTG GCC AAC TTG CAC 
ATC ACA GCC CTG CTG AAT GTC TCC CGA CGG ACC TCC 
GAG GCC TGC ATG ACC CAC CTA CAC TAC AAA TGG ATC 
CCT GTG GAA GAC AGC CAC ACG GCT GAC ATT AGC TCC 
CAC TTT CAA GAA GCA ATA GAC TTC ATT GAC TGT GTC 
AGG GAA AAG GGA GGC AAG GTG CTG
Group C: GAG ATC CTT CCC TTC CTC TAC CAT GCT AGT GCC TAC 
CAT GCT GCC CGG AGA GAC ATG CTG GAC GCC CTG GGC 
ATC ACG GCT CTG TTG AAT GTC TCC TCG GAC TGC CCA 
AAC CAC TTT GAA GGA CAC TAT CAG TAC AAG TGC ATC 
CCA GTG GAA GAT AAC CAC AAG GCC GAC ATC AGC TCC 
TGG TTC ATG GAA GCC ATA GAG TAC ATC GAT GCC GTG 
AAG GAC TGC CGT GGG CGC GTG CTG
Group D: GAG GGA CCG ATA AGA TTC CTC TAT CTT CTA AAG CTT 
TAC TCT CCC CGA AAA GTC CTC TAC CGC TCC TCC GCC 
CGG CTC CTC GGT CTG AAG ACA CCG AGA CTC GAC CAG 
ACT CGC CAA CTC CTG AAA GAC TAA
Group E: GAG ATC TTG CCC TAC CTG TTC CTG GGC AGC TGC AGT 
CAC TCG TCA GAC CTG CGG GGC TGC AGG CCT GTG CGA 
TCA CAG CCC GTC CTC AAC GTG TCC GCC AGC TGC CCC 
AAC CAC TTT
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Figure B
Predicted nucleotide sequences of the TYP cDNA clones.
TYP 1: Refer to results section.
TYP 2: GAG ATC CTT TCC TCC CTC TAC CTT GGA GGT GCT TAC CAT 
GCA TCC AAG TGG AAG TTC CTC GAT AAG CTA TAT ATC ACA
GCC CAG CTG AAT GTC CCC ATC CTT GTG GAA GAA GGC
CAC ATG GCT GAC AIT AGC TCT CAC TTT CAA GAA GCA ATA 
GAC TTC ATT GAC TGT GTC AGA GAA AAG AAA GGC AAG GTC 
CTG GTC CAC TGT GAA GCT GGG TTC TCC TGT TCA CCC ACC
TYP 3: GAG ATC TTG CCC TAC CTG TTC CTG GGC AGC TGC AGT CAC 
TCG TCA GAC CTG CAG GGG CTG CAG GCC TGT GGC ATC ACA 
GCC GTC CTC AAC GTG TCC GCC AGC TGC CCC AAC CAC TTT 
GAG GGC CTT TTC CGC TAC AAG AGT ATC CCT GTG GAG GAC 
AAC CAG ATG GTG GAG ATC AGT GCC TGG TTC CAG GAG GCC 
ATA GGC TTC ATT GAC TGG GTG AAG AAC AGC GGA GGC CGG 
GTG CTG
TYP 4: GCT GAC ATT AGC TCC CAC TTT CAA GAA GCA AIT GAT TTT
A IT GAC TGC GTC AGG GAA GGA GGA GGC AAG GTC CTA GTC 
CAC TGT GAG GCT GGG GTC TCG AGG TCA CCC ACC ATC TGC 
ATG GCG TAC CTC ATG AAG ACC AAG CAG TTC CGC CTG AAG 
GAG GCC TTC GAC ATC GTC AAG CAG AGG AGG AGC GTG ATC 
TCT CCC AAC TTT GGC TTT ATG
TYP 5: See Group B
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